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Systemic	   fungal	   infections	   represent	   a	   significant	   contributor	   to	  human	  morbidity	  
and	  mortality.	  	  To	  lower	  the	  impact	  of	  invasive	  fungal	  pathogens	  on	  the	  global	  population,	  
more	  progress	  must	   be	  made	   in	   the	   areas	   of	   diagnostic	   tests	   and	   safe	   and	   effective	  new	  
therapies.	   	   	  Although	  Amphotericin	  B	  (AmB)	  has	  served	  as	  the	  last	  line	  of	  defense	  against	  
invasive	  fungal	  infections	  without	  significant	  pathogen	  resistance,	  its	  clinical	  application	  is	  
restricted	  by	  severe	  dose-­‐limiting	  toxicity.	   	  Efforts	  to	  improve	  AmB’s	  therapeutic	  index	  (a	  
comparison	  between	   the	  dose	   that	   causes	   the	  desired	   therapeutic	   effect	   to	   the	  dose	   that	  
causes	  toxicity)	  have	  not	  been	  successful.	  	  This	  lack	  of	  progress	  is	  in	  large	  part	  attributable	  
to	  an	  incorrect	  understanding	  of	  AmB’s	  primary	  mechanism	  of	  action.	  	  
For	  more	  than	  5	  decades	  AmB	  has	  been	  perceived	  to	  primarily	  exist	  and	  operate	  as	  
a	   self	   assembled	   ion	   channel	   complex—exerting	   cytotoxicity	   through	   the	   efflux	   of	  
intracellular	  ions	  leading	  to	  the	  disruption	  of	  critical	  electrochemical	  gradients.	  	  Although	  a	  
beautiful	   and	   rare	  phenomenon	   for	   a	   small	  molecule,	   the	   ion	   channel	  model	  has	  masked	  
AmB’s	  underlying	  mechanism	  of	  action.	  	  	  
In	  this	  body	  of	  work	  we	  will	  discuss	  how,	  through	  the	  systematic	  synthesis	  of	  single	  
functional	   group	   deficient	   derivatives	   of	   AmB,	   coupled	   with	   state-­‐of-­‐the-­‐art	   biophysical	  
and	   biological	   experiments	   we	   have	   been	   able	   to	   fully	   elucidate	   AmB’s	   mechanism	   of	  
action.	  	  We	  discuss	  how	  AmB	  predominantly	  exists	  as	  an	  extramembranous	  sterol	  sponge	  
that	   primarily	   kills	   yeast	   and	   human	   cells	   by	   binding	   and	   extracting	   sterols	   in	   a	  
mycosamine	   dependent	   fashion.	   	   	   Additionally,	   the	   C2’-­‐OH	   and	   C3’-­‐NH3+	   are	   critical	  
residues	  on	  the	  mycosamine	  appendage,	  which	  are	  potentially	  responsible	  for	  stabilizing	  a	  
conformation	  that	  allows	  for	  the	  binding	  of	  both	  ergosterol	  and	  cholesterol.	  	  When	  either	  of	  
these	  residues	  is	  deleted,	  AmB	  can	  still	  bind	  ergosterol	  but	  can	  no	  longer	  bind	  cholesterol.	  	  
This	  shift	  in	  sterol	  binding	  directly	  correlates	  to	  a	  substantial	  loss	  of	  toxicity.	  	  These	  results	  
suggest	  that	  the	  C2’-­‐OH	  and	  C3’-­‐NH3+	  do	  not	  directly	  bind	  sterols	  but	  are	  potential	  sites	  of	  
allosteric	  modification.	  
Empowered	  with	  an	  accurate	  macroscopic	  and	  atomistic	  understanding	  of	  AmB,	  we	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Ac	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C2’epiAmE	   	   	   C2’epi	  amphotericin	  B	  	  
methyl	  ester	  
	   	   	   	   	   	   	   	  
	   	  
Chol	   	   	   	   cholesterol	  
	  
	  
CSA	   	   	   	   (±)-­‐10-­‐camphorsulfonic	  acid	  	  
	  
DCM	   	   	   	   dichloromethane	  
	  
DEIPS	   	   	   	   diethylisopropylsilyl	  
	  
DIAD	   	   	   	   diisopropyl	  azodicarboxylate	  
	  
DDQ	   	   	   	   2,3-­‐dichloro-­‐5,6-­‐dicyano-­‐1,4-­‐benzoquinone	  	  
	  
DMAP	   	   	   	   4-­‐(dimethylamino)-­‐pyridine	  	  
	  
	  
DMF	   	   	   	   dimethyl	  formamide	  	  
	  
	  
DMP	   	   	   	   Dess-­‐Martin	  periodinane	  
	  
	  


































Erg	   	   	   	   ergosterol	  
	  
HMPA	  	   	   	   hexamethylphosphoramide	  
	  
HPLC	   	   	   	   high	  performance	  liquid	  chromatography	  
	  
ICC	   	   	   	   iterative	  cross-­‐coupling	  
	  
ITC	   	   	   	   isothermal	  titration	  calorimetry	  
	  
LUV	   	   	   	   large	  unilamellar	  vesicle	  
	  
MeAmB	   	   	  	  	  	  	  	  	  	  	  	  	  	  C41-­‐methyl	  amphotericinB	  	  
	  
MeAmdeB	   C41-­‐methyl	  	  
amphoteronolide	  B	  
	  
MIC	   	   	   	   minimum	  inhibitory	  concentration	  
	  
MIDA	   	   	   	   N-­‐methyliminodiacetic	  acid	  	  
	  
MIDA	  salt	   	   	   bis-­‐sodium	  N-­‐methyliminodiacetate	  	  
	  
NOE	   	   	   	   nuclear	  Overhauser	  effect	  
	  
Ph3P	   	   	   	   triphenylphosphine	  
	  























































pyr	   	   	   	   pyridine	  	  
	  








TES	   	   	   	   triethylsilyl	  	  
	  
	  
Tf	   	   	   	   trifluoromethane	  sulfonate	  	  
	  
THF	   	   	   	   tetrahydrofuran	  	  
	  
TLC	   	   	   	   thin	  layer	  chromatography	  
	  
TMSE	   	   	   	   2-­‐(trimethylsilyl)ethyl	  	  
	  
UV	   	   	   	   ultraviolet	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CHAPTER	  1:	  TREATMENT	  OF	  SYSTEMIC	  FUNGAL	  INFECTIONS	  
	  
1-­‐1:	  GLOBAL	  IMPACT	  OF	  SYSTEMIC	  FUNGAL	  INFECTIONS	  
	  
	  	   As	  the	  population	  with	   immunodeficiency	  has	  expanded	  over	  the	  past	   four	  decades,	  
systemic	  fungal	  infections	  have	  emerged	  as	  one	  of	  the	  leading	  causes	  of	  human	  morbidity	  
and	   mortality	   worldwide.	   Between	   1979	   and	   2000,	   the	   annual	   number	   of	   sepsis	   cases	  
caused	   by	   fungal	   organisms	   has	   increased	   by	   207%.1	   Patients	   who	   are	  
immunocompromised	  (e.g	  HIV/AIDS	   infection,	   chemotherapy,	  organ	   transplantation	  with	  
long-­‐term	   administration	   of	   corticosteroids,	   or	   the	   elderly)	   are	   substantially	   more	  
susceptible	   to	   contracting	   invasive	   fungal	   infections.	   	  Candida	  albicans	   infections	   are	   the	  
fourth	   most	   common	   hospital	   acquired	   blood-­‐stream	   infections2	   with	   an	   estimated	  
300,000	  cases	  globally	  per	  year.3	  Cryptococcus	  neoformans	  a	  pathogenic	  fungus	  responsible	  
for	   Cryptoccocal	  meningitis—a	   fungal	   infection	   of	   the	  meninges,	   the	   tissue	   covering	   the	  
brain—can	  infect	  immuno-­‐competent	  persons	  but	  is	  typically	  found	  in	  patients	  with	  AIDS.	  
It	   is	   estimated	   that	   there	  
are	   1,000,000	   cases	   of	  
Cryptococcus	   infections	  
globally	  per	  year,	  and	  it	  is	  
the	  second	  most	  common	  
AIDS-­‐defining	   illness	   in	  
Africa4.	   Aspergillus	  
fumigatis,	   the	   most	  
common	   species	  
responsible	  for	  invasive	  Aspergillus	  infections,	  is	  estimated	  to	  cause	  350,000	  cases	  per	  year	  
globally.	  	  The	  average	  mortality	  rate	  for	  all	  of	  these	  infections	  is	  50%	  for	  patients	  receiving	  
treatment.5	  	  	  Worldwide	  deaths	  from	  fungal	  infections	  outnumber	  those	  of	  tuberculosis	  and	  
malaria	   annually	   (Fig.	   1.1	   A).5	   	   In	   the	   US	   alone	   the	   annual	   cost	   associated	   with	   these	  
infections	   will	   top	   $1	   billion.6	   	   Furthermore,	   quickly	   emerging	   resistance	   to	   nearly	   all	  
pharmaceutical	   treatments	   for	   invasive	   fungal	   infections	   poses	   an	   alarming	   threat	   of	  



























Figure 1.1 A) Total deaths per year from invasive fungal infections (blue) compared to 
total deaths per year from   tuberculosis and malaria respectively.  B) Average mortality 

















	   The	  polyene	  macrolide	  natural	  product	  Amphotericin	  B	  (AmB)	   is	  a	  powerful	  broad-­‐
spectrum	  antifungal	  drug	  that	  has	  served	  as	  the	  prototypical	  treatment	  for	  systemic	  fungal	  
infections.	  Discovered	  in	  1955	  by	  Gold	  and	  coworkers	  and	  rapidly	  approved	  by	  the	  FDA	  in	  
1957,9	   AmB	  has	  marked	   a	   paradigm	   shift	   in	   the	   treatment	   of	   systemic	   fungal	   infections.	  	  
Prior	   to	   its	   discovery,	   the	   prognosis	   for	   such	   infections	   was	   exceptionally	   bleak,	   with	   a	  
mortality	  rate	  close	  to	  100%.10	  	  Furthermore,	  pathogen	  resistance	  to	  AmB	  is	  exceptionally	  
rare	  despite	  its	  clinical	  use	  for	  nearly	  60	  years.11	  	  	  Unfortunately,	  however	  AmB	  is	  so	  highly	  
toxic	  that	  its	  effective	  utilization	  as	  the	  last	  line	  of	  defense	  against	  life-­‐threatening	  systemic	  
fungal	   infections	   is	  often	  precluded.12	   	   Intravenous	  AmB	   treatment	   can	   cause	   severe	  and	  
irreversible	   damage	   to	   multiple	   organs,	   most	   notably	   nephrotoxicity	   (kidney)	   and	  
hepatotoxicity	   (liver).	   	   AmB	  will	   also	   disrupt	   the	   soft	  muscle	   tissue	   of	   the	   heart,	   causing	  
serious	   cardiac	   arrhythmias	   and,	   in	   some	   cases,	   sudden	   cardiac	   failure.	   	   Additionally,	   a	  
course	   of	   AmB	   treatment	   will	   cause	   anemia	   and	   electrolyte	   imbalances	   such	   as	  
hypoalkemia	  and	  hypomagnesemia	  as	  a	  result	  of	  systemic	  hemolysis	  of	  erythrocytes	  (red	  
blood	   cells).	   	   The	   severity	   of	   these	   treatment	   effects	   have	   underlined	   how	   critically	  
important	  it	  is	  to	  develop	  a	  way	  to	  improve	  the	  therapeutic	  index	  of	  Amphotericin	  B.12	  	  
Despite	  more	  than	  five	  decades	  of	  extensive	  efforts	  worldwide,13	  a	  clinically	  viable	  
derivative	   of	   AmB	   with	   an	   improved	   therapeutic	   index	   has	   yet	   to	   emerge.	  	   In	   1972,	  
Mechlinski	   and	   Schaffner	   discovered	   that	  methylation	   of	   the	   C41	   carboxylate	   of	   AmB	   to	  
generate	  amphotericin	  B	  methyl	  ester	  (AME)	  somewhat	  improved	  the	  therapeutic	  index	  in	  
vitro.14	  	   These	   studies	   showed	   that	   AME	   had	   decreased	   hemolytic	   activity	   (lysis	   of	   red	  
blood	  cells)	  while	  maintaining	   comparable	  broad-­‐spectrum	  antifungal	   activity.14	   In	  1976,	  
researchers	  at	  the	  Squibb	  Institute	  for	  Medical	  Research	  conducted	  a	  1-­‐month	  comparative	  
toxicology	  study	  of	  AME	  and	  AmB	  in	  mouse,	  rat	  and	  dog	  models.	  	  Importantly,	  the	  material	  
used	  in	  theses	  studies	  was	  only	  57%	  pure.	   It	  was	  concluded	  from	  these	  experiments	  that	  
less	  toxic	  that	  AmB.15	  	  In	  1978,	  the	  same	  only	  57%	  pure	  material	  was	  expedited	  into	  human	  
clinical	   trials	  as	  an	  experimental	  new	  treatment	   for	  systemic	   fungal	   infections.	   	  However,	  
the	   trial	   was	   prematurely	   halted	   due	   to	   numerous	   patient	   deaths	   resulting	   from	  
unexpected	  leukoencepalopathy.16,17	  The	  causes	  of	  this	  side	  effect	  remains	  unclear.	  
Aside	   from	   covalently	  modifying	   the	   structure	   of	   AmB	   to	   improve	   its	   therapeutic	  
index,	   another	   strategy	   has	   been	   to	   incorporate	   AmB	   into	   liposomes.18,19	   Due	   to	   their	  
 3 
higher	   cost	   and	   associated	   storage	   requirements,20	   LFAmB	   treatments	   are	   much	   less	  
accessible	  to	  impoverished	  populations	  in	  the	  global	  south	  where	  these	  pathogens	  have	  the	  
highest	   impact.5	  	  Additionally,	  LFAmBs	  are	  similarly	   toxic	   to	   the	  AmBD	  formulation	   if	   the	  
required	  course	  of	  treatment	  is	  extended.21	  	  	  
	   Two	   other	   classes	   of	   broad-­‐spectrum	   antifungal	   drugs	   have	   also	   been	  
contemporaneously	  developed22	   for	   the	   treatment	   of	   systemic	   fungal	   infections:	  Azoles23	  
and	   echinocandins.24	   	   Azole	   drugs	   like	   fluconazole	   and	   itraconazole	   were	   discovered	   to	  
inhibit	   the	   ergosterol	   biosynthesis	   pathway	   by	   inhibiting	   the	   enzyme	   lanosterol	   14	   α-­‐
demethylase,	  a	  cytochrome	  P450	  enzyme	  responsible	  for	  the	  conversion	  of	  lanosterol	  into	  
ergosterol	   (a	   critical	   sterol	   in	   fungal	   cell	  membranes).22	   	   Echinocandins	   like	   caspofungin	  
inhibit	   fungal	   cell	   wall	   construction	   by	   targeting	   the	   1,3-­‐β-­‐glucan	   synthase,	   a	  
glycosyltransferase	  responsible	  for	  β-­‐glucan	  synthesis.22	  	  	  Although	  these	  drugs	  have	  been	  
shown	   to	   be	   efficacious	   and	   less	   toxic	   compared	   to	   AmB,	   they	   suffer	   from	   a	   narrower	  
spectrum	   of	   application	   and	   significant	   clinical	   resistance	   appearing	   shortly	   after	   their	  
approval	  (Fig.	  1.2).22b-­‐c	  
	  
	   Therefore,	  due	  to	  the	  rise	  of	  significant	  microbial	  resistance	  to	  alternative	  therapies	  
for	   the	   treatment	  of	   systemic	   fungal	   infections,	   efforts	   to	   create	  a	   less	   toxic	  derivative	  of	  
AmB	   are	   of	   utmost	   importance.	   However,	   a	   major	   contributor	   to	   the	   lack	   of	   progress	  
towards	  this	  endeavor	  has	  been	  the	  poor	  understanding	  of	  the	  mechanisms	  by	  which	  AmB	  
is	  cytotoxic	  to	  yeast	  and	  human	  cells.	  	  A	  thorough	  mechanistic	  understanding	  of	  this	  natural	  
product	  stands	  to	  enable	  the	  rational	  design	  of	  antifungal	  drugs	  with	  improved	  therapeutic	  
indices.	   Furthermore,	   a	   deeper	  understanding	  of	  AmB’s	  mechanism	  may	   also	   lead	   to	   the	  
development	   of	   other	   resistance-­‐refractory	   antibiotics,	   thereby	   combating	   the	   growing	  
threat	  of	  resistance	  to	  the	  modern	  pharmaceutical	  arsenal.	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   For	  more	  than	  50	  years,	  the	  prevailing	  explanation	  for	  AmB’s	  mechanism	  of	  action	  
was	  permeabilization	  of	  lipid	  membranes	  via	  the	  formation	  of	  ion	  channels.	   	  Evidence	  for	  
this	   model	   came	   from	   early	   observations	   that	   AmB	   and	   other	   mycosamine	   containing	  
polyene	   macrolides	   caused	   efflux	   of	   intracellular	   ions	   from	   yeast	   cells	   and	   liposomes.	  	  
These	   findings	  were	  supported	  by	  electrophysiology	  experiments	  using	  planar	  black	   lipid	  
membranes	   where	   both	   AmB	   and	   nystatin	   form	   discrete	   single	   ion	   channels.1,2	   Similar	  
experiments	  with	  other	  membrane	  active	  polyenes	  such	  as	  filipin,	  which	  in	  contrast	  do	  not	  
contain	   mycosamine,	   caused	  
global	   disruption	   of	   cell	  
membranes	   rather	   than	  
discrete	   ion	   channel	  
formation.3	   Andreoli	   and	  
coworkers	   demonstrated	   that	  
the	   size	   of	   the	   pores	   formed	  
by	  AmB,	  were	  between	  7	   and	  
10	  Å	  by	  the	  examination	  of	  the	  
relative	   permeability	   of	   the	  
AmB	   channel	   to	   solutes	   of	  
increasing	  size.4	  
	   Collectively	   these	   experiments	   led	   to	   the	  proposal	   of	   the	   classic	   barrel-­‐stave	  model	  
for	  AmB	  ion	  channel	  formation	  (Fig.2.1).3,5,6	  Further	  computational	  modeling	  predicted	  that	  
a	  collection	  of	  eight	  AmB	  monomers	  self-­‐assemble	  into	  an	  ion	  channel	  complex	  where	  the	  
hydrophilic	   polyol	   regions	   form	   a	   pore	   that	   allows	   the	   passage	   of	   hydrated	   ions.	   The	  
exterior	  of	  the	  channel	  complex	  is	  lined	  by	  the	  hydrophobic	  polyenes	  and	  engage	  in	  van	  der	  
Waals	   interactions	   with	   the	   hydrophobic	   lipid	   tails	   of	   the	   lipid	   bilayer.	   	   	   It	   has	   been	  
























channel:	  the	  C41	  carboxylate	  and	  the	  C19	  mycosamine.7	  
	   Efforts	  to	  probe	  the	  role	  of	  these	  functional	  groups	  in	  the	  formation	  of	   ion	  channels	  
have	  relied	  on	  covalent	  modifications,	  i.e.	  methylation	  of	  the	  carboxylate	  or	  acylation	  of	  the	  
C3’-­‐amine	   on	   the	   sugar.1,7,8	   However,	   the	   results	   garnered	   from	   these	   experiments	   are	  
complicated	   by	   new	   steric	   interactions	   in	   the	   corresponding	   derivatives,	   which	   may	  
disrupt	   intermolecular	   contacts.	   Additionally,	   the	   potential	   for	   these	   groups	   to	  maintain	  
hydrogen	  bonding	  potential	  (i.e.	  the	  carbonyl	  of	  the	  C41	  methyl	  ester	  interacting	  with	  the	  
ammonium,	  or	  the	  acyl	  group	  on	  the	  amide	  with	  the	  carboxylate)	  further	  complicates	  the	  
interpretation	   of	   these	   results.8	   	   Palacios	   et	   al.	   employed	   a	   functional	   group	   deletion	  
strategy—similar	  to	  alanine	  scanning	  in	  protein	  science—to	  determine	  the	  role	  of	  the	  C41	  
carboxylate	  and	  C19	  mycosamine	   in	  AmB’s	  mechanism	  of	  action.9	  They	  synthesized	  three	  
AmB	   derivatives:	   amphotronolide	   B	   (AmdeB,	   AmB	   aglycone—lacking	   the	   mycosamine),	  
C41	  methyl	  AmB	  (C41MeAmB,	  C41-­‐COOH	  fully	  reduced	  to	  a	  methyl	  group)	  and	  the	  hybrid	  
C41	   methyl	   amphotronlide	   B	   (C41MeAmdeB,	   lacking	   both	   mycosamine	   and	   	   the	   C41-­‐
COOH).	   	   Deletion	   of	   the	   C41	   carboxylate	   (C41MeAmB)	   did	   not	   attenuate	   the	   antifungal	  
activity	   of	   AmB,	   however,	   both	   derivatives	   lacking	   mycosamine	   (AmdeB	   and	  
C41MeAmdeB)	   were	   completely	   inactive.9	   These	   results	   indicated	   that	   the	   C19	  
mycosamine	  was	  clearly	  required	  for	  biological	  activity	  and	  that	  the	  C41	  carboxylate	  was	  
not.9	  	  	  	  	  
	   Palacios	   et	  al.	   further	   investigated	   the	  mycosamine’s	   relationship	   to	   the	   underlying	  
cause	  of	  AmB’s	  biological	  activity.	   	  Early	  reports	  have	  underlined	  the	  fact	   that	  sterols	  are	  
necessary	  for	  AmB’s	  ability	  to	  kill	  yeast	  cells	  and	  form	  channels.7	  	  However,	  it	  was	  unclear	  
how	   the	   membrane	   embedded	   sterols	   were	   interacting	   with	   AmB.	   	   There	   are	   various	  
reports	  supporting	  indirect	  sterol	  effects,	  the	  direct	  binding	  of	  AmB	  and	  sterols,	  or	  both	  as	  
plausible	  roles	  for	  sterols.10	  Palacios	  et	  al.	  conducted	  isothermal	  titration	  calorimetry	  (ITC)	  
with	   the	   aforementioned	   AmB	   derivatives	   in	   liposomes	   embedded	   with	   and	   without	  
ergosterol.11	   A	   significant	   exotherm	   was	   observed	   with	   AmB	   and	   C41MeAmB	   in	   the	  
erosterol-­‐containing	  liposomes,	  indicative	  of	  a	  direct	  binding	  event.	  AmdeB	  and	  MeAmdeB	  
did	  not	  produce	  significant	  exotherms,	  strongly	  suggesting	  that	  the	  mycosamine	  is	  critical	  
to	   bind	   sterol	   and	   that	   this	   key	   small	   molecule-­‐small	   molecule	   interaction	   is	   absolutely	  
required	  for	  AmB’s	  biological	  activity.11	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   At	   this	  point	   two	  main	  mechanisms	  of	  action	  were	  possible:	   i)	  permeabilization	  of	  
lipid	  bilayers	  mediated	  by	  sterol	  binding	  causes	  cytotoxicity,	  or	   ii)	  sterol	  binding	  alone	   is	  
responsible	   for	   cytotoxicity	   (Fig.	  2.2	  B).	   	   In	  order	   to	  differentiate	  between	   these	  possible	  
mechanisms	  we	  needed	  to	  synthesize	  a	  derivative	  of	  AmB	  that	  maintains	  the	  ability	  to	  bind	  
ergosterol	  but	  lacks	  the	  ability	  to	  form	  channels.12	  	  	  
	   The	   hydroxyl	   group	   at	  
C35	   on	   AmB	   has	   been	  
predicted	  to	  be	  critical	  in	  the	  
formation	   of	   ion	   channels.	  
Hypothetically,	   the	   C35-­‐OH	  
stabilizes	   the	   ion	   channel	  
complex	   through	   hydrogen	  
bonding	   to	   the	   phospholipid	  
head	   groups	   (single	   barrel	  
model)	   or	   to	   another	  
octomeric	  complex	  of	  AmB	  molecules	  (double	  barrel	  model)	  (Fig.	  2.2	  C).	  If	  this	  prediction	  
were	  correct,	  an	  AmB	  derivative	  lacking	  the	  C35-­‐OH	  group	  (C35deOAmB)	  would	  be	  unable	  
to	  form	  channels.12	  	  
	  
	  
2-­‐2:	  SYNTHESIS	  OF	  C35-­‐DEOXY	  AMB	  BUILDING	  BLOCKS,	  INSPIRING	  A	  NOVEL	  








We	  synthesized	  C35deOAmB	  through	  the	  iterative	  cross-­‐coupling	  of	  three	  building	  
blocks	  BB1,	  BB2,	  and	  BB3	  (Fig.	  2.3A).	  Our	  synthetic	  strategy	  hinged	  on	  the	  synthesis	  of	  N-­‐
A B
C
Figure 2.2 A) AmB interacting with ergosterol through the mycosamine. B) AmB's 2 contributing 
mechanisms C) AmB Ion channel formation is dependant on  C35-OH in bothe single and double barrel 
models.














































methylimmino	   diacetic	   acid	   (MIDA)	   protected	   boronic	   acid	   building	   blocks.	   	   MIDA	  
boronates	   are	   inert	   to	   anhydrous	   Suzuki-­‐Miyaura	   cross-­‐coupling	   conditions,	   but	   can	   b	  
deprotected	   to	   reveal	   the	   free	   boronic	   acid	   under	  mild	   aqueous	   basic	   conditions.	   These	  
characteristics	  allow	  for	  the	  sequentially	  assembly	  of	  each	  building	  block	  (Fig.	  2.3B).12	  My	  
main	  contributions	   to	   the	  synthesis	  of	  C35deOAmB	  were	   in	   the	   large-­‐scale	  production	  of	  
BB1	  and	  BB2.	  	  BB1	  was	  derived	  via	  chemical	  degradation	  of	  the	  natural	  product.	  	  BB2	  was	  
synthesized	   via	   iterative	   Stille	   couplings,13a	   which	   required	   large	   quantities	   of	   MIDA	  
boronate	  2.1	   (Scheme	  2.1	  A).	  Large	   scale	   access	   to	   trans-­‐(2-­‐bromovinyl)	  MIDA	  boronate	  
2.1	  proved	  to	  be	  difficult	  with	  our	  synthetic	  procedure	  at	  the	  time.13b	  	  The	  first	  generation	  
synthesis	  of	  2.1,	  initiated	  with	  the	  highly	  exothermic	  addition	  of	  BBr3	  across	  acetylene	  gas.	  
The	   resulting	   intermediate	   dibromoborane	   would	   then	   need	   to	   be	   purified	   away	   from	  
polymeric	  byproducts	  via	  distillation	  under	  reduced	  pressure	  while	  ensuring	  the	  rigorous	  
exclusion	   of	   air	   and	   water.14,15	   Once	   purified	   the	   dibromoborane	   intermediate	   was	  
transferred	   to	   a	   DMSO	   suspension	   of	  
MIDA	   in	   the	   presence	   of	   2,6-­‐lutidine.	  
MIDA	   boronate	   2.1	   was	   afforded	   after	  
aqueous	  work-­‐up	  and	   chromatographic	  
purification	  (Scheme	  2.1	  B).	  	  
Difficulty	   accessing	   2.1	   in	   large	  
quantities	   inspired	   us	   to	   investigate	  
alternative	   synthetic	   methods	   for	   the	  
construction	   of	   2.1	   that	   could	   also	   be	  
employed	  to	  generate	  other	  inaccessible	  
small	   vinyl	   MIDA	   boronates.	   	   We	  
therefore	   hypothesized	   that	   the	  
interesting,	   yet	   synthetically	   challenging	  vinyl	  MIDA	  boronate	  2.3,	  would	  be	  an	  excellent	  
model	  system	  for	  this	  investigation.	  	  
Most	  MIDA	  boronates	  can	  be	  easily	  prepared	  by	  complexation	  of	  the	  corresponding	  
boronic	  acids	  with	  MIDA	  under	  Dean–Stark-­‐type	  conditions.17,18	  Alternatively,	  vinyl	  MIDA	  
boronates	   can	   be	   prepared	   through	   the	   hydroboration	   of	   alkynes,	   or	   vinyl	   Grignard	  
additions	   to	   trialkoxyboranes,	   followed	   by	   the	   same	   dean-­‐stark	   MIDA	   complexation	  
GeEt3
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2. I2, MeOH, -78 oC
3. Pd2(dba)3, Ph3As
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Scheme 2.1 A) Synthesis of all trans-trienyl-iodide MIDA boronate BB2 from trans-
bromovinyl MIDA boronate 2.1. B) First generation synthesis of trans-bromovinyl 


























conditions.	  However,	  our	  initial	  efforts	  to	  prepare	  vinyl	  MIDA	  boronate	  2.3	  using	  the	  above	  
approaches	   were	   thwarted	   by	   rapid	   decomposition	   of	   vinyl	   boronic	   acid/ester	  
intermediate19	   during	   MIDA	   complexation.	   	   A	   ‘hot	   protocol’	   was	   later	   developed	   by	   my	  
colleague	  in	  the	  context	  of	  2-­‐pyridyl	  MIDA	  boronate	  synthesis	  and	  other	  unstable	  hetero-­‐
aryl	  MIDA	  boronates.20	  	  Synthesis	  of	  these	  MIDA	  boronates	  was	  previously	  inaccessible	  due	  
to	  the	  extremely	  unstable	  nature	  of	  the	  intermediate	  2-­‐pyridyl-­‐boronic	  acids/esters.	  Here,	  
slow	  addition	  of	   the	   intermediate	   lithium	  2-­‐pyridyl-­‐trisopropoxyboronate	  salt	  was	  added	  
to	   a	   DMSO	   solution	   of	  MIDA	   at	   120	   °C,	   which	   rapidly	   facilitated	   the	   complexation	   to	   2-­‐
pyridyl	   MIDA	   boronate.20	   	   In	   principle,	   this	   operationally	   complex	   procedure	   could	  
successfully	   generate	  2.3.	  However,	   vinylmagnesium	  bromide	   is	   an	  unstable	   reagent	  and	  
unreliable	  from	  commercial	  sources,	  further	  complicating	  the	  procedure.21	  
Based	   on	   our	   prior	   experience	  
with	   the	   first	   generation	   synthesis	   of	  
2.1,	   we	   knew	   that	   vinyl-­‐
dibromoboranes	   were	   efficiently	  
trapped	   by	   MIDA	   in	   the	   presence	   of	  
exogenous	   base.	   Silicon	   to	   boron	  
transmetalation	  of	  vinyl	  silanes	  has	  also	  
been	   previously	   reported	   by	   Singleton	   and	   coworkers.16	   	   	   We	   therefore	   attempted	   to	  
prepare	  vinyl	  MIDA	  boronate	  2.3	  via	  BBr3-­‐promoted	  transmetalation16,	  22,	  23	  of	  the	  readily	  
available	  vinyltrimethylsilane	  2.4	  into	  the	  corresponding	  dibromoborane	  intermediate	  2.5,	  
16,	  23,	  24	  followed	   by	   trapping	   of	  2.5	  with	  MIDA	   in	   the	   presence	   of	   2,6-­‐lutidine	   and	  DMSO	  
(Table	  2.1,	  entry	  1).	  	  We	  were	  encouraged	  to	  observe	  the	  formation	  of	  significant	  quantities	  
of	  2.3	  using	  this	  protocol,	  yet	  important	  limitations	  still	  remained.	  Specifically,	  in	  addition	  
to	  providing	  only	  moderate	  yield,	  this	  procedure	  requires	  the	  utilization	  of	  2.0	  equivalents	  
of	  2,6-­‐lutidine	  to	  scavenge	  the	  HBr	  generated	  upon	  MIDA	  complexation.	  We	  reasoned	  that	  
alternatively	   trapping	   this	   same	  
dibromoborane	   intermediate	   2.5	   with	   the	  
pre-­‐formed	   bis-­‐sodium	   salt	   of	   MIDA	  















0 oC, 1 h
Entry Ligand Base Solvent % yield
1 MIDA 2,6-lutidine DMSO 51
2 MIDA Salt None DMSO 18
3 MIDA Salt None CH3CN 86
2.4 2.5 2.3














MeCN, 0 to 23oC
55%64%
Scheme 2.2: MIDA salt is solubilized by trimethylsilation and demonstrated 








NaBr	   as	   a	   stoichiometric	   byproduct	   and	   thereby	   obviate	   the	   use	   of	   2,6-­‐lutidine.	   This	  
approach	  was	  not	  very	  successful	  when	  using	  DMSO	  as	  solvent	  (Table	  2.1,	  entry	  2).	  	  	  
	  Switching	   to	  MeCN	   resulted	   in	   a	   robust	   and	  high-­‐yielding	   synthesis	   of	  2.3	   (Table	  
2.1,	   entry	   3).	   	   By	   employing	  MeCN	   a	   solvent,	  we	   obviated	   all	   of	   the	   procedural	   burdens	  
when	  DMSO	  is	  the	  solvent.	  	  However,	  we	  questioned	  how	  the	  MIDA-­‐MeCN	  suspension	  was	  
allowing	   complexation	   due	   to	   the	   fact	   the	   by	   1H	   NMR,	   MIDA	   and—the	   less	   soluble	  
MIDA2−Na+2	   salt—is	   completely	   insoluble	   in	   MeCN	   and	   that	   these	   conditions	   do	   not	  
translate	   to	   MIDA	  
complexation	   of	   other	  
boronic	   acid	   or	   ester	  
intermediates.	  	  	  
Through	  a	  series	  of	  1H	  
NMR	   experiments,	   I	  
discovered	   that	   the	  
stoichiometric	   byproduct	   in	   the	   SiàB	   transmetalation	   step,	   bromotrimethylsilane	   was	  
fully	  silylating	  the	  MIDA2−Na+2	  salt	  and	  responsible	  for	  solubilizing	  it	  to	  a	  small	  extent,	  thus	  
facilitating	  complexation.	   	  To	   further	  demonstrate	  the	  necessity	   for	  TMS-­‐X	   in	  MIDA2−Na+2	  
salt	   complexation	   of	   haloboranes	   in	   MeCN,	   we	   targeted	   the	   synthesis	   of	   Br-­‐B(MIDA).	  	  
Adapting	  the	  complexation	  procedure	  to	  prepare	   2.3,	  without	  the	  addition	  of	  TMS-­‐Cl,	   the	  
complexation	  of	  BBr3	  with	  MIDA2−Na+2	  salt	  in	  MeCN	  was	  not	  productive.	  	  However,	  with	  1.0	  
equivalent	   of	   TMS-­‐Cl	   under	   the	   same	   conditions,	   Br-­‐B(MIDA)	   boronate	   was	   afforded	   in	  
64%	  yield	  (Scheme	  2.2).	  	  This	  procedure	  was	  also	  amenable	  in	  the	  preparation	  H-­‐B(MIDA)	  
boronate	   from	   dibromoborane-­‐DMS	   complex	   in	   55%	   yield.	   	   However,	   these	   MIDA	  
boronates	   proved	   to	   be	   as	   inert	   as	   they	   are	   novel.	   	   Because	   the	   boron	   center	   is	  
pyramidalized,	  these	  compounds	  were	  unreactive	  at	  boron	  to	  any	  useful	  functionalization	  
condition.	  	  
	  	   Given	  the	  simple	  nature	  of	  the	  procedure	  to	  generate	  2.3,	  we	  were	  keenly	  interested	  
to	   explore	   its	   scalability.	   We	   first	   developed	   a	   convenient,	   >100	  g	   scale	   procedure	   for	  
transforming	  MIDA	  into	  the	  corresponding	  bis-­‐sodium	  salt	  via	  the	  treatment	  with	  aqueous	  
sodium	   hydroxide	   followed	   by	   a	   simple	   filtration	   procedure.	   Having	   secured	   large-­‐scale	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2.3
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to	   the	   30	  mmol	   scale	   (Scheme	   2.3).	   The	   product	   was	   purified	   by	   filtration	   and	  
recrystallization—No	  aqueous	  work-­‐up	  or	   chromatography—affording	  2.3	   as	  a	   colorless,	  
free-­‐flowing,	   crystalline	   solid.	   Single	   crystal	   X-­‐ray	   analysis	   confirmed	   the	   predicted	  
structure	  of	  2.3	  having	  a	  pyramidalized	  boron	  center.	  We	  have	  stored	  novel	  vinyl	  borane	  
2.3	   on	   the	   benchtop	   under	   air	   for	   more	   than	   3	   months	   without	   any	   noticeable	  
decomposition.	  	  
I	  then	  applied	  the	  identical	  conditons	  used	  to	  synthesize	  2.3	  to	  synthesize	  2.1.	  The	  
only	  difference	  was	   the	  use	  of	   commercially	  available	  2-­‐bromovinyl	   silane	  2.2	   instead	  of	  
vinyl	   trimethylsilane.	   	  Although	  2-­‐bromovinyl	  
silane	  2.2	  is	  typically	  prepared	  (or	  purchased)	  
as	   a	  mixture	   of	   E	   and	   Z	   isomers,	   it	   has	   been	  
previously	  observed	  that	  transmetalation	  of	  Z-­‐
alkenyl	   silanes	   with	   BBr3	   yields	  
predominantly	   the	   corresponding	   E-­‐alkenyl	  
boranes	  (E:Z	  ∼9:1)16.	  Fortuitously,	  we	  found	  that	  transmetalation	  of	  2.2	  (E:Z	  9:1)	  with	  BBr3	  
at	  0	  °C	  followed	  by	  trapping	  with	  MIDA2−Na+2	  yields	  trans-­‐(2-­‐bromovinyl)	  MIDA	  boronate	  
2.1	  as	  a	  single	  stereoisomer	  (Scheme	  2.2).	  	  We	  were	  able	  to	  run	  this	  much	  more	  convenient	  
procedure	  on	  30	  mmol	  scale	  to	  prepare	  4.8	  g	  (61%	  yield)	  of	  2.1	  in	  a	  single	  step	  without	  the	  
need	  for	  an	  aqueous	  workup	  or	  chromatographic	  purification.	  	  
	  
	  
2-­‐3:	  FUNCTIONALIZATION	  OF	  VINYL	  MIDA	  BORONATE	  
	  
With	   a	   simple	   and	   readily	   scalable	  
synthesis	  of	  2.3	  in	  hand,	  we	  have	  preliminarily	  
explored	   its	   utility	   as	   a	   starting	   material	   for	  
the	   preparation	   of	   a	   range	   of	   new	   MIDA	  
boronate	  building	  blocks.	  For	  example,	  due	  to	  
its	   sensitivity	   to	   protodeboronation,	  
cyclopropyl	  boronic	  acid	  2.6	  can	  be	  difficult	  to	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Scheme 2.4: 2nd generation synthesis of trans-bromovinyl MIDA boronate
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proceeds	   in	  excellent	  yields	  using	  Pd(OAc)2	  and	  diazomethane	  to	  yield	  cyclopropyl	  MIDA	  
boronate	  2.7	  as	  an	  air-­‐	  and	  chromatographically	  stable	  solid	  (Scheme	  2.5).	  The	  success	  of	  
this	  formal	  [2+1]	  cycloaddition	  prompted	  us	  to	  consider	  the	  related	  epoxidation	  reaction.	  
In	   pioneering	   studies,	  Molander	   and	   co-­‐workers	   have	   demonstrated	   the	   compatibility	   of	  
substituted	   alkenyltrifluoroborate	   salts	   with	   epoxidation	   mediated	   by	   DMDO.28	   mCPBA	  
was	   also	   effective	   in	   these	   studies,	   but	   the	   incompatibility	   of	   trifluoroborate	   salts	   with	  
chromatography	  precluded	   the	  separation	  of	   the	  epoxide	  products	   from	  the	  benzoic	  acid	  
byproducts.28	   In	   contrast,	   mCPBA	   promoted	   the	   epoxidation	   of	   1	   and,	   remarkably,	   the	  
resulting	  novel	  oxiranyl	  MIDA	  boronate	  2.8	  is	  stable	  to	  silica	  gel	  chromatography	  and	  can	  
be	   isolated	   in	   pure	   form.	   We	   are	   unaware	   of	   any	   prior	   synthesis	   of	   an	   unsubstituted	  
oxiranylborane.	  Single	  crystal	  X-­‐ray	  analysis	  confirmed	  unambiguously	  the	  structure	  of	  this	  
very	  interesting	  and	  potentially	  highly	  versatile	  new	  building	  block.	  	  
We	   further	  explored	  the	  compatibility	  of	  vinyl	  MIDA	  boronate	  2.3	  with	  a	  series	  of	  
transition	  metal-­‐mediated	   transformations	  of	   the	  vinyl	  handle	  (Scheme	  2.6).	  Whiting	  and	  
co-­‐workers	   have	   developed	   a	   series	   of	   selective	   Heck-­‐type	   couplings	   of	   aryl	   and	   vinyl	  
halides	   with	   sterically	   bulky	   vinyl	   boronic	   esters	   to	   generate	   styrenyl	   and	   polyenyl	  
boranes,	   respectively.29	  We	  have	   found	   that	   in	   the	  absence	  of	  water	  MIDA	  boronates	  are	  
unreactive	  toward	  cross-­‐coupling,18	  which	  led	  us	  to	  question	  whether	  it	  might	  be	  possible	  
to	   similarly	   achieve	   high	   selectivity	   for	   a	   Heck	   reaction	   between	   organohalides	   and	  2.3	  
under	   anhydrous	   conditions.	   In	   fact,	   as	   shown	   in	   Scheme	   2.6,	   p-­‐bromoacetophenone	  
readily	   coupled	   with	   2.3	   with	   to	   yield	   MIDA	   boronate	   2.9	   as	   a	   single	   regio	   and	  
stereoisomer.	  	  
The	   oxidative	   Heck	  
reaction30,31	   provides	   a	  
complementary	   opportunity	   to	  
generate	   similar	   products	   from	  
boronic	   acid	   rather	   than	  
organohalide	   starting	   materials.	  
For	   example,	   it	   has	   been	  
demonstrated	   that	   tolylboronic	  













































Scheme 2.6: Vinyl MIDA boronate 2.3 as a bifunctional building block
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manifold.7	   The	   White	   catalyst	   PdII-­‐bissulfoxide	   (2.12)32	   was	   recently	   found	   to	   be	   a	  
powerful	  and	  highly	   selective	  promoter	  of	  oxidative	  Heck	  reactions	  with	  a	  wide	  range	  of	  
aryl	  and	  alkenyl	  boranes.33	  We	  found	  that	  2.12	  also	  promotes	  the	  oxidative	  coupling	  of	  2.3	  
and	   phenylboronic	   acid	   to	   yield	   styrenyl	   MIDA	   boronate	   2.12	   as	   a	   single	   regio	   and	  
stereoisomer.	  Importantly,	  products	  2.9	  and	  2.10	  retain	  the	  capacity	  for	  subsequent	  cross-­‐
coupling	   via	   the	   MIDA	   boronate-­‐
masked	   boronic	   acid.	   In	   this	  way,	  
vinyl	   MIDA	   boronate	   2.3	  
represents	   a	   new	   type	   of	  
bifunctional	   MIDA	   boronate	  
building	  block,	   rich	  with	  potential	  
for	   a	   variety	   of	   iterative	   cross-­‐
coupling	  based	  applications.	  	  
The	   cross-­‐metathesis	   of	  
terminal	   olefins	   developed	   by	  
Grubbs	  and	  co-­‐workers	  with	  vinyl	  
or	  propenyl	  pinacol	  boronic	  esters34	  represents	  a	  powerful	  approach	  for	  the	  preparation	  of	  
alkenyl	   boranes	  with	  many	   advantages	   over	   conventional	  methods,	   including	   the	   use	   of	  
readily	   available	   and	   chemically	   robust	   terminal	   olefins	   as	   starting	   materials,	   excellent	  
functional	  group	  compatibility,	  and	  generally	  good	  yields	  and	  stereoselectivities.	  However,	  
there	  are	  some	  important	  limitations	  of	  this	  method,	  including	  instabilities	  of	  many	  alkenyl	  
pinacol	   boronic	   esters	   to	   long-­‐term	   storage	   and/or	   silica	   gel	   chromatography,34b	   and	  
suboptimal	   E:Z	   ratios	   for	   cross-­‐metathesis	  with	   some	   important	   olefin	   classes,	   including	  
unfunctionalized	  terminal	  olefins.34b	  
Given	  that	  alkenyl	  MIDA	  boronates	  are	  invariably	  stable	  to	  benchtop	  storage	  under	  
air	  and	  chromatography,	  we	  were	  attracted	  to	  the	  use	  of	  2.3	  as	  an	  alternative	  vinyl	  borane	  
for	   cross-­‐metathesis	   applications.	   Moreover,	   we	   hypothesized	   that	   the	   sterically	   bulky	  
nature	   of	   the	   MIDA	   boronate	   group	   would	   cause	   2.3	   to	   behave	   like	   a	   type	   III	   olefin35	  
(analogous	   to	   tert-­‐butylethylene),	   thereby	  avoiding	  any	  homodimerization	  and	  providing	  
high	   yields	   and	   stereoselectivities	  with	   alkenes	   of	   types	   I	   and	   II.	   Our	   initial	   experiments	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Scheme 2.7: Preliminary scope of Vinyl MIDA boronate 2.3 as a type III olefin in ruthenium cross
metathesis.
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cross-­‐metathesis	  between	  2.3	  and	  unfunctionalized	  terminal	  olefin	  1-­‐octene,	  generated	  the	  
corresponding	   octenyl	   MIDA	   boronate	   2.11	   as	   an	   air-­‐	   and	   chromatographically	   stable	  
crystalline	  solid	  in	  good	  yield	  and	  with	  a	  >20:1	  E:Z	  ratio	  (the	  Z	  isomer	  was	  not	  observed	  by	  
1H	  NMR).	  	  
A	  similar	  cross-­‐metathesis	   reaction	  using	  propenyl	  pinacol	  boronic	  ester	  has	  been	  
reported	   to	   proceed	   with	   only	   a	   9:1	   E:Z	   ratio.34b	   Moreover,	   the	   alkenyl	   pinacol	   boronic	  
ester	  products	  are	  somewhat	  unstable	  to	  silica	  gel	  chromatography.34b	  Encouraged	  by	  the	  
exceptional	  yield	  and	  stereoselectivity	  observed	  for	  the	  preparation	  of	  2.11,	  we	  decided	  to	  
preliminarily	  explore	  the	  scope	  of	  the	  cross-­‐metathesis	  with	  2.3.	  As	  shown	  in	  Scheme	  2.7,	  
this	  reaction	  is	  in	  fact	  highly	  effective	  with	  a	  range	  of	  olefin	  substrates,	  invariably	  providing	  
the	   corresponding	   alkenyl	   MIDA	   boronates	   in	   good	   to	   excellent	   yields	   and	   outstanding	  
stereoselectivities	   (all	   >20:1,	   i.e.,	   Z	   isomers	  were	   not	   observed	   by	   1H	  NMR).	   Specifically,	  
cross-­‐metathesis	  with	  allyltriisopropylsilane	  and	  a	  pair	  of	  2-­‐butenediol	  derivatives	  were	  all	  
highly	   effective,	   yielding	   a	   new	   collection	   of	   potentially	   bifunctional	   MIDA	   boronate	  
building	  blocks	  2.13,	  2.14	  and	  2.15.	  As	  is	  common	  with	  many	  cross-­‐metathesis	  reactions,	  
34,35	   increased	   substitution	   at	   the	   allylic	   position	   was	   also	   well	   tolerated	   and	   styrene	  
derivatives	   proved	   to	   be	   excellent	   substrates.	   Specifically,	   all	   the	   regioisomers	   of	  
bromostyrene	  were	  successfully	  employed	  to	  yield	  a	  series	  of	  halo	  MIDA	  boronates	   2.19,	  
2.20	   and	   2.21,	   which	   represent	   excellent	   building	   blocks	   for	   iterative	   cross-­‐coupling	  
applications.18a	  Moreover,	  given	  that	  alkenyl	  MIDA	  boronates	  can	  be	  readily	  converted	  into	  
the	   corresponding	  boronic	  acids	  under	  mild	   conditions	   (NaOH/THF	  or	  NaHCO3/MeOH)18	  
or	   used	   directly	   as	   cross-­‐coupling	   partners	   under	   aqueous	   basic	   Suzuki–Miyaura	  

































































building	   blocks	   for	   synthesis.	   	   In	   Furstner	   and	   coworker’s	   synthesis	   of	   Leiodermatolide,	  
they	  took	  advantage	  of	  vinyl	  MIDA	  boronate	  as	  a	  bifunctional	  building	  block.	  They	  installed	  
3	   with	  with	   cross-­‐metathesis	   and	   coupled	   the	   resulting	   alkenyl	  MIDA	   boronate	   building	  
block	  to	  a	  late	  stage	  complex	  vinyl	  iodide	  (Scheme	  2.8).37	  	  	  
	  
	  
Furthermore,	  MIDA	  boronate	  2.3	  is	  successfully	  cross-­‐coupled	  under	  ‘slow-­‐release’	  
Suzuki-­‐Miyaura	  conditions	   to	  a	  variety	  of	  aryl	  and	  vinyl	  chlorides	  and	  bromides	  (Scheme	  
2.9).36	   	  Because	  is	  capable	  of	  efficiently	  cross	  coupling	  with	  a	  variety	  of	  aryl	  halides,	  vinyl	  
MIDA	  boronate	  is	  arguably	  the	  most	  robust	  and	  best	  vinylating	  reagent.	  	  Additionally,	  2.3	  is	  
a	   non-­‐toxic	   crystalline	   solid	   that	   is	   easily	   synthesized	   or	   commercially	   available	   in	   bulk	  
from	  at	  least	  3	  chemical	  companies	  including	  Sigma-­‐Aldrich	  and	  Allychem.	  
	  
	  
2-­‐4:	  C35DEOAMB	  REVEALS	  AMPHOTERICIN	  B	  PRIMARILY	  BINDS	  STEROLS	  AND	  EXISTS	  
AS	  AN	  EXTRAMEMBRANEOUS	  STEROL	  SPONGE	  
	  
With	  a	  robust	  and	  scalable	  route	   to	   the	   three	  building	  blocks	   for	  C35deOAmB,	  my	  
colleagues	   assembled	   them	   via	   iterative	   Suzuki-­‐Miyaura	   cross-­‐coupling,	  
macrolactonization	   and	   global	   deprotection,	   arriving	   at	   milligram	   quantities	   of	  
C35deOAmB.12	   	   The	   synthesis	   of	   this	   complex	   derivative	   proved	   to	   be	   quite	   challenging.	  	  
Since	   removal	   of	   the	   C35-­‐OH	   engendered	  more	   conformational	   flexibility	   in	   the	   polyene	  
core,	   the	   final	   deprotection	   steps	   previously	   optimized	   and	   modeled	   on	   AmB,	   caused	  
decomposition	   in	   the	   case	   of	   C35deOAmB.	   Therefore,	   the	   optimization	   of	   the	   protecting	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Gratifyingly,	  biophysical	  studies	  revealed	  that	  C35deOAmB	  is	   incapable	  of	   forming	  
channels	  yet	   readily	  binds	  ergosterol	   (Erg).	   	   Furthermore,	  C35deOAmB	  maintains	  potent	  
fungicidal	  activity	  (MIC	  in	  S.	  cerevisiae	  3.0	  µM	  and	  0.5	  µM	  respectively).12	   	  These	  findings	  
demonstrate	  that	  AmB	  primarily	  kills	  yeast	  cells	  
by	   simply	   binding	   Erg	   (Fig.	   2.4	   A)	   and	   that	  
channel	   formation	   provides	   an	   additional	  
enhancement	   of	   cytotoxicity.	   	   However,	   the	  
structural	  and	  biophysical	  underpinnings	  of	   this	  
small	  molecule-­‐small	  molecule	  interaction	  (AmB-­‐
Erg)	   and	   its	   connection	   to	   cell	   killing	   remained	  
unclear.	  
	  Sterols,	  including	  Erg	  in	  yeast,	  have	  many	  
essential	   roles	   in	   eukaryotic	   cell	   physiology,	  
including	   functional	   regulation	   of	   membrane	  
proteins,	   micro-­‐domain	   formation,	   endocytosis,	  
vacuole	   fusion,	   cell	  division	  and	  cell	   signaling.38-­‐
41	   We	   thus	   hypothesized	   that	   sequestering	   Erg	  
and	   thereby	  concomitantly	  precluding	   its	  participation	   in	  multiple	  cellular	   functions	  may	  
underlie	   the	   fungicidal	   action	   of	   AmB.	   Guided	   by	   this	   hypothesis,	   we	   considered	   three	  
possible	  models	   for	   the	   primary	   structure	   and	   function	   of	   AmB	   in	   the	   presence	   of	   Erg-­‐
containing	  phospholipid	  membranes	  (Fig.	  2.4	  B–D):	  (i)	   in	  the	  classic	  channel	  model,	  AmB	  
primarily	   exists	   in	   the	   form	   of	   small	   (~1	   nm)	   ion	   channel	   aggregates	   inserted	   into	   the	  
membrane,	   perpendicular	   to	   the	   membrane	   surface,	   with	   Erg	   molecules	   interdigitated	  
between	  AmB	  molecules	  (Fig.	  2.4	  B)5-­‐7,42-­‐50	  (ii)	  In	  an	  alternative	  surface	  adsorption	  model,	  
AmB	  is	  primarily	  positioned	  in	  the	  intermediate–head	  group	  region,	  oriented	  parallel	  to	  the	  
plane	  of	  the	  membrane,	  sequestering	  Erg	  to	  the	  membrane	  surface	  (Fig.	  2.4	  C)7,49	  (iii)	  In	  a	  
new	  sterol	  sponge	  model,	  AmB	  primarily	  exists	  as	  large	  extramembranous	  aggregates	  that	  
extract	   Erg	   from	   lipid	   bilayers	   (Fig.	   2.4	  D).	   In	   the	   latter	   two	  models,	  we	   envisioned	   that	  
membrane-­‐permeabilizing	  ion	  channels	  represent	  relatively	  minor	  contributors	  to	  both	  the	  










































Figure 2.4 A)  AmB and C35deAmB bind sterols through the 
mycosamine.  B) Classic ion channel model. C) Surface adsorption 
model. D) A new sterol sponge model, in which AmB primarily exists 
in the form of a large extramembranous aggregates.
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cell-­‐based	   experiments	   we	   have	   deterimined	   that	   AmB	   exists	   as	   an	   extramembranous	  
sterol	  sponge	  model	  (Fig.	  2.4	  D).51	  	  
Based	  on	  the	  classic	  ion	  channel	  model,	  many	  efforts	  over	  the	  past	  several	  decades	  
to	  improve	  the	  therapeutic	  index	  of	  AmB	  have	  focused	  on	  selectively	  permeablizing	  yeast	  
versus	  human	  cells.7,42	  	  The	  sterol	  sponge	  model	  on	  the	  other	  hand	  suggests	  that	  the	  much	  
simpler	  extraction	  of	  cholesterol	  (Chol)	  by	  large	  extramembranous	  aggregates	  of	  AmB	  may	  
be	  primarily	  responsible	  for	  toxicity	  to	  human	  cells	  (Fig.	  2.4	  D).51	  	  This,	  in	  turn,	  suggests	  a	  
much	   more	   actionable	   roadmap	   to	   an	   improved	   therapeutic	   index	   that	   involves	   simply	  
maximizing	  the	  relative	  binding	  affinity	  of	  AmB	  aggregates	  for	  Erg	  versus	  Chol.	  
	  
	  
2-­‐5:	  EXPERIMENTAL	  SECTION	  
	  
Materials	  
Commercial	  reagents	  were	  purchased	  from	  Sigma–Aldrich,	  Fisher	  Scientific,	  Alfa	  Aesar,	  TCI	  
America,	   or	   Frontier	   Scientific,	   and	   were	   used	   without	   further	   purification	   unless	  
otherwise	  noted.	  Solvents	  were	  purified	  via	  passage	  through	  packed	  columns	  as	  described	  
by	   Pangborn	   and	   co-­‐workers52	   (THF,	   Et2O,	   CH3CN,	   CH2Cl2:	   dry	   neutral	   alumina;	   hexane,	  
benzene,	   and	   toluene,	   dry	   neutral	   alumina	   and	   Q5	   reactant;	   DMSO,	   DMF:	   activated	  
molecular	  sieves).	  All	  water	  was	  deionized	  prior	  to	  use.	  Triethylamine,	  diisopropylamine,	  
diethylamine,	   pyridine,	   2,6-­‐lutidine,	   and	   ethanol	   were	   freshly	   distilled	   under	   an	  
atmosphere	   of	   nitrogen	   from	   CaH2.	   Grubbs	   II	   catalyst	   (Aldrich	   569747)	   and	   Quadrasil	  
(Aldrich	  680427)	  silica	  supported	  Ru	  scavenger	  kits	   [TA	  (Aldrich	  679496),	  MTU	  (Aldrich	  
679518),	  MP	  (Aldrich	  679526),	  and	  AP	  (Aldrich	  679534)]	  were	  generous	  gifts	  from	  Sigma–
Aldrich	  (Milwaukee,	  WI).	  
	  
General	  experimental	  procedures	  
Unless	   noted,	   all	   reactions	   were	   performed	   in	   flame-­‐dried	   round-­‐bottom	   or	   modified	  
Schlenk	   flasks	   fitted	   with	   rubber	   septa	   under	   a	   positive	   pressure	   of	   argon.	   Organic	  
solutions	  were	   concentrated	   via	   rotary	   evaporation	   under	   reduced	   pressure	  with	   a	   bath	  
temperature	  of	  40	  °C.	  Reactions	  were	  monitored	  by	  analytical	   thin	   layer	  chromatography	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(TLC)	  performed	  using	  the	  indicated	  solvent	  on	  E.	  Merck	  silica	  gel	  60	  F254	  plates	  (0.25	  mm).	  
Compounds	   were	   visualized	   by	   exposure	   to	   a	   UV	   lamp	   (λ=254	  nm),	   a	   glass	   chamber	  
containing	   iodine,	   and/or	   a	   solution	  of	  KMnO4,	   an	  acidic	   solution	  of	  p-­‐anisaldehyde,	   or	   a	  
solution	  of	  ceric	  ammonium	  molybdate	  (CAM)	  followed	  by	  brief	  heating	  using	  a	  Varitemp	  
heat	   gun.	   MIDA	   boronates	   are	   compatible	   with	   standard	   silica	   gel	   chromatography,	   51	  
including	  standard	  loading	  techniques.	  For	  this	  study,	  chromatography	  was	  performed	  on	  a	  
Teledyne-­‐Isco	  CombiFlash	  Rf	  purification	  system	  using	  Merck	  silica	  gel	  grade	  9385	  (60	  Å,	  
230–400	   mesh).	   For	   loading,	   compounds	   were	   adsorbed	   onto	   Celite	   in	   vacuo	   from	   an	  
acetone	  solution.	  Specifically,	  for	  a	  1	  g	  mixture	  of	  crude	  material	  the	  sample	  is	  dissolved	  in	  
reagent	  grade	  acetone	  (25–50	  mL)	  and	  to	  the	  flask	  is	  added	  Celite	  545	  Filter	  Aid	  (5–15	  g).	  
The	  mixture	  is	  then	  concentrated	  in	  vacuo	  to	  afford	  a	  powder,	  which	  is	  then	  loaded	  on	  top	  
of	  a	  silica	  gel	  column.	  The	  procedure	  is	  typically	  repeated	  with	  a	  small	  amount	  of	  acetone	  
(5	  mL)	   and	   Celite	   (2	  g)	   to	   ensure	   quantitative	   transfer.	   Purification	   was	   generally	  
performed	  using	  a	  gradient	  of	  Et2O→Et2O/CH3CN	  3:2.	  
	  
Structural	  analysis	  
1H	  NMR	  spectra	  were	  recorded	  at	  23	  °C	  on	  one	  of	  the	  following	  instruments:	  Varian	  Unity	  
400,	  Varian	  Unity	  500,	  Varian	  Unity	  Inova	  500NB.	  Chemical	  shifts	  (δ)	  are	  reported	  in	  parts	  
per	  million	  (ppm)	  downfield	  from	  tetramethylsilane	  and	  referenced	  to	  residual	  protium	  in	  
the	  NMR	   solvent	   (CHCl3,	   δ=7.26;	   CD2HCN,	   δ=1.93,	   center	   line;	   CD3C(O)CD3δ=2.04,	   center	  
line)	  or	  to	  added	  tetramethylsilane	  (δ=	  0.00).	  Data	  are	  reported	  as	  follows:	  chemical	  shift,	  
multiplicity	   (s=singlet,	   d=doublet,	   t=triplet,	   q=quartet,	   quint=quintet,	   sept=septet,	  
m=multiplet,	  br=broad,	  app=apparent),	  coupling	  constant	  (J)	  in	  hertz	  (Hz),	  and	  integration.	  
13C	   NMR	   spectra	  were	   recorded	   at	   23	  °C	   on	   a	   Varian	   Unity	   500.	   Chemical	   shifts	   (δ)	   are	  
reported	   in	  parts	  per	  million	  downfield	   from	  tetramethylsilane	  and	  referenced	   to	  carbon	  
resonances	   in	   the	   NMR	   solvent	   (CDCl3,	   δ=77.0,	   center	   line;	   CD3CN,	   δ=1.30,	   center	   line,	  
CD3C(O)CD3δ=29.80,	  center	  line)	  or	  to	  added	  tetramethylsilane	  (δ=	  0.00).	  Carbons	  bearing	  
boron	   substituents	  were	  not	  observed	   (quadrupolar	   relaxation).	   11B	  NMR	  were	   recorded	  
using	  a	  General	  Electric	  GN300WB	   instrument	  and	  referenced	   to	  an	  external	   standard	  of	  
(BF3·Et2O).	  High-­‐resolution	  mass	  spectra	  (HRMS)	  were	  performed	  by	  Furong	  Sun	  and	  Dr.	  
Steve	  Mullen	  at	   the	  University	  of	   Illinois	   School	  of	  Chemical	   Sciences	  Mass	  Spectrometry	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Laboratory.	   Infrared	  spectra	  were	  collected	   from	  a	  thin	   film	  on	  NaCl	  plates	  (a	  solution	  of	  
each	  compound	  was	  placed	  on	  the	  salt	  plate	  and	  then	  evaporated	  to	  dryness)	  on	  a	  Perkin–
Elmer	   Spectrum	   BX	   FT-­‐IR	   spectrometer.	   Absorption	   maxima	   (νmax)	   are	   reported	   in	  
wavenumbers	   (cm−1).	  X-­‐ray	   crystallographic	  analyses	  of	  2.3	   and	  2.8	  were	   carried	  out	  by	  
Dr.	  Scott	  Wilson	  and	  Mr.	  Heath	  Timmons	  at	  the	  University	  of	  Illinois	  George	  L.	  Clark	  X-­‐ray	  
facility.	  
	  




To	  a	  500	  mL	  Schlenk	  flask	  equipped	  a	  stir	  bar	  was	  added	  BBr3	  (1.0	  M	  in	  CH2Cl2,	  30	  mmol)	  
and	   CH2Cl2	   (270	  mL)	   and	   the	   solution	   was	   cooled	   to	   0	  °C.	   To	   the	   solution	   was	   added	  
dropwise	   2-­‐bromo-­‐vinyltrimethylsilane	   2.2	   (5.0	  mL,	   33	  mmol).	   The	   stirred	   solution	   was	  
maintained	  at	  0	  °C	  for	  3	  h	  and	  then	  added	  dropwise	  via	  cannula	  to	  a	  mixture	  of	  sodium	  salt	  
6	  (10.0	  g,	  52.3	  mmol)	  in	  MeCN	  (300	  mL)	  stirred	  at	  0	  °C.	  The	  rate	  of	  addition	  was	  controlled	  
such	  that	  the	  internal	  temperature	  did	  not	  exceed	  5	  °C.	  Following	  the	  addition,	  the	  mixture	  
was	  stirred	  at	  0	  °C	  for	  30	  min	  and	  was	  then	  filtered	  through	  a	  fine	  glass-­‐fritted	  funnel.	  The	  
filter	   cake	   was	   extracted	   with	   acetone.	   The	   filtrate	   was	   concentrated	   in	   vacuo	   and	   the	  
resulting	  residue	  was	  purified	  via	  flash	  chromatography	  (SiO2,	  Et2O→Et2O/MeCN	  65:45)	  to	  
yield	  2.1	  as	  a	  colorless,	  crystalline	  solid	  (4.79	  g,	  60%).	  For	  characterization	  of	  2.1	  see	  Ref.	  












0 to 23 oC, 2 h;
MIDA Salt,
CH3CN,





























A	   50	  mL	   Schlenk	   flask	   equipped	  with	   a	   stir	   bar	  was	   charged	  with	  BBr3	   (1.0	  M	   in	  CH2Cl2,	  
30	  mmol)	   and	   the	   solution	   was	   cooled	   to	   0	  °C.	   To	   this	   solution	   was	   added	   dropwise	  
vinyltrimethylsilane	   2.4	   (4.49	  mL,	   31.5	  mmol).	   The	   solution	   was	   maintained	   at	   0	  °C	   for	  
20	  min	   and	   then	   was	   allowed	   to	   warm	   to	   23	  °C	   with	   stirring	   for	   an	   additional	   2	  h.	   The	  
resulting	  solution	  was	  added	  dropwise	  via	  cannula	  to	  a	  suspension	  of	  bis	  sodium	  MIDA	  salt	  
(5.73	  g,	  30.0	  mmol)	   in	  MeCN	  (50	  mL)	   stirred	  at	  0	   °C.	  The	   rate	  of	   addition	  was	   controlled	  
such	  that	  the	  internal	  temperature	  did	  not	  exceed	  5	  °C.	  Following	  the	  addition,	  the	  mixture	  
was	   allowed	   to	  warm	   to	   23	  °C	  with	   stirring	   for	   1	  h.	   The	   resulting	  white	   suspension	  was	  
filtered	  through	  a	  pad	  of	  Celite	  and	  the	  filter	  cake	  was	  extracted	  three	  times	  with	  acetone.	  
To	  the	  orange	  filtrate	  was	  added	  Et2O	  causing	  the	  crystallization	  of	  2.3	  as	  a	  colorless	  solid	  





1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  d	  5.96	  (dd,	  J=19.0,	  13.5	  Hz,	  1H),	  5.72–5.63	  (m,	  2H),	  4.21	  
(d,	  J=17.0	  Hz,	  2H),	  4.01	  (d,	  J=17.0	  Hz,	  2H),	  3.0	  (s,	  3H)	  
	  










0 to 23 oC, 2.5 h;
MIDA Salt,
CH3CN,










IR	  (thin	  film,	  cm−1)	  3063,	  2997,	  2960,	  1755,	  1617,	  1455,	  1420,	  1345,	  1312,	  1251,	  1175,	  
1155,	  1134,	  1117,	  1090,	  1033,	  987,	  964,	  951,	  865	  
	  
	  
HRMS	  (EI+)	  calculated	  for	  C7H10BNO4	  (M)+:	  	   183.0703	  	  
Found:	  	   	   	   	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   183.0700	  
	  
TLC	  (EtOAc)	  Rf	  =	  0.26,	  visualized	  by	  KMnO4.	  
	  
	  





To	  a	  100	  mL	  Schlenk	   flask	   equipped	  with	   a	   stir	   bar	  was	   added	  vinyl	  MIDA	  boronate	  2.3	  
(183	  mg,	   1.00	  mmol),	   Pd(OAc)2	   (9	  mg,	   0.04	  mmol),	   and	   THF	   (40	  mL).	   The	   solution	   was	  
cooled	  to	  0	  °C.	  To	  the	  solution	  was	  added	  dropwise	  diazomethane	  (0.3	  M	  in	  Et2O,	  5	  mmol,	  
freshly	  prepared)	  and	  the	  resulting	  solution	  was	  stirred	  for	  10	  min.	  To	  the	  flask	  was	  added	  
additional	  Pd(OAc)2	  (18	  mg,	  0.080	  mmol)	  and	  diazomethane	  (0.3	  M	  in	  Et2O,	  5	  mmol).	  The	  
solution	  was	  allowed	  to	  warm	  to	  23	  °C	  with	  stirring	  for	  1	  h.	  The	  solution	  was	  sparged	  with	  
N2	   and	   was	   further	   quenched	   via	   the	   addition	   of	   glacial	   acetic	   acid	   (0.5	  mL).	   The	   dark	  
mixture	   was	   concentrated	   in	   vacuo	   and	   the	   resulting	   residue	   was	   purified	   via	   flash	  


























1H	  NMR	  (500	  MHz,	  CD3CN)	  δ	  3.92	  (d,	  J=17.0	  Hz,	  2H),	  3.80	  (d,	  J=17.0	  Hz,	  2H),	  2.98	  (s,	  3H),	  
0.46	  (dq,	  J=9.5,	  3.0	  Hz,	  2H),	  0.12	  (m,	  2H),	  −0.33	  (m,	  1H)	  
	  
13C	  NMR	  (125	  MHz,	  CD3C(O)CD3)	  δ	  169.0,	  62.7,	  46.8,	  1.2	  
	  
11B	  NMR	  (96	  MHz,	  CD3CN)	  δ	  13.2	  
	  
HRMS	  (FAB+)	  calculated	  for	  C8H13BNO4	  (M+H)+:	  198.0938	  
Found:	  	   	   	   	   	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  198.0937	  
	  
IR	  (thin	  film,	  cm−1)	  2998,	  1744,	  1457,	  1358,	  1337,	  2197,	  1246,	  1129,	  1048,	  985,	  956,	  892,	  
880,	  845,	  865	  
	  
	  





A	  50	  mL	  Schlenk	  flask	  equipped	  with	  a	  stir	  bar	  was	  charged	  with	  vinyl	  MIDA	  boronate	  2.3	  
(183	  mg,	  1.00	  mmol)	  and	  CH2Cl2	  (20	  mL)	  and	  the	  resulting	  suspension	  was	  cooled	  to	  0	  °C.	  
To	  this	  suspension	  was	  added	  in	  one	  portion	  solid	  3-­‐chloroperbenzoic	  acid	  (77%	  mCPBA,	  
713	  mg,	  3.18	  mmol).	  The	  mixture	  was	  allowed	  to	  warm	  to	  23	  °C	  with	  stirring	  for	  18	  h.	  The	  
mixture	  was	  poured	  into	  a	  separatory	  funnel	  charged	  with	  satd	  aq	  NaHCO3	  (10	  mL)	  and	  the	  
mixture	  was	   diluted	  with	   EtOAc	   (40	  mL).	   The	  mixture	  was	   shaken	   and	   the	   phases	  were	  
separated.	  The	  aqueous	  phase	  was	  extracted	  with	  EtOAc	  (2×40	  mL).	  The	  combined	  organic	  
phases	  were	  washed	  with	  brine,	  dried	  over	  MgSO4,	  filtered,	  and	  concentrated	  in	  vacuo.	  The	  
resulting	   residue	  was	  purified	  via	   flash	  chromatography	   (SiO2,	  Et2O→Et2O/CH3CN	  3:2)	   to	  





















1H	  NMR	  (500	  MHz,	  acetone-­‐d6)	  δ	  4.29	  (d,	  J=17.0	  Hz,	  1H),	  4.21	  (d,	  J=17.0	  Hz,	  1H),	  4.13	  (d,	  
J=17.0	  Hz,	  1H),	  3.93	  (d,	  J=17.0	  Hz,	  1H),	  3.27	  (s,	  3H),	  2.76	  (dd,	  J=6.0,	  5.0	  Hz,	  1H),	  2.56	  (dd,	  
J=6.5,	  3.5	  Hz,	  1H),	  2.24	  (t,	  J=4.0	  Hz,	  1H)	  
	  
13C	  NMR	  (125	  MHz,	  CD3C(O)CD3)	  δ	  169.4,	  168.1,	  62.9,	  62.7,	  46.8,	  44.9	  
	  
HRMS	  (EI+)	  calculated	  for	  C7H10BNO5	  (M)+:	  199.0652	  
Found:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  199.0570	  
	  
TLC	  (EtOAc)	  Rf	  =	  0.25,	  visualized	  by	  KMnO4	  
	  
	  




In	  a	  glove	  box,	  to	  a	  20	  mL	  vial	  equipped	  with	  a	  stir	  bar	  was	  added	  vinyl	  MIDA	  boronate	  2.3	  
(183	  mg,	   1.00	  mmol),	   4-­‐bromoacetophenone	   (198	  mg,	   1.00	  mmol),	   Pd(PPh3)4	   (116	  mg,	  
0.100	  mmol),	   Ag3PO4	   (838	  mg,	   2.00	  mmol),	   and	   THF	   (5	  mL).	   The	   vial	   was	   sealed	   with	   a	  
PTFE-­‐lined	   cap,	   removed	   from	   the	   glove	   box,	   and	   maintained	   in	   a	   100	  °C	   oil	   bath	   with	  
stirring	   for	   24	  h.	   The	  mixture	   was	   concentrated	   in	   vacuo	   and	   the	   resulting	   residue	   was	  
purified	  via	  flash	  chromatography	  (SiO2,	  Et2O/MeCN)	  to	  yield	  2.9	  as	  a	  colorless,	  crystalline	  






































1H	   NMR	   (500	  MHz,	   CD3C(O)CD3)	   δ	   7.97	   (d,	   J=8.5	  Hz,	   2H),	   7.65	   (d,	   J=8.5	  Hz,	   2H),	   7.03	   (d,	  
J=18.0	  Hz,	  1H),	  6.55	  (d,	  J=18.0	  Hz,	  1H),	  4.29	  (d,	  J=17.0	  Hz,	  2H),	  4.12	  (d,	  J=17.0	  Hz,	  2H),	  3.09	  
(s,	  3H),	  2.57	  (s,	  3H)	  
	  




HRMS	  (EI+)	  calculated	  for	  C7H10BNO4	  (M)+:	  301.1122	  	  
Found:	  	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  301.1126	  
	  
	  




Under	  ambient	  atmosphere,	  to	  a	  7	  mL	  vial	  equipped	  with	  a	  stir	  bar	  was	  added	  vinyl	  MIDA	  
boronate	   2.3	   (183	  mg,	   1.00	  mmol),	   phenylboronic	   acid	   (305	  mg,	   2.50	  mmol),	   1,2-­‐
bis(phenylsulfinyl)ethane	  palladium(II)	  acetate	  2.12	   (White	  catalyst,	  25	  mg,	  0.050	  mmol),	  
benzoquinone	   (216	  mg,	   2.00	  mmol),	   glacial	   acetic	   acid	   (0.23	  mL,	   4.0	  mmol),	   and	   dioxane	  
(3.0	  mL).	  The	  vial	  was	  sealed	  with	  a	  PTFE-­‐lined	  cap	  and	  maintained	  in	  a	  45	  °C	  oil	  bath	  for	  
48	  h.	   The	   solution	  was	   concentrated	   in	   vacuo	   and	   the	   resulting	   residue	  was	   purified	   via	  
flash	   chromatography	   (SiO2,	   Et2O/CH3CN)	   to	   yield	   2.10	   as	   a	   colorless,	   crystalline	   solid	  




1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  7.51	  (d,	  J=9.0	  Hz,	  2H),	  7.33	  (m,	  3H),	  6.94	  (d,	  J=18.0	  Hz,	  
1H),	  6.35	  (d,	  J=18.5	  Hz,	  1H),	  4.25	  (d,	  J=17.0	  Hz,	  2H),	  4.07	  (d,	  J=17.0	  Hz,	  2H),	  3.05	  (s,	  3H)	  
	  




























HRMS	  (EI+)	  calculated	  for	  C13H14BNO4	  (M)+:	  259.1016	  










In	   a	   glove	  box,	   to	   a	  25	  mL	  Schlenk	   flask	   equipped	  with	   a	   stir	   bar	  was	   added	  vinyl	  MIDA	  
boronate	  2.3	  (183	  mg,	  1.00	  mmol),	  Grubbs	  II	  catalyst	  (85	  mg,	  0.10	  mmol)	  and	  olefin	  (1.50–
2.50	  mmol).	  The	  flask	  was	  sealed	  with	  a	  septum	  and	  removed	  from	  the	  glove	  box.	  To	  the	  
flask	  was	  added	  CH2Cl2	  (10	  mL).	  The	  flask	  was	  fitted	  with	  a	  water-­‐cooled	  reflux	  condenser	  
and	   the	   reaction	  was	   heated	   to	   reflux	  with	   stirring	   for	   24	  h.	   The	  mixture	  was	   cooled	   to	  
23	  °C	  and	  to	  the	  mixture	  was	  added	  400	  mg	  of	  Quadrasil	  (TA,	  MTU,	  or	  AP)	  silica	  supported	  
metal	  scavenger	  (Sigma–Aldrich),	  which	  caused	  significant	  decolorization.	  The	  mixture	  was	  
stirred	  for	  15	  min	  and	  was	  then	  concentrated	  in	  vacuo.	  The	  resulting	  residue	  was	  purified	  
via	  flash	  chromatography	  (SiO2,	  Et2O→Et2O/CH3CN	  3:2).	  The	  products	  were	  thus	  obtained	  
as	   colorless,	   crystalline	   solids.	   Some	   of	   the	   purified	   alkenyl	   MIDA	   boronate	   products	  
contained	   small	   amounts	  of	   styrenyl	  MIDA	  boronate,	   presumably	  derived	   from	   reactions	  
with	  the	  initial	  catalyst	  
	  
	  





























The	   general	   procedure	   was	   followed	   using	   1-­‐octene	   (280	  mg,	   2.50	  mmol)	   to	   yield	   2.11	  
(214	  mg,	  80%).	  	  
	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  6.07	  (dt,	  J=17.5,	  6.5	  Hz,	  1H),	  5.46	  (d,	  J=17.5	  Hz	  1H),	  4.16	  
(d,	  J=17.0	  Hz,	  2H),	  3.97	  (d,	  J=17.0	  Hz,	  2H),	  2.97	  (s,	  3H),	  2.10	  (q,	  J=7.0	  Hz,	  2H),	  1.40	  (m,	  2H),	  
1.29	  (m,	  6H),	  0.86	  (t,	  J=5.0	  Hz,	  3H)	  
	  
13C	  NMR	  (125	  MHz,	  CD3C(O)CD3)	  δ	  169.0,	  146.0,	  62.1,	  47.3,	  36.1,	  32.4,	  32.2,	  30.5,	  23.2,	  14.3	  
	  
HRMS	  (EI+)	  calculated	  for	  C13H22O4NB	  (M)+:	  267.1642	  	  
Found:	  	   	   	   	   	   	  	  	  	  267.1644	  
	  
	  




The	  general	  procedure	  was	   followed	  using	  allyltriisopropylsilane	   (496	  mg,	  2.50	  mmol)	   to	  
yield	  2.13	  (299	  mg,	  85%).	  	  
	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  6.19	  (dt,	  J=17.5,	  8	  Hz,	  1H),	  5.38	  (d,	  J=17.5	  Hz,	  1H),	  4.15	  
(d,	  J=17.0	  Hz,	  2H),	  3.93	  (d,	  J=17.0	  Hz,	  2H),	  2.97	  (s,	  3H),	  1.78	  (dd,	  J=10.0,	  1.0	  Hz,	  2H),	  1.07	  (s,	  
18H),	  1.07	  (s,	  3H)	  
	  
13C	  NMR	  (125	  MHz,	  CD3C(O)CD3)	  δ	  169.1,	  143.2,	  62.3,	  47.2,	  20.2,	  19.0,	  11.7	  
	  
HRMS	  (EI+)	  calculated	  for	  C17H32O4NSiB	  (M)+:	  353.2194	  














The	  general	  procedure	  was	  followed	  using	  cis-­‐1,4-­‐diacetoxy-­‐2-­‐butene	  (431	  mg,	  2.50	  mmol)	  
to	  yield	  2.14	  (213	  mg,	  84%).	  	  
	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  6.12	  (dt,	  J=17.5,	  5.0	  Hz,	  1H),	  5.76	  (dt,	  J=18.0,	  1.5	  Hz,	  1H),	  
4.58	   (dd,	   J=5.0,	   1.5	  Hz,	   2H),	   4.21	   (d,	   J=17.0	  Hz,	   2H),	   4.02	   (d,	   J=17.0	  Hz,	   2H),	   2.99	   (s,	   3H),	  
2.01	  (s,	  3H)	  
	  
13C	  NMR	  (125	  MHz,	  CD3C(O)CD3)	  δ	  170.6,	  168.9,	  139.8,	  66.3,	  62.3,	  47.4,	  20.7	  
	  
HRMS	  (EI+)	  calculated	  for	  C10H14O6NB	  (M)+:	  255.09142	  
Found:	  	   	   	   	   	  	  	   	  	  	  	  255.09137	  
	  
	  




The	  general	  procedure	  was	   followed	  using	  1,4-­‐dibenzoyloxy-­‐2-­‐butene	   (E:Z	  ∼1:1,	  444	  mg,	  
1.50	  mmol)	  to	  yield	  2.15	  (310	  mg,	  98%).	  
	  	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  8.05	  (d,	  J=8.5	  Hz,	  2H),	  7.63	  (tt,	  J=7.0,	  1.5	  Hz,	  1H),	  7.51	  (t,	  
J=7.5	  Hz,	   2H),	   6.28	   (dt,	   J=18.0,	   5.0	  Hz,	   1H),	   5.90	   (dt,	   J=16.0,	   1.5	  Hz,	   1H),	   4.87	   (dd,	   J=4.5,	  
1.0	  Hz,	  2H),	  4.23	  (d,	  J=17.0	  Hz,	  2H),	  4.04	  (d,	  J=17.0	  Hz,	  2H),	  3.01	  (s,	  3H)	  	  
	  
13C	   NMR	   (125	  MHz,	   CD3C(O)CD3)	   δ	   169.0,	   166.4,	   139.0,	   133.9,	   131.2,	   130.2,	   129.4,	   66.9,	  















HRMS	  (EI+)	  calculated	  for	  C15H16O6NB	  (M)+:	  317.10707	  












The	  general	  procedure	  was	  followed	  using	  vinylcyclohexane	  (165	  mg,	  1.50	  mmol)	  to	  yield	  
2.16	  (253	  mg,	  96%).	  
	  
	  1H	  NMR	   (500	  MHz,	  CD3C(O)CD3)	  δ	  6.03	   (dd,	   J=18.0,	  6.5	  Hz,	  1H),	  5.42	   (dd,	   J=18.0,	  1.5	  Hz,	  
1H),	  4.17	  (d,	  J=17.0	  Hz,	  2H),	  3.97	  (d,	  J=17.0	  Hz,	  2H),	  2.96	  (s,	  3H),	  1.99	  (m,	  1H),	  1.71	  (m,	  4H),	  
1.62	  (m,	  1H),	  1.28	  (m,	  2H),	  1.20–1.05	  (m,	  3H)	  
	  
13C	  NMR	  (125	  MHz,	  CD3C(O)CD3)	  δ	  169.1,	  151.4,	  62.1,	  47.3,	  43.7,	  43.2,	  33.2,	  26.8	  
	  
HRMS	  (EI+)	  calculated	  for	  C13H20O4NB	  (M)+:	  265.1485	  
Found:	  	   	   	   	   	   	  	  	  	  265.1488	  
	  
	  




The	  general	  procedure	  was	  followed	  using	  2-­‐methylbut-­‐3-­‐en-­‐2-­‐ol	  (215	  mg,	  2.50	  mmol)	  to	  
















1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  6.22	  (d,	  J=18.0	  Hz,	  1H),	  5.63	  (d,	  J=18.0	  Hz,	  1H),	  4.18	  (d,	  
J=17.0	  Hz,	  2H),	  3.98	  (d,	  J=17.0	  Hz,	  2H),	  3.46	  (s,	  1H),	  2.97	  (s,	  3H),	  1.23	  (s,	  6H)	  	  
	  
13C	  NMR	  (125	  MHz,	  CD3C(O)CD3)	  δ	  169.2,	  153.7,	  71.1,	  62.1,	  47.3,	  30.6	  
	  
	  




The	   general	   procedure	   was	   followed	   using	   styrene	   (260	  mg,	   2.50	  mmol)	   to	   yield	   2.18	  
(240	  mg,	  93%).	  For	  characterization	  of	  2.18,	  see	  above.	  
	  
	  




The	  general	  procedure	  was	   followed	  using	  2-­‐bromostyrene	   (275	  mg,	  1.50	  mmol)	   to	  yield	  
2.19	  (274	  mg,	  81%).	  	  
	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  7.73	  (dd,	  J=7.5,	  1.5	  Hz,	  1H),	  7.59	  (dd,	  J=8.0,	  1.0	  Hz,	  1H),	  
7.36	  (t,	  J=7.5	  Hz,	  1H),	  7.29	  (d,	  J=18.0	  Hz,	  1H),	  7.20	  (td,	  J=7.5,	  1.5	  Hz,	  1H),	  6.36	  (d,	  J=18.0	  Hz,	  
1H),	  4.29	  (d,	  J=17.0	  Hz,	  2H),	  4.11	  (d,	  J=17.0	  Hz,	  2H),	  3.09	  (s,	  3H)	  
	  
13C	  NMR	   (125	  MHz,	  CD3C(O)CD3)	  δ	  169.0,	  140.9,	  138.8,	  133.7,	  130.3,	  128.6,	  128.3,	  124.1,	  
62.4,	  47.5	  
	  




























The	  general	  procedure	  was	   followed	  using	  3-­‐bromostyrene	   (275	  mg,	  1.50	  mmol)	   to	  yield	  
2.20	  (305	  mg,	  91%).	  For	  characterization	  of	  16h	  see	  ref	  4a	  
	  
	  




The	  general	  procedure	  was	   followed	  using	  4-­‐bromostyrene	   (275	  mg,	  1.50	  mmol)	   to	  yield	  
2.21	  (240	  mg,	  93%).	  
1H	   NMR	   (500	  MHz,	   CD3C(O)CD3)	   δ	   7.52	   (d,	   J=8.5	  Hz,	   2H),	   7.47	   (d,	   J=8.5	  Hz,	   2H),	   6.91	   (d,	  
J=18.0	  Hz,	  1H),	  6.39	  (d,	  J=18.0	  Hz,	  1H),	  4.26	  (d,	  J=17.0	  Hz,	  2H),	  4.08	  (d,	  J=17.0	  Hz,	  2H),	  3.06	  
(s,	  3H)	  
	  
13C	  NMR	  (125	  MHz,	  CD3C(O)CD3)	  δ	  169.1,	  141.4,	  138.3,	  132.3,	  129.2,	  121.9,	  62.3,	  47.4	  
	  
HRMS	  (EI+)	  calculated	  for	  C13H13O4NBrB	  (M+):	  	  337.0121	  	  





















To	  a	  300	  mL	  round	  bottom	  flask	  charged	  with	  bis	  sodium	  MIDA	  salt	  (2.293	  g,	  12.0	  mmol,	  
1.2	   equiv),	  MeCN	   (100	  mL),	   and	   chlorotrimethylsilane	   (1.517	  mL,	   12.0	  mmol,	   1.2	   equiv)	  
stirred	   at	  23	   °C	   for	  1	  h	   then	   cooled	   to	  0	  °C.	  BBr3	   (1.0	  M	   in	  DCM:	  10	  mL,	  10.0	  mmol,	   1.0	  
equiv)	  was	  added	  dropwise	  into	  the	  rapidly	  stirring	  suspension	  of	  MIDA	  salt.	  Following	  the	  
addition,	   the	  mixture	   was	   allowed	   to	   warm	   to	   23	  °C	   with	   stirring	   for	   1	  h.	   The	   resulting	  
white	   suspension	  was	   filtered	   through	   a	   pad	   of	   Celite	   and	   the	   filter	   cake	  was	   extracted	  
three	  times	  with	  acetone.	  To	  the	  orange	  filtrate	  was	  added	  Et2O	  causing	  the	  crystallization	  




1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  d	  4.55	  (d,	  J=17.5	  Hz,	  2H),	  4.30	  (d,	  J=17.0	  Hz,	  2H),	  3.33	  (s,	  
3H)	  
	  







































To	  a	  300	  mL	  round	  bottom	  flask	  charged	  with	  bis	  sodium	  MIDA	  salt	  (210.0	  mg,	  1.1	  mmol,	  
1.1	  equiv),	  MeCN	  (20	  mL),	  and	  chlorotrimethylsilane	  (139	  mL,	  1.1	  mmol,	  1.1	  equiv)	  stirred	  
at	   23	   °C	   for	   1	   h	   then	   cooled	   to	   0	   °C.	   HBBr2-­‐DMS	   complex	   (1.0	  M	   in	   DCM:	   120	  mL,	   10.0	  
mmol,	   1.0	   equiv)	  was	   added	   dropwise	   into	   the	   rapidly	   stirring	   suspension	   of	  MIDA	   salt.	  
Following	  the	  addition,	  the	  mixture	  was	  allowed	  to	  warm	  to	  23	  °C	  with	  stirring	  for	  1	  h.	  The	  
resulting	   white	   suspension	   was	   filtered	   through	   a	   pad	   of	   Celite	   and	   the	   filter	   cake	   was	  
extracted	   three	   times	   with	   acetone.	   To	   the	   orange	   filtrate	   was	   added	   Et2O	   causing	   the	  




1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  d	  4.21	  (d,	  J=17.5	  Hz,	  2H),	  4.02	  (d,	  J=17.0	  Hz,	  2H),	  3.16	  (s,	  
3H)	  
	  
TLC	  (EtOAc)	  Rf	  	  =	  0.21,	  visualized	  by	  KMnO4.	  
	  
HRMS	  (EI+)	  calculated	  for	  C5H7O4NB	  (M+):	  	  	   156.04682	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CHAPTER	  3:	  INVESTIGATING	  THE	  ATOMISTIC	  UNDERPINNINGS	  OF	  AMB-­‐STEROL	  
BINDING	  INTERACTION	  
	  
3-­‐1:	  AMB	  PRIMARILY	  KILLS	  CELLS	  BY	  BINDING	  STEROLS	  
	  
For	  half	   a	   century,	  AmB	  has	  widely	  been	  
accepted	   to	   kill	   both	   yeast	   and	   human	   cells	  
through	   ion	   channel-­‐mediated	   membrane	  
permeabilization.1-­‐3	   These	   results	   have	   been	  
interpreted	  through	   the	   lens	   of	   the	   ion	   channel	  
model.	   As	   a	   consequence,	   little	   progress	   has	  
been	   made	   toward	   solving	   the	   challenging	  
problem	   of	   selectively	   forming	   ion	   channels	   in	  
yeast	  vs.	  human	  cells.2,3	  
Through	  our	  synthesis	  of	  C35deOAmB	  we	  
recently	   determined	   that	   AmB	   kills	   yeast	  
primarily	   by	   simply	   binding	   sterols.	   Ergosterol	  
(Erg),	  the	  main	  sterol	  in	  yeast	  has	  many	  essential	  
roles	   in	  eukaryotic	  cell	  physiology,	   including	  functional	  regulation	  of	  membrane	  proteins,	  
microdomain	   formation,	   endocytosis,	   vacuole	   fusion,	   cell	   division	   and	   cell	   signaling.4-­‐7	  
Based	  on	  a	  series	  of	  SSNMR	  and	  TEM	  experiments	  we	  have	  reported	   that	  AmB	  primarily	  
exists	   in	  the	   form	  of	   large	  extramembraneous	  aggregates	  that	  kill	  yeast	  by	  extracting	  Erg	  
from	  lipid	  bilayers	  (Fig.	  3.1	  A).	  8c	  	  
These	  results	  indicate	  that	  channel	  formation	  is	  not	  primarily	  responsible	  for	  killing	  
yeast8c.	   This	   realization	   strongly	   suggests	   that	   binding	   cholesterol	   (Chol)	   may	   account	  
primarily	   for	   the	   toxicity	   of	   AmB	   to	   human	   cells.	   Moreover,	   efforts	   to	   improve	   its	  
therapeutic	  index	  should	  focus	  directly	  on	  the	  relatively	  simpler	  problem	  of	  maximizing	  the	  
binding	  affinity	  for	  Erg	  over	  Chol.8	  
	   Palacios	  et	  al.	  previously	  reported	  that	  the	  mycosamine	  is	  critical	   for	  sterol	  binding.	  	  
Deletion	   of	   the	   mycosamine	   from	   AmB	   eliminates	   its	   capacity	   to	   bind	   both	   sterols.8b	  	  



































Figure 3.1 A) AmB primarily exists as a 'sterol sponge' sequestering 
Erg (green).  Channel formation occurs and contributes minimally.  B) 





undefined.	  There	  are	   four	  heteroatomic	   functional	  groups	   in	   the	  mycosamine	  appendage,	  
C2’-­‐OH,	  C3’-­‐NH3+,	  C4’-­‐OH,	  and	   the	  oxygen	  contained	   in	   the	   tetrahydropyran	  ring.	   	  One	  or	  
more	  of	  these	  heteroatomic	  functional	  groups	  might	  participate	  in	  a	  polar	  interaction	  with	  
the	  3β-­‐hydroxyl	  group	  of	  each	  sterol	  (Fig.	  3.1	  B).	  Computational	  models	  and	  NMR	  studies	  
have	   indicated	   that	  AmB	   interacts	  with	  both	  Erg	   and	  Chol	   via	   a	   similar	   binding	  mode	   in	  
which	   either	   the	   C2’-­‐OH	   or	   C3’-­‐NH3+	   group	   of	   AmB	   form	   a	   critical	   H-­‐bond	   to	   the	   3β-­‐
hydroxyl	  group	  of	   the	  A-­‐ring	  of	   the	   sterol	   (Fig.	  3.1	  B)9.	  To	   test	   these	  binding	  models,	  we	  
initially	  aimed	  to	  remove	  the	  C2′-­‐OH	  from	  AmB	  and	  determine	   its	   impact	  on	  binding	  Erg	  
and	  Chol.10,11	  	  	  
Synthesis	   of	   the	   targeted	   C2′deoxy	   AmB	   (C2′deOAmB),	   however,	   represented	   a	  
major	  challenge.	  This	   is	  because,	   in	  addition	   to	  all	  of	   the	  other	  problems	  associated	  with	  
chemically	  manipulating	   this	   complex	   and	   sensitive	   natural	   product,	   2-­‐deoxy	   sugars	   are	  
substantially	  more	  acid-­‐sensitive	  than	  their	  oxygenated	  counterparts.12	  
	  
3-­‐2:	  SITE-­‐SELECTIVE	  ACYLATION	  OF	  THE	  C2’-­‐OH	  	  
	  
To	   access	   C2’deOAmB	  we	   initially	   employed	   a	   site-­‐selective	   deoxygenation	   of	   the	  
decahydroxylated	   natural	   product.	   This	   led	   to	   the	   discovery	   that	   site-­‐selective	   and	   site-­‐
divergent	  functionalizations	  can	  be	  achieved	  simply	  by	  modifying	  the	  electronic	  properties	  
of	   achiral	   reagents.10	   My	   colleague	   Dr.	   Brandon	   Wilcock	   discovered	   that	   under	   DMAP	  
catalyzed	   conditions,	   the	   acylation	   selectivity	   for	   the	   C2’-­‐OH	   over	   the	   other	   hydroxyl	  
groups	   increased	   with	   more	   electronically	   rich	   acyl	   chloride	   donors.	   For	   example,	   the	  
acylation	   of	   3.1	  with	   electron	   poor	   p-­‐nitrobenzoyl	   chloride	   and	   DMAP	   resulted	   in	   39%	  
yield	  of	  the	  C2’	  acylated	  product.	  In	  comparison,	  the	  yield	  increases	  when	  the	  electron	  rich	  
p-­‐N,N-­‐dimethylaminobenzoyl	   chloride	   is	   employed,	   affording	   the	   C2’	   product	   in	   72%	  
yield.10	  	  	  
We	   hypothesized	   that	   this	   phenomenon	  was	   linked	   to	   the	   Hammond	   postulate,13	  
which	  predicts	  that	  the	  transition	  state	  of	  the	  acylation	  reaction	  will	  become	  more	  product-­‐
like	  as	   the	   reaction	  becomes	   less	  exothermic.	   In	  a	  more	  product-­‐like	   transition	  state,	   the	  
site-­‐discriminating	   interactions	   between	   the	   acylating	   complex	   and	   substrate	   will	   be	  
 40 
magnified	   leading	   to	   increased	   site-­‐selectivity.	   Thus,	  Dr.	  Wilcock	   observed	   that	   electron-­‐
rich	   acyl	   donors	   created	   a	   milder	   catalyst-­‐reagent	   complex,	   which	   resulted	   in	   a	   less	  
exothermic	   reaction	   with	   greater	   site	  
selectivity	  (Fig.	  3.2).10	  
Harnessing	   this	   phenomenon	  
into	   a	   preparatively	   useful	   procedure	  
we	   achieved	   the	   site-­‐selective	  
acylation	   of	   the	   C2’-­‐OH	   of	   AmB	   3.2.	  	  
Following	  silylation	  of	  the	  remaining	  4	  
hydroxyl	   groups	   with	   DEIPS	   groups	  
(3.3),	   the	   C2’-­‐benzoyl	   group	   was	  
hydrolyzed	   with	   KCN	   revealing	   the	  
free	  C2’-­‐OH	  3.4.	  	  We	  then	  proceeded	  to	  
functionalize	  the	  free	  C2’-­‐OH	  3.4	  by	  conversion	  to	  the	  C2’-­‐I	  3.5	  and	  further	  reduction	  to	  the	  
C2’-­‐methylene	   3.6.	   	   I	   converted	   the	   free	   C2’-­‐OH	   3.4	   into	   intermediates	   en	   route	   to	  
C2’epiAmB	  3.7	  and	  a	  C2’Erg	  conjugate	  3.8	  (Scheme	  3.1).	  
	  
With	   C2’-­‐methylene	  3.6	   in	   hand	  we	   proceeded	  with	   the	   final	   global	   deprotection	  
steps.	   However,	   once	   the	   C2’-­‐OH	   group	   is	   removed,	   the	   subsequent	   glycosidic	  
intermediates	   are	   significantly	   less	   stable	   compared	   to	   the	   parent	   natural	   product.	   As	   a	  
result	  the	  final	  deprotection	  steps	  resulted	  in	  a	  low	  yield	  of	  C2′deOAmB	  as	  an	  inseparable	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Figure 3.2: The Hammond postulate applied to site-selective acylation. More electron-rich acyl 
donors are predicted to react via a later, more product-like transition state magnifying the site-
discriminating interactions between the substrate and the acylating reagent. The magnified 
interactions increase the difference between activation energies generating greater selectivity.
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In	   an	   attempt	   to	   circumvent	   the	   issues	   with	   the	   current	   deprotection	   steps,	   we	  
investigated	   other	   protecting	   groups,	   namely	   at	   the	   C3’-­‐nitrogen.	   Since	   amides	   require	  
forcing	  conditions	  to	  remove,	  i.e.	  strong	  base	  or	  strong	  nucleophiles/hydrides,	  carbamates	  
were	   a	   logical	   alternative.	   Although	   they	   are	   easily	   removed	   under	   a	   variety	   of	   mild	  
conditions	   (depending	   on	   the	   carbamate),	   their	   presence	   at	   the	   C3’-­‐position	   completely	  
prevented	  the	  AgOAc	  mediated	  NaBH4	  de-­‐iodination	  of	  the	  neighboring	  C2’-­‐I	  3.5.	  	  
	  With	   this	   knowledge,	   we	   proceeded	   to	   investigate	   new	   amides	   that	   would	  
potentially	  allow	  for	  
both	   the	   de-­‐
iodination	   of	   the	  
C2’-­‐I	   3.5	   and	   their	  
own	   mild	   removal	  
in	   the	   final	   step	  
(scheme	   3.2).	  
Several	   derivatives	  
were	   synthesized	  
(3.9	   and	   3.10	   and	  
3.11).	  We	   had	   predicted	   that	   steric	   constraints	  would	   position	   the	   tethered	   nucleophile	  
directly	  over	  the	  π*	  orbital	  of	  the	  amide	  carbonyl	  prior	  to	  activation.	  	  However,	  these	  acyl	  




3-­‐3:	  HYBRID	  SYNTHESIS	  OF	  C2’DEOAMB	  
	  
	  Although	  the	  site-­‐selective	  acylation	  route	  in	  its	  present	  form	  is	  unable	  to	  produce	  
assayable	   quantities	   of	   C2’deOAmB,	   extensive	   knowledge	   was	   gained	   during	   these	  
studies11.	  Not	  only	  would	  it	  inform	  future	  plans	  to	  mycosamine	  modified	  derivatives	  by	  it	  
also	   bolstered	   an	   alternative	   semisynthetic	   approach	   that	   was	   more	   productive	   and	  





























1. HF-pyridine, MeOH:THF 
    0 to 23 oC 6 h 38%
2. KOH MeCN, 30 oC, 6 h, 32%
3. CSA, THF:H2O 0 oC 3 h, 15%
4. penicillin G amidase 37 oC
    48 h, yield N.D.
Scheme 3.2: A) Deprotection conditions for 2.6 to generate C2'deOAmB. B) New N-protecting groups were ineffective 


















glycosylation	   of	   the	   AmB	   aglycone	   with	   a	   mycosamine	   analog	   lacking	   the	   C2’-­‐OH	  
(acosamine).	  	  This	  route	  was	  beneficial	  because	  it	  1)	  obviated	  the	  robust	  protecting	  groups	  
required	  in	  the	  first-­‐generation	  route,	  and	  2)	  it	  was	  highly	  convergent.	  	  The	  C2-­‐deoxy	  sugar	  
donor	   3.12	   was	   synthesized	   from	   2-­‐acylfuran	   and	   the	   aglycone	   3.13	   was	   derived	   from	  
AmB.	  	  	  
	  
When	  C2’deOAmB	  was	   initially	   targeted	   in	  2006,	   this	  hybrid	  route	  was	  disfavored	  
out	   based	   on	   synthetic	   access	   to	   the	   C2-­‐deoxy	   sugar	   donor	   3.12.	   A	   paucity	   of	  
methodological	   progress	   toward	   β-­‐selective	   glycosylation	   in	   the	   absence	   of	   a	   C2’-­‐
substituent	  presented	  a	   further	  challenge14.	   	  Normally	   these	  types	  of	  β-­‐glycosylations	  are	  
carried	   out	  with	   participating	   groups	   located	   at	   the	   C2-­‐position	   of	   the	   sugar	   donor.	   For	  
example,	  Nicolaou15,16	  and	  coworkers	  have	  synthesized	  β-­‐glycosides	  with	  amphoteronolide	  
B	  substrates	  using	  anchimeric	  assistance	  from	  the	  neighboring	  equatorial	  group	  at	  the	  C2’-­‐
position	  followed	  by	  inversion	  at	  the	  C2	  position. In the case of a C2-deoxysugar this method 
is not an option to 
achieve β-selective 
glycosylation. 
Although	   the	  
glycosylation	   step	  
was	   still	   a	   concern,	  
we	  were	  encouraged	  
by	   the	   report	   of	   a	  
highly	  efficient	  and	  scalable	  epoxy-­‐alcohol	  3.14	   synthesis	  by	  O’Doherty	  and	  coworkers17.	  
































Figure 3.3: Retrosynthesis of C2'deOAmB from sugar donor 2.12 and aglycone 2.13
Scheme 3.3. Hybrid synthesis of C2'deOAmB from epoxyalcohol 2.14.
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We	  first	  generated	  a	  C2′-­‐deoxygenated	  mycosamine	  (L-­‐acosamine)	  donor	  3.12	  from	  
known	  intermediate	  3.14	  (Scheme	  3.3)17.	  I	  determined	  that	  the	  TBS-­‐protected	  derivative	  of	  
this	   2,3-­‐epoxy	   alcohol	   (3.15)	   can	   be	   regioselectively	   opened	   at	   C2’	   using	   lithium	  
triethylborohydride	   in	   THF	   at	   60	   °C	   affording	   3.16	   in	   58%	   yield.	   The	   resulting	   β-­‐C3’-­‐
alcohol	   of	  was	  mesylated	   to	   generate	  2.17	   in	   68%	   yield.	   Displacement	   of	   the	   secondary	  
mesylate	   group	   by	   sodium	   azide	   provided	  3.18	   (80%	   yield).	   Subsequent	   removal	   of	   the	  
PMB	   group	   generated	   the	   deoxysugar	   donor	  3.12	   (65%	   yield).	   Importantly,	   deoxysugar	  
donor	  3.12	  is	  protected	  in	  such	  a	  way	  that	  the	  functional	  groups	  at	  C3′	  and	  C4′	  are	  inert	  to	  
all	   of	   the	   subsequently	   required	   transformations	   yet	   readily	   unmasked	   at	   the	   end	  of	   the	  
synthesis	   using	   mild	   conditions15.	   We	   also	   prepared	   a	   similarly	   protected	   macrolide	  
acceptor	  3.13,	  having	  suitably	  stable	  yet	  readily	  cleavable	  silyl	  groups,	  protecting	  all	  of	  the	  
seven	   secondary	   hydroxyl	   groups	   and	   the	   C41	   carboxylic	   acid.	   Glycosylation	   of	  
persilylated-­‐aglycone	  3.13	  with	  deoxysugar	  donor	   3.12	  proceeded	   to	  yield	   the	  protected	  
C2′deOAmB	  derivative	  3.19	  as	  a	  2:1	  mixture	  of	  α	  and	  β	  anomers.	  	  This	  molecule	  proved	  to	  
be	   much	   more	   amenable	   to	   the	   requisite	   deprotection	   conditions	   than	   in	   the	   previous	  
generation	  allowing	  synthetic	  access	  to	  C2′deOAmB	  (Scheme	  3.3).10	  	  
	  
	  
3-­‐4:	  THE	  C2’-­‐OH	  IS	  NOT	  REQUIRED	  TO	  BIND	  ERGOSTEROL	  BUT	  IS	  CRITICAL	  FOR	  
CHOLESTEROL	  BINDING	  
	  
	   With	  C2’deOAmB	  in	  hand,	  we	  then	  went	  on	  to	  assay	  its	  ability	  to	  bind	  Erg	  and	  Chol.	  	  
via	   an	   optimized	   isothermal	   titration	   calorimetry	   (ITC)-­‐based	   assay	   with	   1-­‐palmitoyl-­‐2-­‐
oleoyl-­‐sn-­‐glycero-­‐3-­‐phosphocholine	  (POPC)	  large	  unilamellar	  vesicles	  (LUVs).	  Surprisingly,	  
C2’deOAmB	  had	  a	   significant	   exotherm	   in	  Erg	   containing	  LUVs	  demonstrating	  a	   retained	  
capacity	   for	   this	   derivative	   to	   bind	   Erg	   (Fig.	   3.4).	   	   Even	   more	   surprisingly,	   C2′deOAmB	  
showed	  no	  evidence	  of	  binding	  Chol	  in	  the	  analogous	  experiment	  (Fig.	  3.4	  A).	  	  Therefore,	  in	  
contrast	   to	   the	  computational	  modeling	  studies,	   the	  C2′-­‐OH	  of	  AmB	  plays	  a	  major	  role	   in	  
binding	  Chol	  but	  is	  not	  required	  to	  bind	  Erg.11	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When	   we	   tested	   the	   minimum	   inhibitory	   concentration	   (MICs)	   of	   C2′deOAmB	  
against	   two	   Erg-­‐containing	   strains	   of	   yeast,	   S.	   cerevisiae	   and	   C.	   albicans	   (the	   latter	  
representing	  the	  most	  common	  cause	  of	  fungal	  infections	  in	  humans),	  we	  observed	  potent	  
antifungal	  activity	   (Fig.	  3.4	  B).	  Finally	  we	  probed	   the	  activity	  against	  human	  cells.	  One	  of	  
the	  most	  prevalent	  toxic	  side	  effects	  associated	  with	  AmB	  is	  anemia	  caused	  by	  damage	  to	  
red	  blood	  cells.	  	  AmB	  causes	  90%	  hemolysis	  of	  human	  red	  blood	  cells	  at	  8.5μM	  (MHC)	  (Fig.	  
3.4	  C).	  In	  stark	  contrast,	  we	  found	  the	  corresponding	  MHCs	  for	  C2′deOAmB,	  which	  does	  not	  
bind	  Chol	  in	  our	  ITC	  assay,	  to	  be	  >500μM.11	  	  Consistent	  with	  the	  lack	  of	  toxicity	  to	  human	  
red	   blood	   cells,	   human	   renal	   epithelial	   cells	   were	  
also	   found	   to	   be	   viable	   after	   being	   exposed	   to	  
C2’deOAmB.	  	  With	  these	  exciting	  results	  in	  hand	  we	  
have	   pursued	   a	   scaled	   up	   synthesis	   of	   C2’deOAmB	  
in	  order	  to	  determine	  this	  derivative’s	  viability	  as	  a	  
potential	   therapeutic	   replacement	   for	   AmB.	   	   In	  
order	   to	   do	   this,	   I	   recently	   prepared	   more	   of	   this	  
material	   to	   preliminarily	   assay	   its	   efficacy	   and	  
toxicity	  in	  a	  C.	  albicans	  infected	  mouse	  model.18	  	  
These	   findings	  collectively	  demonstrate	   that	   the	   leading	  atomistic	  model	   for	  AmB-­‐
sterol	  binding	  (Fig.	  3.1	  B)	  is	  not	  correct.9	  We	  favor	  an	  alternative	  model	  in	  which	  the	  C2′-­‐
OH	  is	  potentially	  involved	  in	  the	  stabilization	  of	  a	  conformer	  of	  AmB	  that	  readily	  binds	  both	  
Erg	   and	   Chol.	   We	   hypothesize	   that	   deletion	   of	   the	   C2’-­‐OH	   favors	   a	   shift	   to	   a	   different	  
conformer	  or	  set	  of	  conformers	  which	  retain	  the	  capacity	  to	  bind	  Erg	  but	  not	  Chol	  due	  to	  
the	  bulkier	  nature	  of	  the	  latter	  (Fig.	  3.5).	  This	  model	  predicts	  deletion	  of	  the	  C2′-­‐OH	  of	  AmB	  






Figure 3.4 A) ITC binding data, B) MIC data, C) MHC and MTC  data 
against human red blood cells (RBC) and human renal epithelial cells 


















Figure 3.5 A) Allosteric model illustrating a shift in ligand binding selectivity between Erg (green) and Chol (blue). B) X-ray cystal structure 
of N-IodoAcyl AmB showing C2'-OH interacting with C13-OH through a molecule of water.
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Although	   further	   studies	   are	   required	   to	   test	   this	   hypothesis,	   we	   note	   that	   in	   the	   X-­‐ray	  
crystal	  structure	  of	  N-­‐iodoacyl	  AmB20	  there	  is	  a	  prominent	  water-­‐bridged	  H-­‐bond	  between	  
the	  hydroxyl	  groups	  at	  C2′	  and	  C13	  that	  may	  serve	  to	  stabilize	  a	  particular	  conformation	  or	  
conformations	  of	   the	  mycosamine	  relative	  to	   the	  macrolide	  core	  that	   is	  able	   to	  bind	  both	  
sterols	  (Fig.	  3.5	  B).	  
	  
	  
3-­‐5:	  EXPERIMENTAL	  SECTION	  
	  
General	  Methods	  Materials	  
Amphotericin	  B	  was	  a	  gift	  from	  the	  Bristol-­‐Myers	  Squibb	  Company.	  All	  other	  commercially	  
available	   reagents	   were	   obtained	   from	   Sigma-­‐Aldrich,	   TCI	   America,	   Fischer	   Scientific,	  
Combi-­‐	   Blocks	   Inc.,	   and	   Oakwood	   Products.	   Chemicals	   were	   used	   without	   further	  
purification	  unless	  otherwise	   specified.	   Camphorsulfonic	   acid	  was	  purified	  before	  use	  by	  
recrystallization	  with	  ethyl	  acetate.	  Triethyl	  amine,	  diisopropylethyl	  amine,	  pyridine,	  and	  
2,6-­‐lutidine	   were	   freshly	   distilled	   over	   calcium	   hydride	   under	   nitrogen	   atmosphere.	   All	  
solvents	   were	   obtained	   from	   a	   solvent	   purification	   system	   utilizing	   packed	   columns	   as	  
described	  by	  Pangborn	  and	  coworkers.21	  
	  
Reactions	  
All	  reactions	  were	  performed	  under	  argon	  atmosphere	  in	  low	  light	  conditions	  with	  flame-­‐
dried	  glassware	  unless	  otherwise	  indicated.	  All	  compounds	  were	  stored	  in	  the	  dark	  under	  
argon	  atmosphere.	  Thin	  layer	  chromatography	  or	  reverse	  phase	  HPLC	  was	  used	  to	  monitor	  
reaction	  progress.	  Thin	  layer	  chromatography	  was	  performed	  on	  silica	  gel	  60	  F254	  plates	  
from	  Merck	  with	  the	  indicated	  solvent.	  Visualization	  of	  the	  compounds	  was	  accomplished	  
with	  a	  UV	  lamp	  (λ254)	  and	  ceric	  ammonium	  molybdate	  (CAM)	  stain.	  Analytical	  HPLC	  was	  
done	  on	  an	  Agilent	  1100	  Series	  HPLC	  with	  a	  C18	  5	  μm,	  4.6	  x	  150	  mm,	  Symmetry®	  column	  
from	  Waters	  Corp	  at	  a	  flow	  rate	  of	  1	  mL/min	  with	  the	  indicated	  solvent	  and	  gradient.	  The	  





Purification	  and	  Analysis	  
Merck	   silica	   gel	   60	   230-­‐400	   mesh	   and	   SiliCycle	   reverse	   phase	   C18	   (17%)	   40-­‐63	   μm	   60	  
angstrom	   silica	   gel	  was	   used	   for	   flash	   chromatography	  with	   the	   indicated	   solvent.	  HPLC	  
reverse	  phase	  purification	  was	  done	  on	  a	  waters	  C18	  5	  μm,	  30	  x	  150	  mm	  Sunfire	  column	  at	  a	  
flow	  rate	  of	  25	  mL/min	  with	  the	  indicated	  solvent	  and	  gradient.	  The	  detection	  wavelength	  
was	  set	   to	  383	  nm.	  1H	  NMR	  spectra	  were	  taken	  at	  23	  °C	  on	  a	  Varian	  Unity	   Inova	  Narrow	  
Bore	   spectrometer	   at	   101a	   1H	   frequency	   of	   500	   MHz	   with	   a	   Varian	   5	   mm	   1H{13C/15N}	  
pulsed-­‐field	  gradient	  Z	  probe.	  Chemical	  shifts	  (δ)	  are	  reported	  in	  parts	  per	  million	  (ppm)	  
downfield	  from	  tetramethylsilane	  and	  referenced	  internally	  to	  the	  residual	  protium	  in	  the	  
NMR	   solvent	   (CHD2OD,	   δ	   =	   3.30,	   center	   line;	   CD3C(O)CHD2,	   δ	   =	   2.04,	   center	   line;	  
CD3S(O)CHD2,	  δ	  =	  2.50,	  center	  line;	  CCl3H,	  δ	  =	  7.26,	  center	  line).	  Data	  is	  reported	  as	  follows:	  
chemical	  shift,	  multiplicity	  (s	  =	  singlet,	  d	  =	  doublet,	  t	  =	  triplet,	  dd	  =	  doublet	  of	  doublets,	  td	  =	  
triplet	  of	  doublets,	  m	  =	  multiplet,	  b	  =	  broad,	  app	  =	  apparent),	  coupling	  constant	  (J)	  in	  Hertz	  
(Hz)	   and	   integration.	   13C	   spectra	   were	   obtained	   at	   23	   °C	   with	   a	   Varian	   Unity	   Inova	  
spectrometer	  at	  a	  13C	  frequency	  of	  125	  MHz	  with	  a	  5	  mm	  Nalorac	  gradient	  {13C/15N}1H	  
quad	   probe.	   Chemical	   shifts	   (δ)	   are	   reported	   downfield	   of	   tetramethylsilane	   and	   are	  
referenced	   to	   the	   carbon	   resonances	   in	   the	   NMR	   solvent	   (CD3OD,	   δ	   =	   49.0,	   center	   line;	  
CD3C(O)CD3,	  δ	  =	  29.8,	  center	  line;	  CD3S(O)CD3,	  δ	  =	  39.5,	  center	  line;	  CDCl3,	  δ	  =	  77.0,	  center	  
line).	   ESI	   high-­‐resolution	  mass	   spectra	   (HRMS),	   ESI	   low	   resolution	  mass	   spectra	   (LRMS)	  
and	   matrix-­‐assisted	   laser	   desorption/ionization	   (MALDI)	   spectra	   were	   obtained	   at	   the	  
















Phenyl	  acetic	  acid	  (662	  mg,	  1.62	  mmol,	  3.0	  equiv)	  was	  dissolved	  in	  THF	  (30	  mL).	  Trimethyl	  
acetyl	  chloride	  (400	  μL,	  3.25	  mmol,	  2.0	  equiv)	  was	  added	  followed	  by	  triethyl	  amine	  (900	  
μL,	  6.46	  mmol,	  4	  equiv).	  The	  reaction	  was	  allowed	  to	  stir	  for	  8	  hours	  at	  room	  temperature.	  
The	  reaction	  was	  placed	  in	  an	  ice	  bath,	  and	  DMSO	  (30	  mL)	  was	  added	  over	  2	  minutes	  as	  it	  
cooled.	  Once	  the	  reaction	  reached	  0	  °C,	  AmB	  (1.5	  g,	  1.62	  mmol,	  1.0	  equiv)	  was	  added.	  The	  
yellow-­‐tan	  suspension	  slowly	  became	  soluble	  over	  90	  minutes	  stirring	  at	  0	  °C.	  The	  reaction	  
was	  poured	   slowly	   into	   rapidly	   stirring	  diethyl	   ether	   (1.8	  L)	   at	  0	   °C.	  After	  15	  minutes	  of	  
stirring,	   the	   resulting	   yellow	   precipitate	   was	   vacuum	   filtered	   with	   a	   Buchner	   funnel	  
equipped	  with	  Whatman	  50	  filter	  paper	  and	  washed	  3	  times	  with	  diethyl	  ether	  (200	  mL).	  
The	  yellow	  powder	  was	  dried	  under	  vacuum	  for	  8	  hours.	  
	  
The	   powder	   was	   then	   suspended	   in	   THF:MeOH	   1:1	   (60	   mL)	   and	   cooled	   to	   0	   °C.	  
Camphorsulfonic	   acid	   (94	   mg,	   405	   μmol,	   0.25	   equiv)	   was	   added,	   and	   the	   yellow-­‐tan	  
suspension	   slowly	   became	   soluble	   over	   45	  minutes	   of	   stirring	   at	   0	   °C.	   The	   reaction	  was	  
quenched	  by	  triethyl	  amine	  (57	  μL,	  405	  μmol,	  0.25	  equiv)	  at	  0	  °C.	  The	  reaction	  solution	  was	  
concentrated	   by	   approximately	   2/5	   by	   rotary	   evaporation	   and	   poured	   into	   diethyl	  
ether:hexane	   1:1	   (1.2	   L)	   while	   stirring	   rapidly.	   After	   stirring	   15	   minutes,	   the	   yellow	  
precipitate	  was	  collected	   in	  a	  Buchner	   funnel	  equipped	  with	  Whatman	  50	   filter	  paper	  by	  
vacuum	   filtration.	   The	  precipitate	  was	  washed	  3	   times	  with	  diethyl	   ether	   (200	  mL).	   The	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The	   powder	   was	   suspended	   in	   THF	   (60	   mL)	   and	   cooled	   to	   0	   °C.	   Freshly	   distilled	  
diazomethane	   (8.10	   mmol,	   5	   equiv)	   was	   added	   drop	   wise	   to	   the	   suspension	   over	   20	  
minutes	  at	  0	   °C.	  The	  reaction	  was	  allowed	  to	  stir	   for	  30	  additional	  minutes	  at	  0	   °C.	  After	  
quenching	  with	  acetic	  acid	  (8.10	  mmol,	  5	  equiv)	  at	  0	  °C,	  the	  solution	  was	  then	  concentrated	  
under	   reduced	  pressure	   and	  purified	   by	   flash	   chromatography	   (SiO2;	  DCM:MeOH	  9:1)	   to	  




TLC	  (DCM:MeOH	  9:1)	  Rf	  =	  0.2,	  stained	  by	  CAM	  
	  
HPLC	  Rt	  =	  18.1	  min;	  flow	  rate	  =	  1mL/min,	  gradient	  =	  5	  →	  95	  %	  MeCN	  in	  water	  over	  30	  min.	  
	  
1H	  NMR	  (500	  MHz,	  pyridine	  d-­‐5:CD3OD	  10:1)	  δ	  9.01	  (d,	  J	  =	  8.5	  Hz,	  1H),	  7.53	  (m,	  2H),	  7.25	  
(m,	  3H),	  6.58-­‐6.32	  (m,	  12H),	  6.23	  (m,	  1H),	  5.69	  (m,	  2H),	  4.95	  (m,	  1H),	  4.90	  (s,	  1H),	  4.83	  (m,	  
1H),	  4.67	  (m,	  2H),	  4.46	  (m,	  2H),	  4.38	  (app	  d,	  J	  =	  3	  Hz,	  1H),	  4.17	  (m,	  1H),	  4.01	  (m,	  2H),	  3.86	  
(m,	  2H),	  3.74	  (m,	  5H),	  3.56	  (m,	  1H),	  3.26	  (s,	  3H),	  2.94	  (m,	  1H),	  2.84	  (t,	  J	  =	  10.5	  Hz,	  1H),	  2.69	  
(m,	  2H),	  2.54	  (m,	  1H),	  2.31-­‐1.81	  (m,	  13	  H),	  1.72	  (m,	  1H),	  1.57	  (d,	  J	  =	  6	  Hz,	  3H),	  1.44	  (d,	  J	  =	  6	  
Hz,	  3H),	  1.32	  (d,	  J	  =	  6.5	  Hz,	  3H),	  1.24	  (d,	  J	  =	  7	  Hz,	  3H)	  
	  
13C	   NMR	   (125	  MHz,	  pyridine	  d-­‐5:CD3OD	  10:1)	  δ	  174.4,	  174.2,	  172.3,	  171.9,	  137.9,	  137.5,	  
134.8,	   134.7,	   134.3,	   134.2,	   133.8,	   133.7,	   133.6,	   133.5,	   133.1,	   132.9,	   132.4,	   130.5,	   130.1,	  
129.1,	  127.3,	  102.3,	  99.4,	  78.2,	  75.8,	  75.7,	  75.4,	  75.0,	  72.1,	  71.4,	  71.0,	  68.5,	  67.8,	  67.7,	  67.1,	  
57.8,	  56.8,	  52.2,	  45.2,	  44.1,	  43.8,	  43.6,	  42.1,	  36.6,	  31.0,	  19.2,	  18.9,	  18.0,	  12.8.	  
	  
HRMS	  (ESI)	  Calculated	  for	  C57H83NO18	  (M	  +	  Na)+:	   1092.5508	  	  

























To	   a	   suspension	   of	   SI3.1	   (1.50	   g,	   1.40	  mmol,	   1.0	   equiv)	   in	  MeOH:THF	   2:1	   (17	  mL)	  was	  
added	  anisaldehyde	  dimethyl	  acetal	  (2	  mL)	  followed	  by	  camphorsulfonic	  acid	  (81	  mg,	  0.35	  
mmol,	  0.25	  equiv).	  The	  solution	  was	  stirred	   for	  20	  min.	  The	  reaction	  was	  quenched	  with	  
triethylamine	  drop	  wise	  until	  the	  dark	  tan	  solution	  underwent	  a	  color	  change	  to	  light	  tan.	  
The	   reaction	  was	   poured	   into	   saturated	   sodium	   bicarbonate	   and	   extracted	   3	   times	  with	  
ethyl	   acetate.	   The	   organic	   layers	   were	   washed	   with	   water	   followed	   by	   a	   wash	   with	  
saturated	   sodium	   chloride.	   The	   organic	   layers	   were	   combined	   and	   dried	   over	   sodium	  
sulfate,	   filtered,	   and	   concentrated	   under	   reduced	   pressure.	   Flash	   chromatography	   (SiO2;	  
EtOAc:Hexane:MeOH	   77:20:3)	   purification	   yielded	  3.1	   as	   a	   yellow-­‐	   orange	   solid	   (1.10	   g,	  
0.84	  mmol,	  60	  %).	  
	  
	  
TLC	  (EtOAc:Hexane:MeOH	  77:20:3)	  Rf	  	  =	  0.25,	  stained	  by	  CAM	  
	  
HPLC	  Rt=	  15.4	  min;	  flow	  rate	  =	  1mL/min,	  gradient	  =	  5%	  MeCN	  in	  water	  for	  2	  min	  then	  5	  →	  
































































1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  7.42	  (m,	  2H),	  7.35	  (m,	  4H),	  7.29	  (m,	  2H),	  7.21	  (m,	  2H),	  
6.86	  (m,	  4H),	  6.43-­‐6.20	  (m,	  12H),	  5.88	  (m,	  1H),	  5.58	  (m,	  1H),	  5.51	  (s,	  1H),	  5.46	  (s,	  1H),	  5.26	  
(m,	  1H),	  4.64	  (m,	  1H),	  4.58	  (app	  s,	  1H),	  4.20-­‐4.10	  (m,	  2H),	  4.02	  (m,	  1H),	  3.95-­‐3.86	  (m,	  3H),	  
3.78	  (m,	  6H),	  3.75	  (m,	  2H),	  3.66	  (s,	  3H),	  3.63	  (m,	  1H),	  3.45	  (m,	  2H),	  3.36	  (m,	  1H),	  3.30	  (m,	  
2H),	  3.05	  (s,	  3H),	  2.57	  (m,	  1H),	  2.40	  (m,	  1H),	  2.31-­‐2.24	  (m,	  3H),	  1.96	  (m,	  1H),	  1.89-­‐1.45	  (m,	  
9H),	  1.37	  (m,	  2H),	  1.22	  (m,	  4H),	  1.19	  (d,	  J	  =	  6	  Hz,	  3H),	  1.17	  (m,	  1H),	  1.11	  (d,	  J	  =	  6.5	  Hz,	  3H),	  
1.01	  (d,	  J	  =	  7.5	  Hz,	  3H)	  
	  
13C	  NMR	   (125	  MHz,	  CD3C(O)CD3)	  δ	  173.6,	  172.7,	  169.7,	  160.6,	  160.5,	  137.5,	  136.9,	  136.2,	  
134.1,	   134.0,	   133.9,	   133.7,	   133.6,	   133.5,	   132.9,	   132.6,	   132.5,	   132.2,	   129.9,	   129.8,	   128.9,	  
128.3,	   128.2,	   127.2,	   120.9,	   117.6,	   113.8,	   101.0,	   100.7,	   100.6,	   98.1,	   81.1,	   77.9,	   76.2,	   74.7,	  
74.4,	  73.2,	  73.1,	  72.9,	  72.8,	  70.7,	  70.5,	  67.2,	  66.9,	  57.3,	  56.4,	  55.4,	  51.8,	  48.6,	  43.4,	  43.3,	  42.6,	  
41.8,	  41.5,	  37.8,	  36.8,	  33.8,	  33.2,	  28.7,	  18.7,	  18.0,	  17.4,	  11.8.	  
	  
HRMS	  (ESI)	  Calculated	  for	  C73H95NO20	  (M	  +	  Na)+:	   1328.6369	  	  
Found:	   	   	   	   	   	   	   1328.6388	  
	  
	  




THF	  (160	  mL)	  was	  added	   to	  a	   flask	  containing	  3.1	   (6.16	  g,	  4.72	  mmol,	  1.0	  equiv).	  DMAP	  
(922	  mg)	  was	  added	  to	  a	  separate	  flask	  and	  dissolved	  in	  THF	  (100	  mL).	  4-­‐tertbutylbenzoyl	  
chloride	   (1.29	   mL,	   6.60	   mmol,	   1.4	   equiv)	   was	   added	   drop	   wise	   to	   the	   DMAP	   solution	  













































solution	  of	  3.1.	  A	  portion	  of	   the	  white	  suspension	  was	   then	   transferred	  drop	  wise	   to	   the	  
solution	   of	  3.1	   and	   DIPEA	   (over	   approximately	   1	   h)	   until	   the	  majority	   of	  3.1	   had	   been	  
consumed	  as	  evidenced	  by	  TLC.	  The	  reaction	  was	  pored	  into	  EtOAc	  and	  washed	  with	  water	  
followed	  by	  saturated	  sodium	  bicarbonate.	  Two	  more	  washes	  with	  water	  were	  performed	  
followed	  by	  a	  wash	  with	  saturated	  sodium	  chloride.	  The	  organic	  layer	  was	  then	  dried	  over	  
sodium	  sulfate	  and	  filtered.	  The	  solvent	  was	  removed	  under	  reduced	  pressure	  and	  column	  
chromatography	  (SiO2;	  EtOAc:Hexane:MeOH	  60:37:3)	  purification	  yielded	  3.2	  as	  a	  yellow-­‐




TLC	  (EtOAc:Hexane:MeOH	  60:37:3)	  Rf	  =	  0.22,	  stained	  by	  CAM	  
	  
HPLC	  Rt	  =	  19.4	  min;	  flow	  rate	  =	  1mL/min,	  gradient	  =	  5%	  MeCN	  in	  water	  for	  2	  min	  then	  5	  →	  
54%	  MeCN	  in	  water	  over	  3	  min	  then	  54	  →	  95%	  MeCN	  in	  water	  over	  13	  min.	  
	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  7.99	  (d,	  J	  =	  8.5	  Hz,	  2H),	  7.59	  (d,	  J	  =	  8.5	  Hz,	  2H),	  7.39	  (m,	  
3H),	   7.34	   (m,	   2H),	   7.23	   (m,	   2H),	   7.17	   (m,	   2H),	   7.12	   (m,	   1H),	   6.85	   (m,	   4H),	   6.39-­‐6.13	   (m,	  
10H),	  6.07	  (m,	  1H),	  5.92	  (m,	  1H),	  5.76	  (m,	  1H),	  5.68	  (m,	  1H),	  5.56	  (m,	  1H),	  5.48	  (s,	  1H),	  5.43	  
(s,	  1H),	  5.14	  (m,	  1H),	  4.88	  (app	  s,	  1H),	  4.65	  (m,	  1H),	  4.24	  (m,	  1H),	  4.15	  (m,	  2H),	  3.97	  (m,	  
1H),	  3.91-­‐3.82	  (m,	  2H),	  3.77	  (s,	  6H),	  3.68	  (m,	  5H),	  3.51	  (m,	  2H),	  3.47	  (m,	  1H),	  3.40	  (m,	  2H),	  
2.84	  (s,	  3H),	  2.54	  (m,	  1H),	  2.41	  (m,	  1H),	  2.27	  (m,	  1H),	  2.13	  (m,	  1H),	  1.95	  (m,	  1H),	  1.86	  (m,	  
1H),	  1.78-­‐1.42	   (m,	  10H),	  1.40-­‐	  1.31	   (m,	  13H),	  1.30-­‐1.19	   (m,	  2H),	  1.18	   (d,	   J	  =	  6.5	  Hz,	  3H),	  























13C	  NMR	   (125	  MHz,	  CD3C(O)CD3)	  δ	  172.7,	  171.1,	  169.2,	  165.3,	  160.1,	  160.0,	  156.7,	  137.1,	  
136.4,	   136.3,	   133.6,	   133.5,	   133.4,	   133.3,	   133.2,	   133.1,	   132.5,	   132.1,	   132.0,	   131.2,	   131.1,	  
130.0,	   129.4,	   128.3,	   127.7,	   126.5,	   125.6,	   120.7,	   113.3,	   100.5,	   96.1,	   80.5,	   77.2,	   75.7,	   74.1,	  
73.1,	  72.6,	  72.4,	  71.7,	  70.6,	  66.4,	  66.2,	  57.2,	  54.8,	  54.1,	  51.3,	  47.9,	  43.0,	  42.7,	  41.9,	  40.9,	  37.2,	  
36.3,	  35.1,	  33.4,	  32.6,	  30.8,	  17.8,	  17.4,	  11.3.	  
	  
	  
HRMS	  (ESI)	  Calculated	  for	  C84H107NO21	  (M	  +	  Na)+:	  	   1488.7233	  	  
Found:	   	   	   	   	   	   	   1488.7212	  
	  




3.2	  (2.30	  g,	  1.57	  mmol,	  1.0	  equiv)	  was	  azeotropically	  dried	  with	  acetonitrile	  and	  left	  under	  
vacuum	   overnight.	   DCM	   (40	   mL)	   was	   added	   followed	   by	   hexane	   (40	   mL)	   slowly	   while	  
stirring	   to	  prevent	  3.2	   from	  crashing	  out	  of	  solution.	  2,6-­‐lutidine	  (2.4	  mL,	  20.4	  mmol,	  13	  
equiv)	   was	   added	   and	   the	   solution	   was	   cooled	   to	   0	   °C.	   Diethylisopropylsilyl	   triflate	  
(DEIPSOTf)	  (2.5	  mL,	  12.5	  mmol,	  8.0	  equiv)	  was	  added	  drop	  wise	  at	  0	  °C	  over	  20	  min.	  The	  
reaction	  was	  stirred	  for	  an	  additional	  30	  min.	  The	  reaction	  was	  diluted	  with	  diethyl	  ether	  
and	  quenched	  with	  saturated	  sodium	  bicarbonate	  at	  0	  °C.	  The	  reaction	  was	  extracted	  with	  
diethyl	   ether	   and	   washed	   with	   1.0	   M	   copper	   sulfate	   until	   no	   white	   precipitate	   was	  
observed.	  The	  organic	  layers	  were	  washed	  twice	  with	  water	  and	  then	  once	  with	  saturated	  
sodium	  chloride.	  The	  organic	  layers	  were	  then	  dried	  over	  sodium	  sulfate	  and	  filtered.	  The	  












































EtOAc:Hexane	   1:9	  →	   1:4)	   purification	   yielded	  3.3	   as	   a	   yellow-­‐orange	   solid	   (2.24	   g,	   1.13	  




TLC	  (EtOAc:Hexane	  1:3)	  Rf	  =	  0.25,	  stained	  by	  CAM	  
	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  8.01	  (d,	  J	  =	  8.5	  Hz,	  2H),	  7.63	  (d,	  J	  =	  8.5	  Hz,	  2H),	  7.34	  (m,	  
4H),	  7.22	  (m,	  3H),	  7.17	  (m,	  3H),	  6.84	  (m,	  4H),	  6.35-­‐6.13	  (m,	  9H),	  6.04	  (m,	  1H),	  5.91	  (m,	  1H),	  
5.74	  (m,	  2H),	  5.49	  (m,	  1H),	  5.41	  (s,	  1H),	  5.39	  (s,	  1H),	  4.92	  (app	  s,	  1H),	  4.75	  (m,	  1H),	  4.66	  (m,	  
1H),	  4.31	  (m,	  1H),	  4.25	  (m,	  1H),	  4.12	  (m,	  1H),	  3.84	  (m,	  1H),	  3.81-­‐3.77	  (m,	  9H),	  3.68	  (m,	  4H),	  
3.64	  (s,	  3H),	  3.57-­‐	  3.45	  (m,	  3H),	  2.74	  (s,	  3H),	  2.45	  (m,	  2H),	  2.26	  (m,	  1H),	  2.17	  (m,	  1H),	  2.09	  
(m,	  1H),	  1.90	  (m,	  2H),	  1.73-­‐1.59	  (m,	  4H),	  1.51-­‐1.34	  (m,	  18H),	  1.26-­‐1.11	  (m,	  6H),	  1.08-­‐0.76	  
(m,	  54H),	  0.73-­‐	  0.39	  (m,	  19H).	  
	  
13C	  NMR	   (125	  MHz,	  CD3C(O)CD3)	  δ	  173.1,	  171.1,	  169.8,	  165.9,	  160.7,	  157.4,	  138.2,	  136.5,	  
134.6,	   134.4,	   134.2,	   133.9,	   133.8,	   133.4,	   132.8,	   132.7,	   132.5,	   132.1,	   131.1,	   130.7,	   130.6,	  
130.2,	   129.0,	   128.9,	   128.8,	   128.6,	   128.2,	   127.1,	   126.2,	   121.3,	   117.9,	   115.1,	   113.8,	   113.7,	  
101.7,	  100.9,	  100.5,	  96.6,	  81.3,	  75.6,	  74.7,	  73.7,	  73.2,	  72.9,	  72.7,	  72.6,	  68.6,	  66.6,	  58.1,	  55.4,	  
54.5,	  51.8,	  48.3,	  43.4,	  41.0,	  37.9,	  36.8,	  35.7,	  31.4,	  19.0,	  18.0,	  17.9,	  17.8,	  17.7,	  17.6,	  17.4,	  14.0,	  
13.8,	  13.4,	  7.7,	  7.6,	  7.5,	  7.4,	  7.1,	  5.1,	  4.8,	  4.7,	  4.6,	  4.4,	  4.1.	  
	  
HRMS	  (ESI)	  Calculated	  for	  C112H171NO21Si4	  (M	  +	  Na)+:	  	   	   2001.1318	  	  




























3.3	   (550	  mg,	   278	   μmol,	   1.0	   equiv)	  was	   dissolved	   in	   THF:MeOH	  1:2	   (13.5	  mL),	   and	  KCN	  
(27.0	  mg,	  417	  μmol,	  1.5	  equiv)	  was	  added.	  The	  reaction	  was	  heated	  to	  40	  °C	  for	  2	  days.	  The	  
reaction	  was	  diluted	  with	  diethyl	  ether	  and	  washed	  with	  water	  three	  times	  followed	  by	  a	  
wash	  of	  saturated	  sodium	  chloride.	  The	  organic	  layers	  were	  dried	  over	  sodium	  sulfate	  and	  
filtered.	   The	   solvent	  was	   removed	   under	   reduced	   pressure	   and	   column	   chromatography	  
(SiO2;	  EtOAc:Hexane	  1:4	  →	  3:7)	  purification	  yielded	  3.4	  as	  a	  yellow-­‐orange	  solid	  (329	  mg,	  




TLC	  (EtOAc:Hexane	  3:7)	  Rf	  =	  0.22,	  stained	  by	  CAM	  
	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  7.35	  (m,	  6H),	  7.29	  (m,	  2H),	  7.22	  (m,	  1H),	  6.93	  (d,	  J	  =	  9.5	  
Hz,	  1H),	  6.85	  (m,	  4H),	  6.40-­‐6.17	  (m,	  11H),	  6.09	  (m,	  1H),	  5.82	  (m,	  1H),	  5.77	  (m,	  1H),	  5.43	  (s,	  
1H),	  5.42	  (s,	  1H),	  4.80	  (m,	  1H),	  4.62	  (m,	  1H),	  4.60	  (app	  s,	  1H),	  4.23	  (m,	  1H),	  4.15	  (m,	  1H),	  
3.98	  (m,	  1H),	  3.85	  (m,	  3H),	  3.78	  (m,	  7H),	  3.71	  (m,	  4H),	  3.66	  (m,	  2H),	  3.62	  (s,	  3H),	  3.58-­‐3.50	  
(m,	  2H),	  3.32	  (m,	  1H),	  3.02	  (s,	  3H),	  2.48	  (m,	  1H),	  2.42	  (m,	  1H),	  2.29-­‐2.19	  (m,	  3H),	  1.95-­‐1.87	  
(m,	  3H),	  1.74	  (m,	  2H),	  1.62-­‐	  1.28	  (m,	  7H),	  1.24-­‐1.15	  (m,	  7H),	  1.04-­‐0.76	  (m,	  56H),	  0.72-­‐0.50	  





























































13C	  NMR	   (125	  MHz,	  CD3C(O)CD3)	  δ	  173.4,	  170.8,	  169.9,	  160.8,	  160.6,	  137.2,	  136.9,	  134.6,	  
134.5,	   134.1,	   133.9,	   133.8,	   133.6,	   133.2,	   132.7,	   132.6,	   132.2,	   130.9,	   130.3,	   129.5,	   129.1,	  
128.7,	  128.3,	  127.3,	  121.3,	  117.9,	  113.9,	  113.8,	  110.6,	  101.8,	  101.1,	  100.8,	  98.5,	  81.4,	  75.9,	  
75.0,	  74.7,	  74.6,	  73.4,	  73.0,	  72.8,	  71.5,	  68.8,	  67.1,	  57.7,	  55.8,	  55.5,	  52.0,	  48.5,	  43.8,	  43.0,	  41.2,	  
37.9,	  36.7,	  33.5,	  32.7,	  28.1,	  18.9,	  18.0,	  17.9,	  17.8,	  17.4,	  14.0,	  13.9,	  13.8,	  13.5,	  7.7,	  7.6,	  7.5,	  7.2,	  
5.1,	  4.9,	  4.7,	  4.6,	  4.4,	  4.1.	  
	  
HRMS	  (ESI)	  Calculated	  for	  C101H159NO20Si4	  (M	  +	  Na)+:	   	   1841.0430	  	  
Found:	   	   	   	   	   	   	   	   1841.0464	  
	  
	  




3.4	   (350	   mg,	   192	   μmol,	   1.0	   equiv),	   triiodoimidazole	   (130	   mg,	   288	   μmol,	   1.5	   equiv),	  
triphenylphosphine	   (152	  mg,	  378	  μmol,	   3.0	   equiv),	   and	   imidazole	   (60	  mg,	  866	  μmol,	   4.5	  
equiv)	  were	  placed	  in	  a	  flask	  and	  dissolved	  in	  toluene	  (9.6	  mL).	  The	  reaction	  was	  heated	  to	  
70	   °C	   for	   3	   h.	   The	   reaction	   was	   diluted	   with	   diethyl	   ether	   and	   washed	   with	   saturated	  
sodium	   bicarbonate	   followed	   by	   water	   four	   times.	   A	   final	   wash	   of	   saturated	   sodium	  
chloride	   was	   performed,	   and	   the	   organic	   layers	   were	   dried	   over	   sodium	   sulfate	   and	  
filtered.	   The	   solvent	  was	   removed	   under	   reduced	   pressure	   and	   column	   chromatography	  
(SiO2;	  EtOAc:Hexane	  3:17)	  purification	  yielded	  3.5	  as	  a	  yellow-­‐	  orange	  solid	  (296	  mg,	  154	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TLC	  (EtOAc:Hexane	  3:7)	  Rf	  =	  0.55,	  stained	  by	  CAM	  
	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  7.38-­‐7.28	  (m,	  9H),	  7.22	  (m,	  1H),	  6.86	  (m,	  4H),	  6.40-­‐6.09	  
(m,	  12H),	  5.83	  (m,	  2H),	  5.43	  (s,	  1H),	  5.41	  (s,	  1H),	  4.79	  (m,	  1H),	  4.69	  (app	  d,	  J	  =	  7.5	  Hz,	  1H),	  
4.57	  (m,	  1H),	  4.28	  (m,	  1H),	  4.15	  (m,	  1H),	  4.04	  (m,	  1H),	  3.89	  (m,	  1H),	  3.84	  (m,	  1H),	  3.77	  (m,	  
7H),	  3.72	  (m,	  3H),	  3.65	  (s,	  3H),	  3.57	  (m,	  2H),	  3.40	  (m,	  1H),	  3.05	  (s,	  3H),	  2.51-­‐2.40	  (m,	  2H),	  
2.25	  (m,	  3H),	  2.00	  (m,	  1H),	  1.88	  (m,	  2H),	  1.74	  (m,	  2H),	  1.62-­‐1.40	  (m,	  7H),	  1.31-­‐1.15	  (m,	  9H),	  
1.07-­‐0.76	  (m,	  58H),	  0.72-­‐	  0.50	  (m,	  13H),	  0.44-­‐0.36	  (m,	  4H).	  
	  
13C	  NMR	   (125	  MHz,	  CD3C(O)CD3)	  δ	  172.5,	  169.3,	  160.6,	  160.2,	  160.0,	  158.4,	  137.5,	  134.2,	  
134.1,	   133.9,	   133.6,	   133.4,	   133.2,	   132.9,	   132.5,	   132.1,	   132.0,	   131.9,	   131.3,	   130.2,	   130.0,	  
128.3,	  128.1,	  127.7,	  126.8,	  113.3,	  113.2,	  102.1,	  101.3,	  100.5,	  100.1,	  94.2,	  80.8,	  76.3,	  75.4,	  
74.4,	  74.0,	  72.5,	  72.2,	  68.1,	  66.7,	  57.0,	  54.8,	  51.4,	  47.9,	  43.8,	  43.4,	  42.5,	  40.6,	  37.3,	  36.8,	  32.9,	  
27.5,	  18.1,	  17.4,	  17.3,	  17.2,	  16.8,	  13.4,	  13.2,	  12.9,	  7.1,	  7.0,	  6.9,	  6.6,	  4.5,	  4.3,	  4.2,	  4.1,	  3.8,	  3.6.	  
	  
HRMS	  (ESI)	  Calculated	  for	  C101H158NO19Si4I	  (M	  +	  Na)+:	   	   1950.9448	  
































3.5	   (320	   mg,	   166	   μmol,	   1.0	   equiv)	   was	   placed	   in	   a	   vial	   and	   azeotropically	   dried	   with	  
toluene	  and	  placed	  under	  vacuum	  overnight.	  The	  vial	  was	  backfilled	  with	  argon	  and	  DMPU	  
(6.6	   mL)	   was	   added.	   Sodium	   borohydride	   (50	   mg,	   1.33	   mmol,	   8.0	   equiv)	   and	   silver(I)	  
acetate	  (42	  mg,	  249	  μmol,	  1.5	  equiv)	  was	  added	  in	  a	  glovebox.	  The	  reaction	  was	  heated	  in	  
the	  range	  of	  50-­‐55	  °C	  for	  3	  h.	  After	  3	  h,	  an	  aliquot	  was	  removed	  in	  the	  glovebox	  every	  30	  
min	  to	  monitor	  the	  reaction	  by	  TLC.	  The	  reaction	  was	  allowed	  to	  run	  to	  approximately	  85	  
%	  conversion	  until	  the	  rate	  of	  decomposition	  exceeded	  conversion	  of	  the	  starting	  material.	  
The	  reaction	  was	  cooled	  to	  room	  temperature	  and	  then	  diluted	  with	  dry	  diethyl	  ether	  that	  
had	  been	   cooled	   to	  0	   °C.	   The	   reaction	  was	  quenched	  with	   saturated	   sodium	  bicarbonate	  
cooled	  to	  0	  °C.	  Room	  temperature	  diethyl	  ether	  was	  used	  to	  extract	  the	  aqueous	  layer.	  The	  
organic	  layer	  was	  then	  washed	  with	  water	  twice.	  A	  final	  wash	  of	  saturated	  sodium	  chloride	  
was	   performed,	   and	   the	   organic	   layers	  were	   dried	   over	   sodium	   sulfate	   and	   filtered.	   The	  
solvent	   was	   removed	   under	   reduced	   pressure	   and	   column	   chromatography	   (SiO2;	  
EtOAc:Hexane	  3:17)	  purification	  yielded	  3.6	  as	  a	  yellow-­‐orange	  solid	  (89.8	  mg,	  49.8	  μmol,	  
30	  %).	  
	  
This	  reaction	  is	  quite	  sensitive	  to	  water	  and	  air.	  DMPU	  was	  obtained	  from	  Aldrich	  absolute	  
over	  molecular	  sieves	  H2O	  ≤	  0.03%.	  The	  product	  is	  unstable	  to	  the	  reaction	  conditions	  and	  
decomposes	   over	   time;	   the	   best	   yields	   are	   obtained	   by	   stopping	   the	   reaction	   before	  
complete	  conversion	  is	  reached.	  The	  reaction	  was	  found	  to	  be	  dependent	  upon	  the	  identity	  
of	  the	  protecting	  group	  on	  the	  C3’	  amine.	  Extensive	  elimination	  or	  inactivity	  was	  observed	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TLC	  (EtOAc:Hexane	  1:3)	  Rf	  =	  0.47,	  stained	  by	  CAM	  
	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  7.40-­‐7.33	  (m,	  9H),	  7.26	  (m,	  1H),	  6.87	  (m,	  4H),	  6.42-­‐6.06	  
(m,	  12H),	  5.70	  (m,	  2H),	  5.46	  (s,	  1H),	  5.44	  (s,	  1H),	  4.69	  (app	  d,	  J	  =	  5	  Hz,	  1H),	  4.97	  (m,	  1H),	  
4.23	  (m,	  3H),	  3.93	  (m,	  1H),	  3.82-­‐	  3.70	  (m,	  10H),	  3.66	  (m,	  4H),	  3.58	  (m,	  2H),	  3.39	  (m,	  1H),	  
3.17	  (m,	  1H),	  3.04	  (s,	  3H),	  2.63	  (m,	  2H),	  2.42	  (m,	  1H),	  2.30	  (m,	  3H),	  1.98	  (m,	  1H),	  1.88	  (m,	  
1H),	  1.76-­‐1.34	  (m,	  10H),	  1.29-­‐1.14	  (m,	  8H),	  1.05-­‐0.76	  (m,	  59H),	  0.72-­‐0.50	  (m,	  13H),	  0.44-­‐
0.36	  (m,	  4H).	  
	  
13C	  NMR	   (125	  MHz,	  CD3C(O)CD3)	  δ	  173.6,	  170.0,	  160.8,	  160.7,	  136.9,	  134.6,	  134.3,	  133.6,	  
136.4,	   133.0,	   132.6,	   132.5,	   130.0,	   129.4,	   128.7,	   128.4,	   127.6,	   113.9,	   113.8,	   102.0,	   101.2,	  
81.7,	  80.9,	  76.5,	  75.2,	  73.4,	  73.1,	  55.5,	  51.7,	  44.1,	  43.8,	  42.7,	  41.5,	  37.9,	  33.6,	  32.6,	  28.5,	  18.0,	  
17.9,	  17.8,	  17.6,	  17.4,	  13.9,	  13.5,	  7.7,	  7.6,	  7.5,	  7.4,	  7.2,	  4.8,	  4.7,	  4.4,	  4.2.	  
	  
HRMS	  (ESI)	  Calculated	  for	  C101H159NO19Si4	  (M	  +	  Na)+:	   1825.0481	  	  
































3.5	  (18.2	  mg,	  10	  μmol,	  1.0	  equiv),	  triphenylphosphine	  (4.0	  mg,	  15	  μmol,	  1.5	  equiv),	  and	  p-­‐
nitrobenzoic	  acid	  (2.0	  mg,	  12	  μmol,	  1.15	  equiv)	  were	  placed	   in	  a	   flask	  and	  azeotroped	   in	  
toluene	   to	  dryness	  (3x	  0.5	  mL).	  The	  reaction	  was	   then	  dissolved	   in	   toluene	  (0.3	  mL)	  and	  
cooled	  to	  0	  °C	  for	  the	  drop	  wise	  addition	  of	  DIAD	  (3.0	  μL,	  15	  μmol,	  1.5	  equiv).	  The	  reaction	  
was	  stirred	  for	  20	  min	  at	  0	  °C	  then	  heated	  to	  70	  °C	  for	  2	  h.	  The	  reaction	  was	  diluted	  with	  
diethyl	   ether	   (10	   mL)	   and	   washed	   with	   saturated	   sodium	   bicarbonate	   (3.0	   mL).	   The	  
aqueous	  phase	  was	  extracted	  with	  diethyl	  ether	  (10	  mL).	  A	  final	  wash	  of	  saturated	  sodium	  
chloride	   was	   performed,	   and	   the	   organic	   layers	   were	   dried	   over	   sodium	   sulfate	   and	  
filtered.	   The	   solvent	  was	   removed	   under	   reduced	   pressure	   and	   column	   chromatography	  
(SiO2;	   EtOAc:Hexane	   5:95	   to	   1:3)	   purification	   yielded	   the	   C2’	   nitrobenzoate	   ester	   as	   a	  
yellow-­‐orange	  solid.	  Two	  reactions	  were	  run:	  (11.7	  mg,	  5.9	  μmol,	  59	  %)	  (13.5	  mg,	  6.8	  μmol,	  
68%)	  
	  
The	  C2’	  p-­‐nitrobenzoate	  ester	  was	  combined	  (25.2	  mg,	  12.8	  μmol,	  1.0	  equiv)	  and	  taken	  up	  
in	  MeOH:THF	  2:1	  (435	  μL).	  Potassium	  cyanide	  (2.5	  mg,	  38	  μmol,	  3.0	  equiv)	  was	  then	  added	  
and	  the	  reaction	  was	  stirred	  for	  72	  h	  at	  30	  °C.	  The	  reaction	  was	  then	  diluted	  with	  diethyl	  
ether	  (10	  mL)	  and	  washed	  with	  saturated	  sodium	  bicarbonate	  (3.0	  mL).	  The	  aqueous	  phase	  
was	  extracted	  with	  diethyl	  ether	  (2x	  10	  ml).	  A	  final	  wash	  of	  saturated	  sodium	  chloride	  was	  
performed,	  and	  the	  organic	  layers	  were	  dried	  over	  sodium	  sulfate	  and	  filtered.	  The	  solvent	  
was	   removed	  under	   reduced	  pressure	   and	   column	   chromatography	   (SiO2:	   EtOAc:Hexane	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TLC	  (EtOAc:Hexane	  3:7)	  Rf	  =	  0.2,	  stained	  by	  CAM	  
	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  7.36	  (m,	  6H),	  7.28	  (m,	  2H),	  7.21	  (m,	  1H),	  7.15	  (m,	  1H),	  
6.86	  (m,	  4H),	  6.41-­‐6.18	  (m,	  11H),	  6.10	  (m,	  1H),	  5.86	  (m,	  1H),	  5.77	  (m,	  1H),	  5.44	  (s,	  1H),	  5.43	  
(s,	  1H),	  4.81	  (m,	  1H),	  4.56	  (m,	  1H),	  4.36	  (app	  d,	  J	  =	  7.5,	  1H),	  4.26	  (m,	  1H),	  4.17	  (m,	  1H),	  3.97-­‐
3.85	  (m,	  4H),	  3.79	  (m,	  7H),	  3.73	  (m,	  4H),	  3.66	  (s,	  3H),	  3.61-­‐3.48	  (m,	  3H),	  3.43	  (m,	  1H),	  3.33	  
(m,	  1H),	  3.04	  (s,	  3H),	  2.49	  (m,	  1H),	  2.42	  (m,	  1H),	  2.30-­‐2.21	  (m,	  3H),	  1.95-­‐1.87	  (m,	  3H),	  1.80-­‐
1.67	  (m,	  3H),	  1.64-­‐1.27	  (m,	  6H),	  1.24-­‐1.16	  (m,	  7H),	  1.04-­‐0.76	  (m,	  56H),	  0.73-­‐0.51	  (m,	  13H),	  
0.46-­‐0.37	  (m,	  4H).	  
	  
13C	  NMR	   (125	  MHz,	  CD3C(O)CD3)	  δ	  173.9,	  172.1,	  170.1,	  161.0,	  137.9,	  137.0,	  134.8,	  134.7,	  
134.3,	   134.1,	   133.9,	   133.7,	   133.3,	   132.9,	   132.4,	   131.1,	   130.5,	   129.7,	   129.1,	   128.9,	   128.5,	  
127.3,	  114.1,	  114.0,	  103.4,	  102.0,	  101.3,	  100.9,	  81.6,	  76.5,	  76.1,	  75.2,	  74.7,	  73.3,	  73.0,	  69.0,	  
67.6,	  57.8,	  55.6,	  52.1,	  48.6,	  44.3,	  44.2,	  38.1,	  33.7,	  32.9,	  19.1,	  18.2,	  18.1,	  18.0,	  17.6,	  14.3,	  14.2,	  
14.1,	  13.7,	  7.8,	  7.7,	  7.6,	  7.3,	  5.4,	  5.1,	  5.0,	  4.9,	  4.6,	  4.4	  
	  
HRMS	  (ESI)	  Calculated	  for	  C101H159NO20Si4	  (M	  +	  Na)+:	   	   1841.0430	  	  































Ergosterol	  (400	  mg,	  1.01	  mmol,	  1.0	  equiv)	  and	  succinic	  anhydride	  (1.01	  g,	  10.1	  mmol,	  10.0	  
equiv)	  were	  azeotroped	  with	  toluene	  (3x	  1.0	  mL)	  in	  a	  40	  mL	  vial.	  Dry	  pyridine	  (20	  mL	  0.05	  
M)	   was	   then	   added	   followed	   by	   dimethylaminopyridine	   (DMAP)	   (154.2	  mg,	   1.26	  mmol,	  
1.25	  equiv).	  The	  reaction	  was	  sealed	  with	  a	  Teflon	  lined	  cap	  and	  heated	  to	  140	  °C	  for	  16	  h.	  
The	   resulting	   black	   solution	  was	   extracted	  with	   HCl	   (10%	   v/v)	   and	   EtOAc.	   The	   organic	  
phase	  was	   dried	  with	   sodium	   sulfate,	   filtered,	   and	   concentrated.	   Chromatography	   (SiO2;	  
EtOAc:Hexane	   1:5	  with	   1%	  AcOH)	   purification	   yielded	  A	   as	   a	  white	   solid	   (282	  mg,	   0.57	  
mmol,	  56%).	  
	  
A	  (12.5	  mg,	  25	  μmol,	  2.5	  equiv)	  was	  dissolved	  in	  toluene	  (0.3	  mL)	  and	  oxalyl	  chloride	  (10.0	  
μL,	  118	  μmol,	  4.75	  equiv)	  was	  added	  and	  the	  reaction	  was	  heated	  to	  50	  °C	  and	  stirred	  for	  
15	  min.	  The	  resulting	  yellow	  solution	  was	  azeotroped	  with	  toluene	  (3x	  0.3	  mL)	  to	  dryness.	  
The	  resulting	  off-­‐	  white	  solid	  B	  was	  then	  dissolved	  in	  THF	  (0.3	  mL)	  whereupon	  DMAP	  (3.1	  
mg,	  25	  μmol,	  2.5	  equiv)	  was	  added	  to	  generate	  a	  cloudy	  white	  suspension.	  In	  a	  separate	  vial	  
3.4	   (18.2	  mg,	   10	   μmol,	   1.0	   equiv)	  was	   dissolved	   in	   THF	   (0.15	  mL)	   and	   diethylisopropyl	  
amine	   (10	  μL,	   57	  μmol,	   5.7	   equiv)	  was	   added.	  The	   resulting	   yellow/orange	   solution	  was	  
added	   drop	   wise	   via	   cannula	   to	   the	   first	   suspension	   and	   stirred	   for	   3	   h	   at	   room	  
temperature.	   The	   reaction	   was	   diluted	   with	   diethyl	   ether	   (10	   mL)	   and	   washed	   with	  
















































































ether	   (2x	   10	   mL).	   A	   final	   wash	   of	   saturated	   sodium	   chloride	   was	   performed,	   and	   the	  
organic	  layers	  were	  dried	  over	  sodium	  sulfate	  and	  filtered.	  The	  solvent	  was	  removed	  under	  
reduced	   pressure	   and	   column	   chromatography	   (SiO2;	   EtOAc:Hexane	   5:95	   →	   1:3)	  




TLC	  (EtOAc:Hexane	  1:3)	  Rf	  =	  0.76,	  stained	  by	  CAM	  
	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  7.36	  (m,	  4H),	  7.28	  (m,	  4H),	  7.23	  (m,	  1H),	  6.93	  (m,	  1H),	  
6.86	   (m,	  4H),	   6.39-­‐6.12	   (m,	  12H),	   5.84(m,	  2H),	   5.61	   (m,	  1H),	   5.41	   (m,	  3H),	   5.26	   (m,	  3H),	  
5.83-­‐4.61	  (m,	  4H),	  4.29-­‐4.13	  (m,	  3H),	  3.90-­‐3.81	  (m,	  3H),	  3.79	  (s,	  3H),	  3.78	  (s,	  3H),	  3.72	  (m,	  
2H),	  3.67	  (s,	  3H),	  3.56	  (m,	  2H),	  3.47	  (m,	  2H),	  3.00	  (s,	  3H),	  2.71-­‐2.34	  (m,	  9H),	  2.31-­‐2.08	  (m,	  
5H),	  2.00-­‐1.45	  (m,	  30H),	  1.41-­‐0.38	  (m,	  98H)	  
	  
13C	  NMR	   (125	  MHz,	  CD3C(O)CD3)	  δ	  173.4,	  173.2,	  172.3,	  171.2,	  170.1,	  160.8,	  142.3,	  139.6,	  
137.8,	   136.8,	   136.7,	   134.8,	   134.5,	   134.1,	   133.7,	   133.3,	   132.9,	   132.6,	   132.1,	   131.0,	   130.5,	  
129.2,	  128.9,	  128.5,	  127.5,	  126.2,	  121.4,	  117.5,	  114.1,	  114.0,	  102.0,	  101.3,	  100.9,	  81.6,	  76.2,	  
75.2,	  75.1,	  74.1,	  73.9,	  73.3,	  73.1,	  72.3,	  68.9,	  67.1,	  58.1,	  56.7,	  55.7,	  55.4,	  54.6	  52.1,	  48.8,	  47.1,	  
44.2,	  43.9,	  43.8,	  43.7,	  43.2,	  41.4,	  39.9,	  38.8,	  38.0,	  37.6,	  34.0,	  33.8,	  30.9,	  29.1,	  29.0,	  28.4,	  23.9,	  
21.7,	  20.5,	  20.2,	  19.2,	  18.3,	  18.2,	  18.1,	  18.0,	  17.9,	  17.6,	  16.6,	  14.2,	  14.1,	  13.7,	  12.6,	  7.9,	  7.8,	  
7.7,	  7.6,	  7.3,	  5.4,	  5.1,	  5.0,	  4.9,	  4.7,	  4.4,	  1.5	  
	  
MS	  (MALDI)	  Calculated	  for	  C133H205NO23Si4	  (M	  +	  Na)+:	   2319	  	  
































Epoxide	  intermediate	  3.15	  (8	  g,	  21	  mmol,	  1.0	  equiv)	  was	  dissolved	  in	  THF	  (263	  mL).	  The	  
resulting	   solution	  was	   cooled	   to	  0	  °C,	   and	  LiHBEt3	   (1M	   in	  THF)	   (105	  mL,	  105	  mmol,	   5.0	  
equiv)	  was	  added	  slowly.	  The	  reaction	  heated	  to	  60	  °C	  for	  2.5	  h.	  The	  reaction	  was	  cooled	  to	  
0	  °C	  and	  quenched	  with	  1M	  ammonium	  chloride.	  The	  mixture	  was	   extracted	  with	   ether.	  
The	  organic	  layer	  was	  washed	  with	  water	  and	  saturated	  sodium	  chloride.	  The	  organic	  layer	  
was	   dried	   with	   sodium	   sulfate	   and	   filtered.	   The	   solvent	   was	   removed	   under	   reduced	  
pressure,	  and	  column	  chromatography	  (SiO2;	  Ether:Hexane	  1:4	  →	  1:3)	  purification	  yielded	  




TLC	  (Ether:Hexane	  3:7)	  Rf	  =	  0.38,	  stained	  by	  CAM	  
	  
1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  7.27	  (d,	  J	  =	  8.5	  Hz,	  2H),	  6.88	  (d,	  J	  =	  9	  Hz,	  2H),	  4.87	  (d,	  J	  =	  4	  Hz,	  
1H),	  4.66	  (d,	  J	  =	  12	  Hz,	  1H),	  4.44	  (d,	  J	  =	  11.5	  Hz,	  1H),	  4.04	  (m,	  1H),	  3.92	  (m,	  1H),	  3.81	  (s,	  3H),	  
3.32	  (dd,	  J	  =	  3	  Hz,	  J	  =	  9.5	  Hz,	  1H),	  3.19	  (m,	  1H),	  2.14	  (dd,	  J	  =	  3.5	  Hz,	  J	  =	  15	  Hz,	  1H),	  1.89	  (td,	  J	  
=	  3.5	  Hz,	  J	  =	  14.5	  Hz,	  1H),	  1.26	  (d,	  J	  =	  6.5	  Hz,	  3H),	  0.93	  (s,	  9H),	  0.12	  (s,	  6H)	  
	  
13C	   NMR	   (125	  MHz,	   CDCl3)	   δ	   159.5,	   129.9,	   114.0,	   95.7,	   75.1,	   68.9,	   68.0,	   63.7,	   55.5,	   35.7,	  
26.1,	  18.4,	  -­‐4.0,	  -­‐4.4	  
	  
HRMS	  (ESI)	  Calculated	  for	  C20H34O5Si	  (M	  +	  Na)+:	  	   405.2073	  	  



















Synthesis	  of	  3.17	  
	  
	  
3.16	  (4.83	  g,	  12.6	  mmol,	  1	  equiv)	  was	  dissolved	  in	  THF	  (15	  mL).	  Pyridine	  (10.2	  mL,	  126	  
mmol,	  10	  equiv)	  and	  MsCl	  (3.17	  mL,	  41	  mmol,	  3.25	  equiv)	  were	  added.	  The	  reaction	  was	  
stirred	   overnight.	   The	   reaction	   was	   then	   quenched	   with	   saturated	   aqueous	   sodium	  
bicarbonate	  and	  extracted	  with	  ether.	  The	  organic	  layer	  was	  washed	  with	  1M	  ammonium	  
chloride,	  water,	  and	  saturated	  sodium	  chloride.	  The	  organic	   layer	  was	  dried	  with	  sodium	  
sulfate	   and	   filtered.	   The	   solvent	   was	   removed	   under	   reduced	   pressure,	   and	   column	  
chromatography	  (SiO2;	  Ether:Hexane	  2:3)	  purification	  yielded	  3.17	   as	  a	  solid	  (4.24	  g,	  9.2	  
mmol,	  73	  %).	  
	  
	  
TLC	  (Ether:Hexane	  2:3)	  Rf	  	  =	  0.27,	  stained	  by	  CAM	  
	  
1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  7.27	  (d,	  J	  =	  9	  Hz,	  2H),	  6.88	  (d,	  J	  =	  8.5	  Hz,	  2H),	  4.90	  (dd,	  J	  =	  3	  Hz,	  
J	  =	  8	  Hz,	  2H),	  4.66	  (d,	  J	  =	  11.5	  Hz,	  1H),	  4.35	  (d,	  J	  =	  11	  Hz,	  1H),	  4.13	  (m,	  1H),	  3.80	  (s,	  3H),	  3.43	  
(dd,	  J	  =	  3	  Hz,	  J	  =	  9	  Hz,	  1H),	  2.91	  (s,	  3H),	  2.41	  (dd,	  J	  =	  3	  Hz,	  J	  =	  15	  Hz,	  1H),	  1.96	  (m,	  1H),	  1.23	  
(d,	  J	  =	  6.5	  Hz,	  3H),	  0.93	  (s,	  9H),	  0.14	  (s,	  3H),	  0.11	  (s,	  3H)	  
	  
13C	  NMR	   (125	  MHz,	  CDCl3)	  δ	  159.4,	  130.2,	  129.6,	  113.9,	  94.8,	  77.5,	  72.7,	  69.1,	  64.3,	  55.5,	  
39.9,	  34.5,	  26.0,	  18.3,	  -­‐3.9,	  -­‐	  4.6	  
	  
HRMS	  (ESI)	  Calculated	  for	  C21H36O5Si	  (M	  +	  Na)+:	  	   483.1849	  	  






















3.17	  (1.6	  g,	  3.47	  mmol,	  1.0	  equiv)	  was	  dissolved	  in	  DMF	  (15	  mL).	  Sodium	  azide	  (1.6	  g,	  24.3	  
mmol,	  7	  equiv)	  was	  added.	  The	  reaction	  heated	  to	  160	  °C	  for	  1.5	  h.	  The	  reaction	  was	  cooled	  
to	   room	   temperature.	   The	   reaction	   was	   quenched	   with	   saturated	   aqueous	   sodium	  
bicarbonate	   and	   extracted	   with	   ether.	   The	   organic	   layer	   was	   washed	   with	   water,	   and	  
saturated	   sodium	  chloride.	  The	  organic	   layer	  was	  dried	  with	   sodium	  sulfate	  and	   filtered.	  
The	   solvent	   was	   removed	   under	   reduced	   pressure,	   and	   column	   chromatography	   (SiO2;	  




TLC	  (Ether:Hexane	  1:19)	  Rf	  =	  0.30,	  stained	  by	  CAM	  
	  
1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  7.29	  (d,	  J	  =	  9	  Hz,	  2H),	  6.91	  (d,	  J	  =	  8.5	  Hz,	  2H),	  4.91	  (d,	  J	  =	  3	  Hz,	  
2H),	  4.61	  (d,	  J	  =	  11.5	  Hz,	  1H),	  4.39	  (d,	  J	  =	  11	  Hz,	  1H),	  3.82	  (s,	  3H),	  3.71	  (m,	  2H),	  3.10	  (t,	  J	  =	  9	  
Hz,	  1H),	  2.19	  (dd,	  J	  =	  5	  Hz,	  J	  =	  13.5	  Hz,	  1H),	  1.73	  (td,	  J	  =	  4	  Hz,	  J	  =	  12.5	  Hz,	  1H),	  1.27	  (d,	  J	  =	  6	  
Hz,	  3H),	  0.94	  (s,	  9H),	  0.22	  (s,	  3H),	  0.13	  (s,	  3H).	  
	  
13C	  NMR	   (125	  MHz,	  CDCl3)	  δ	  159.6,	  129.9,	  129.8,	  114.1,	  95.4,	  76.7,	  68.9,	  68.8,	  61.8,	  55.5,	  
35.9,	  26.2,	  18.7,	  18.4,	  -­‐3.9,	  -­‐	  4.0.	  
	  
	  
HRMS	  (ESI)	  Calculated	  for	  C20H33N3O4Si	  (M	  +	  Na)+:	   430.2138	  	  





















3.18	   (6.5	  g,	  15.9	  mmol,	  1.0	  equiv)	  was	  dissolved	   in	  DCM:H2O	  9:1	  (160	  mL).	  The	  solution	  
was	   cooled	   to	  0	   °C,	   and	  DDQ	   (4.3	   g,	   19.1	  mmol,	   1.2	   equiv)	  was	   added.	  The	   reaction	  was	  
warmed	   to	   room	   temperature	   and	   stirred	   for	   2	   h.	   The	   reaction	   was	   quenched	   with	  
saturated	   aqueous	   sodium	   bicarbonate	   and	   extracted	  with	   ether.	   The	   organic	   layer	   was	  
washed	   with	   water,	   and	   saturated	   sodium	   chloride.	   The	   organic	   layer	   was	   dried	   with	  
sodium	  sulfate	  and	  filtered.	  The	  solvent	  was	  removed	  under	  reduced	  pressure,	  and	  column	  
chromatography	  (SiO2;	  Ether:Hexane	  1:19)	  purification	  followed	  by	  (C18	  SiO2,	  water:MeCN	  




TLC	   (EtOAc:Hexane	  1:4)	  Rf	  =	  0.31,	   stained	  by	  CAM	  (H2O:MeCN	  1:4)	  Rf	  =	  0.50,	   stained	  by	  
CAM	  
	  
HRMS	  (ESI)	  Calculated	  for	  C12H25N3O3Si	  (M	  +	  Na)+:	  	   	   310.1563	  	  



























Intermediate	  SI3.2	   (15.8	   g,	   7.20	  mmol,	   1.0	   equiv)	  was	   azeotropically	   dried	  with	   toluene	  
and	  placed	  under	  vacuum	  overnight.	  Hexane	  (240	  mL)	  and	  2,6-­‐lutidine	  (2.9	  mL,	  25.2	  mmol,	  
3.5eq)	  were	  added.	  The	  resulting	  solution	  was	  cooled	  to	  0	  °C	  and	  triisopropylsilyl	  triflate	  
(2.9	  mL,	  10.8	  mmol,	  1.5eq)	  was	  added	  slowly	  over	  15	  min.	  The	  reaction	  was	  quenched	  after	  
1	  h	  with	  saturated	  aqueous	  sodium	  bicarbonate	  and	  extracted	  with	  ether.	  The	  organic	  layer	  
was	  washed	  with	  copper	  sulfate,	  water,	  and	  finally	  saturated	  sodium	  chloride.	  The	  organic	  
layer	  was	  dried	  with	  sodium	  sulfate	  and	  filtered.	  The	  solvent	  was	  removed	  under	  reduced	  
pressure,	   and	   column	   chromatography	   (SiO2;	   Ether:Hexane	   5:95	   →	   1:4)	   purification	  




TLC	  (Ether:Hexane	  0.1%	  Et3N	  3:7)	  Rf	  =	  0.72,	  stained	  by	  CAM	  
	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)δ	  7.86	  (d,	  J	  =	  7.5	  Hz,	  2H),	  7.69	  (d,	  J	  =	  7.5	  Hz,	  2H),	  7.41	  (t,	  J	  =	  
7.5	  Hz,	  2H),	  7.33	  (t,	  J	  =	  7.5	  Hz,	  2H),	  6.53-­‐6.05	  (m,	  12H),	  5.51	  (m,	  1H),	  5.34	  (m,	  1H),	  4.65	  (m,	  
2H),	  4.47	  (m,	  3H),	  4.34	  (m,	  2H),	  4.24	  (m,	  2H),	  4.13	  (m,	  1H),	  3.98	  (m,	  2H),	  3.90	  (m,	  1H),	  3.83	  


























































2.10-­‐2.01	  (m,	  3H),	  1.94-­‐1.59	  (m,	  12H),	  1.50	  (m,	  1H),	  1.38-­‐1.30	  (m,	  4H),	  1.23	  (m,	  4H),	  1.16	  
(m,	  20H),	  1.07-­‐0.89	  (m,	  85H),	  0.78-­‐0.55	  (m,	  56H).	  
	  
13C	  NMR	   (125	  MHz,	  CD3C(O)CD3)	  δ	  172.3,	  170.5,	  156.2,	  145.0,	  142.1,	  139.0,	  135.7,	  135.3,	  
135.2,	   134.7,	   133.8,	   132.9,	   132.8,	   132.7,	   132.5,	   131.4,	   130.7,	   130.6,	   128.4,	   127.8,	   125.8,	  
125.7,	  120.7,	  101.2,	  99.5,	  76.7,	  74.6,	  74.0,	  73.9,	  73.2,	  71.1,	  69.4,	  68.0,	  67.5,	  67.3,	  67.2,	  59.0,	  
58.2,	  48.2,	  48.0,	  47.8,	  44.3,	  43.4,	  42.1,	  41.2,	  37.2,	  35.6,	  27.4,	  19.9,	  19.2,	  19.0,	  18.4,	  18.2,	  12.9,	  
11.3,	  7.6,	  7.5,	  7.4,	  7.3,	  6.4,	  6.2,	  6.1,	  6.0,	  5.9,	  5.8.	  
	  
LRMS	  (ESI)	  Calculated	  for	  C126H231NO19Si10	  (M	  +	  Na)+:	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   2365.5	  
Found:	   	   	   	   	   	   	   	   	  	   2365.1	  	  
	  




Intermediate	  SI3.3	   (12.5	   g,	   5.35	  mmol,	   1.0	   equiv)	  was	   azeotropically	   dried	  with	   toluene	  
and	  placed	  under	  vacuum	  overnight.	  THF	  (100	  mL)	  was	  added.	  The	  resulting	  solution	  was	  
cooled	  to	  0	  °C,	  and	  DDQ	  (1.82	  g,	  8.03	  mmol,	  1.5eq)	  and	  CaCO3	  (5.3	  g,	  53.5	  mmol,	  10	  equiv)	  
were	  added.	  The	   reaction	  was	  warmed	   to	   room	   temperature	  and	  quenched	  after	  30	  min	  
with	   saturated	   aqueous	   sodium	  bicarbonate	   and	   extracted	  with	   ether.	   The	   organic	   layer	  
was	  washed	  with	  water	  and	  then	  saturated	  sodium	  chloride.	  The	  organic	   layer	  was	  dried	  
with	   sodium	  sulfate	   and	   filtered.	  The	   solvent	  was	   removed	  under	   reduced	  pressure,	   and	  
flash	  column	  chromatography	  (SiO2;	  Ether:Hexane	  1:4)	  purification	  yielded	  the	  enone	  as	  a	  
dark	  red	  solid.	  This	  intermediate	  is	  sensitive	  to	  silica	  gel	  and	  was	  immediately	  subjected	  to	  





























    THF, 0 oC, 30 min
2. NaBH4
   THF:MeOH 0 oC









TLC	  (Ether:Hexane	  3:17)	  Rf	  =	  0.35,	  stained	  by	  CAM	  
	  
LRMS	  (ESI)	  Calculated	  for	  C93H180NO14Si8	  (M	  +	  Na)+:	   	   1768.1	  	  
Found:	   	   	   	   	   	   	   	   1768.0	  
	  
The	  enone	  intermediate	  was	  azeotropically	  dried	  with	  toluene.	  THF	  (10	  mL)	  and	  MeOH	  (20	  
mL)	  was	  added.	  The	  resulting	  solution	  was	  cooled	  to	  0	  °C,	  and	  NaBH4	  (1.08	  g,	  28.6	  mmol,	  
5.3	   equiv)	   was	   added.	   The	   reaction	   was	   quenched	   after	   30	   min	   with	   1M	   aqueous	  
ammonium	  chloride	  and	  extracted	  with	  ether.	  The	  organic	   layer	  was	  washed	  with	  water	  
and	  then	  saturated	  sodium	  chloride.	  The	  organic	  layer	  was	  dried	  with	  sodium	  sulfate	  and	  
filtered.	   The	   solvent	   was	   removed	   under	   reduced	   pressure,	   and	   flash	   column	  
chromatography	  (SiO2;	  Ether:Hexane	  1:9	  →	  1:4)	  purification	  yielded	  the	  3.13	  as	  a	  yellow-­‐
orange	  solid.	  This	  intermediate	  is	  not	  stable	  to	  long	  term	  storage	  and	  extended	  periods	  on	  




TLC	  (Ether:Hexane	  1:4)	  Rf	  =	  0.44,	  stained	  by	  CAM	  
	  
1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  6.49-­‐6.10	  (m,	  13H),	  5.53	  (m,	  1H),	  4.68	  (m,	  1H),	  4.50	  (m,	  
2H),	  4.22	  (m,	  1H),	  4.15	  (m,	  1H),	  4.06	  (m,	  1H),	  4.00	  (m,	  1H),	  3.91	  (d,	  J	  =	  4	  Hz,	  1H),	  3.83	  (m,	  





























(m,	  1H),	  2.01	  (m,	  2H),	  1.95-­‐1.70	  (m,	  8H),	  1.63	  (m,	  3H),	  1.49	  (m,	  1H),	  1.31	  (m,	  3H),	  1.18-­‐1.14	  
(m,	  20H),	  1.07-­‐0.96	  (m,	  69H),	  0.77-­‐0.61	  (m,	  43H).	  
	  
13C	  NMR	   (125	  MHz,	  CD3C(O)CD3)	  δ	  172.2,	  170.5,	  139.6,	  138.6,	  134.8,	  134.7,	  134.0,	  133.3,	  
133.1,	   133.0,	   132.8,	   132.7,	   131.7,	   131.6,	   130.8,	   127.9,	   101.1,	   76.7,	   74.0,	   73.2,	   71.0,	   69.3,	  
69.1,	  67.4,	  67.3,	  59.2,	  48.0,	  47.8,	  44.4,	  43.5,	  41.8,	  41.3,	  40.6,	  35.5,	  27.4,	  19.8,	  19.2,	  18.4,	  18.3,	  
12.8,	  11.2,	  7.7,	  7.6,	  7.5,	  7.4,	  7.3,	  6.4,	  6.2,	  6.1,	  5.9,	  5.8.	  
	  
LRMS	  (ESI)	  Calculated	  for	  C93H182NO14Si8	  (M	  +	  Na)+:	   	   1770.2	  	  
Found:	   	   	   	   	   	   	   	   1770.2	  
	  
	  




Intermediate	  3.13	  (2.5	  g,	  1.29	  mmol,	  1.0	  equiv)	  was	  azeotropically	  dried	  with	  toluene	  and	  
placed	   under	   vacuum	   overnight.	   Hexane	   (80	   mL)	   was	   added	   followed	   by	   activated	   4-­‐
angstrom	  molecular	  sieves.	  The	  resulting	  solution	  was	  allowed	  to	  stir	  at	  room	  temperature	  
while	  the	  sugar	  donor	  was	  prepared.	  The	  sugar	  donor	  3.12	  (739	  mg,	  2.57	  mmol,	  2.0	  equiv)	  
was	   dissolved	   in	   DCM	   (26	  mL).	   Diphenyl	   sulfoxide	   (911	  mg,	   4.50	  mmol,	   3.5	   equiv)	   and	  
activated	  4-­‐angstrom	  molecular	  sieves	  were	  added.	  The	  reaction	  was	  stirred	  for	  4	  hours	  at	  
room	  temperature.	  2,6-­‐lutidine	  (675	  μL,	  5.79	  mmol,	  4.5	  equiv)	  was	  added,	  and	  the	  reaction	  
was	  cooled	  to	  -­‐60	  °C.	  Triflic	  anhydride	  (1M	  in	  DCM)	  (2.57	  mL,	  2.57	  mmol,	  2.0	  equiv)	  was	  
added	  slowly.	  The	  reaction	  was	  warmed	  to	  -­‐20	  °C	  and	  stirred	  for	  1.5	  h.	  2,6-­‐lutidine	  (600	  μL,	  
5.15	  mmol,	  4.0	  equiv)	  was	  added	  to	  the	  solution	  of	  3.12,	  and	  it	  was	  cooled	  to	  -­‐30	  °C.	  The	  








































warmed	   to	   0	   °C	   for	   1hr.	   The	   reaction	   was	   quenched	   with	   saturated	   aqueous	   sodium	  
bicarbonate	  and	  extracted	  with	  ether.	  The	  organic	   layer	  was	  washed	  with	  copper	  sulfate,	  
water,	  and	  saturated	  sodium	  chloride.	  The	  organic	  layer	  was	  dried	  with	  sodium	  sulfate	  and	  
filtered.	  The	   solvent	  was	   removed	  under	   reduced	  pressure,	   and	   column	  chromatography	  
(SiO2;	  Ether:Hexane	  3:47)	  purification	  yielded	  the	  glycosylated	  product	  3.19	  as	  a	  mixture	  
of	  isomers	  ranging	  from	  2:1	  α:β	  (2.12	  g,	  1.06	  mmol,	  82	  %).	  The	  isomers	  were	  inseparable	  at	  





TLC	  (Ether:Hexane	  1:19)	  Rf	  =	  	  0.25,	  stained	  by	  CAM	  
	  
LRMS	  (ESI)	  Calculated	  for	  C105H205N3O16Si9	  (M	  +	  Na)+:	  	  	  	  	   	  2039.9	  
Found:	  	   	   	   	   	   	   	   	   	  2039.3	  
	  




The	  glycosidated	  product	  3.19	  (710	  mg,	  352	  μmol,	  1.0	  equiv)	  was	  azeotropically	  dried	  with	  
toluene	   in	   a	   Teflon	   vial.	   THF	   (3	   mL)	   was	   added,	   and	   the	   solution	   was	   cooled	   to	   0	   °C.	  






















































0 oC to 23 oC
12 h, 26% !-isomer 3.20
R = TES
 72 
pyridine	   was	   added	   slowly	   to	   the	   pyridine-­‐MeOH	   solution	   at	   0	   °C.	   This	   solution	   was	  
transferred	   slowly	   to	   the	   THF	   solution	   of	   glycosylated	   intermediate.	   The	   reaction	   was	  
allowed	  to	  stir	  for	  12	  hours	  at	  room	  temperature.	  The	  reaction	  was	  quenched	  at	  0	  °C	  with	  
excess	  MeOTMS	  and	  diluted	  with	   toluene.	  The	   solution	  was	   concentrated	  under	   reduced	  
pressure	  and	  diluted	  again	  with	  toluene.	  This	  process	  was	  repeated	  3	  times	  to	  remove	  all	  of	  
the	  pyridine.	  The	  product	   is	  base	   sensitive,	   especially	   if	  water	   is	  present,	   –	   care	  must	  be	  
taken	   not	   to	   concentrate	   directly	   to	   solid	   with	   pyridine	   present.	   Reversed	   phase	   HPLC	  
purification	  (C18	  SiO2;	  MeCN:5	  mM	  NH4OAc	  in	  H2O	  1:19	  →	  19:1	  over	  30	  minutes)	  allowed	  
the	  α	  and	  β	  isomers	  to	  be	  separated	  and	  yielded	  260	  mg,	  275	  μmol,	  78	  %.	  (86.7	  mg,	  91.7	  




HPLC	  (C18	  SiO2;	  MeCN:5	  mM	  NH4OAc	  in	  H2O	  1:19	  →	  19:1	  over	  30	  minutes)	  	  
Rt	  =	  17.1	  min,	  α	  	  
Rt	  =	  16.2	  min,	  β	  
	  
1H	  NMR	  (500	  MHz,	  CD3S(O)CD3)	  δ	  6.32-­‐6.05	  (m,	  12H),	  5.81	  (m,	  1H),	  5.60	  (m,	  1H),	  4.97	  (m,	  
1H),	  4.58	  (m,	  1H),	  4.43	  (m,	  1H),	  3.99	  (m,	  1H),	  3.84	  (m,	  1H),	  3.73	  (m,	  2H),	  3.52	  (m,	  2H),	  3.32	  
(m,	  1H),	  3.21	  (m,	  1H),	  3.10	  (m,	  1H),	  3.00	  (s,	  3H),	  2.93	  (m,	  2H),	  2.29	  (m,	  1H),	  2.16	  (m,	  2H),	  
2.01	  (m,	  2H),	  1.76	  (m,	  1H),	  1.68	  (m,	  1H),	  1.52-­‐1.23	  (m,	  14H),	  1.15	  (d,	  J	  =	  5.5	  Hz,	  3H),	  1.11	  (d,	  
J	  =	  5.5	  Hz,	  3H),	  1.03	  (d,	  J	  =	  6	  Hz,	  3H),	  0.89	  (d,	  J	  =	  7	  Hz,	  3H).	  
	  
HRMS	  (ESI)	  	  
Calculated	  for	  C48H73N3O16	  (M	  +	  Na)+:	   970.4889	  	  

























3.20	  (19	  mg,	  20	  μmol,	  1.0	  equiv)	  was	  dissolved	  in	  DMSO	  (657	  μL).	  Added	  water	  (36	  μL,	  200	  
μmol,	  100	  equiv)	  and	  trimethyl	  phosphine	  (1M)	  (60	  μL,	  60	  μmol,	  3.0	  equiv).	  The	  reaction	  
was	   heated	   to	   55	   °C	   for	   3	   h.	   Reversed	   phase	   HPLC	   purification	   (C18	   SiO2;	   MeCN:5	   mM	  




HPLC	  (C18	  SiO2;	  MeCN:5	  mM	  NH4OAc	  in	  H2O	  1:19	  →	  19:1	  over	  30	  minutes)	  
	  Rt	  =	  14.3	  min	  
	  
1H	  NMR	  (500	  MHz,	  CD3S(O)CD3)	  δ	  6.34-­‐6.06	  (m,	  12H),	  5.90	  (m,	  1H),	  5.62	  (m,	  1H),	  4.94	  (m,	  
1H),	  4.63	  (m,	  1H),	  4.52	  (m,	  1H),	  3.97	  (m,	  1H),	  3.90	  (m,	  1H),	  3.73	  (m,	  2H),	  3.56	  (m,	  1H),	  3.38	  
(m,	  1H),	  3.30	  (m,	  1H),	  3.25	  (m,	  1H),	  3.15	  (m,	  1H),	  2.95	  (m,	  5H),	  2.25	  (m,	  4H),	  2.03	  (m,	  1H),	  
1.77	  (m,	  3H),	  1.53-­‐1.24	  (m,	  13H),	  1.17	  (d,	  J	  =	  5	  Hz,	  3H),	  1.11	  (d,	  J	  =	  6	  Hz,	  3H),	  1.03	  (d,	  J	  =	  6	  
Hz,	  3H),	  0.89	  (d,	  J	  =	  6.5	  Hz,	  3H).	  
	  
HRMS	  (ESI)	  Calculated	  for	  C48H75NO16	  (M	  +	  H)+:	   	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  922.5164	  	  

































































3.21	  (5	  mg,	  5.42	  μmol,	  1.0	  equiv)	  was	  placed	  in	  a	  vial.	  180	  μL	  of	  a	  180	  mM	  solution	  of	  CSA	  
in	   2:1	   THF:H2O	   was	   added.	   The	   reaction	   was	   stirred	   for	   30	   min.	   Reversed	   phase	   HPLC	  
purification	  (C18	  SiO2;	  MeCN:5	  mM	  NH4OAc	   in	  H2O	  1:19	  →	  19:1	  over	  30	  minutes)	  yielded	  
C2’-­‐deoxyAmB	  (3.9	  mg,	  4.34	  μmol,	  80	  %).	  
	  
HPLC	  (C18	  SiO2;	  MeCN:5	  mM	  NH4OAc	  in	  H2O	  1:19	  →	  19:1	  over	  30	  minutes)	  	  
Rt	  =	  15.1	  min	  
	  
1H	  NMR	  (500	  MHz,	  CD3S(O)CD3)	  δ	  6.47-­‐5.94	  (m,	  11H),	  5.73	  (m,	  1H),	  5.42	  (m,	  2H),	  5.23	  (m,	  
1H),	  4.77	  (m,	  1H),	  4.61	  (m,	  1H),	  4.38	  (m,	  1H),	  4.26	  (m,	  1H),	  4.15	  (m,	  1H),	  4.06	  (m,	  1H),	  3.99	  
(m,	   1H),	   3.70-­‐3.20	   (m,	   4H),	   3.09	   (m,	   1H),	   2.92	   (m,	   1H),	   2.36-­‐2.16	   (m,	   5H),	   1.99	   (m,	   1H),	  
1.83-­‐1.72	  (m,	  4H),	  1.56-­‐1.51	  (m,	  4H),	  1.39-­‐1.23	  (m,	  7H),	  1.15	  (d,	  J	  =	  5.5	  Hz,	  3H),	  1.11	  (d,	  J	  =	  
6	  Hz,	  3H),	  1.03	  (d,	  J	  =	  6	  Hz,	  3H),	  0.91	  (d,	  J	  =	  6.5	  Hz,	  3H).	  
	  
HRMS	  (ESI)	  Calculated	  for	  C47H73NO16	  (M	  +	  H)+:	   	  	  	  	  	  	  	  	  	  	  	  	  	  908.5008	  































































1.	  	  (a)	  Monk,	  B.	  C.;	  Goffeau,	  A.	  Science	  2008,	  321,	  367.	  	  (b)	  Cannon,	  R.	  D.;	  Lamping,	  E.;	  	  
	  	  	  	  	  	  Holmes,	  A.	  R.;	  Niimi,	  K.;	  Tanabe,	  K.;	  Niimi,	  M.;	  Monk,	  B.	  C.	  Microbiology	  2007,	  153,	  3211.	  
2.	  (a)	  Keim,	  G.	  R.;	  Poutsiaka,	  J.	  W.;	  Kirpan,	  J.;	  Keysser,	  C.	  H.	  Science	  1973,	  179,	  584.	  (b)	  Ellis,	  	  
	  	  	  	  	  	  W.	  G.;	  Sorbel,	  R.	  A.;	  Nielsen,	  S.	  L.	  J.	  Infect.	  Dis.	  1982,	  146,	  125.	  (c)	  Cheron,	  M.;	  Cybulska,	  	  
	  	  	  	  	  	  B.;	  Mazerski,	  J.;	  Grzybowska,	  J.;	  Czerwinski,	  A.;	  Borowski,	  E.	  Biochem.	  Pharmacol.	  1988,	  	  
	  	  	  	  	  37,	  827.	  (d)	  Driver,	  M.	  J.;	  Greenless,	  A.	  R.;	  Macpherson,	  D.	  T.	  J.	  Chem.	  Soc.,	  Perkin	  Trans.	  1	  	  
	  	  	  	  	  1992,	  3155.	  (e)	  Slisz,	  M.;	  Cybulska,	  B.;	  Mazerski,	  J.;	  Grzybowska,	  J.;	  Borowski,	  E.	  J.	  	  
	  	  	  	  	  Antibiot.	  2004,	  57,	  669.	  (f)	  Paquet,	  V.;	  Volmer,	  A.	  A.;	  Carreira,	  E.	  M.	  Chem.	  Eur.	  J.	  2008,	  14,	  	  
	  	  	  	  	  2465.	  (g)	  Volmer,	  A.	  A.;	  Szpilman,	  A.	  M.;	  Carreira,	  E.	  M.	  Nat.	  Prod.	  Rep.	  2010,	  27,	  1329.	  
3.	  (a)	  Finkelstein,	  A.;	  Holz,	  R.	  In	  Lipid	  Bilayers	  and	  Antibiotics;	  Eisenman,	  G.,	  Ed.;	  Dekker:	  	  	  	  
	  	  	  	  	  New	  York,	  1973;	  p	  377.	  (b)	  Andreoli,	  T.	  E.	  Ann.	  N.Y.	  Acad.	  Sci.	  1974,	  235,	  448.	  (c)	  de	  	  
	  	  	  	  	  Kruijff,	  B.;	  Demel,	  R.	  A.	  Biochim.	  Biophys.	  Acta	  1974,	  339,	  57.	  (d)	  Bolard,	  J.	  Biochim.	  	  
	  	  	  	  	  Biophys.	  Acta	  1986,	  864,	  257.	  (e)	  Baginski,	  M.;	  Resat,	  H.;	  Borowski,	  E.	  Biochim.	  Biophys.	  	  
	  	  	  	  	  Acta	  2002,	  1567,	  63.	  (f)	  Cereghetti,	  D.	  M.;	  Carreira,	  E.	  M.	  Synthesis	  2006,	  6,	  914.	  (g)	  	  
	  	  	  	  	  Murata,	  M.;	  Kasai,	  Y.;	  Umegawa,	  Y.;	  Matsushita,	  N.;	  Tsuchikawa,	  H.;	  Matsumori,	  N.;	  Oishi,	  	  
	  	  	  	  	  T.	  Pure	  Appl.	  Chem.	  2009,	   81,	   1123.	   (h)	   Zietse,	  R.;	   Zoutendijk,	  R.;	  Hoorn,	   E.	   J.	  Nat.	  Rev.	  	  
	  	  	  	  	  Nephrol.	  2009,	  5,	  193.	  
4.	  	  Jin,	  H.,	  McCaffery,	  J.M.	  &	  Grote,	  E.	  J.	  Cell	  Biol.	  2008,	  180,	  813–826	  
5.	  	  Kato,	  M.	  &	  Wickner,	  W.	  EMBO	  J.	  2001,	  20,	  4035–4040	  (2001).	  
6.	  Heese-­‐Peck,	  A.	  et	  al.	  Mol.	  Biol.	  Cell	  	  2002,	  13,	  2664–2680.	  
7.	  te	  Welscher,	  Y.M.	  et	  al.	  Proc.	  Natl.	  Acad.	  Sci.	  USA	  2012,	  109,	  11156–11159	  
8.	  (a)	  Gray,	  K.	  C.;	  Palacios,	  D.	  S.;	  Dailey,	  I.;	  Endo,	  M.	  M.;	  Uno,	  B.	  E.;	  Wilcock,	  B.	  C.;	  Burke,	  M.	  D.	  	  
	  	  	  	  	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  2012,	  109,	  2234.	  	  (b)	  Palacios,	  D.	  S.;	  Dailey,	  I.;	  Siebert,	  D.	  M.;	  	  
	  	  	  	  	  Wilcock,	  B.	  C.;	  Burke,	  M.	  D.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  2011,	  108,	  6733.	  (c)	  Anderson,	  T.	  	  
	  	  	  	  	  M.;	  Clay,	  M.	  C.;	  Cioffi,	  A.	  G.;	  Diaz,	  K.	  A.;	  Hisao,	  G.	  S.;	  Tuttle,	  M.	  D.;	  	  	  	  	  	  
	  	  	  	  	  Nieuwkoop,	  	  A.	  J.;	  Comellas,	  G.;	  Maryum,	  N.;	  Wang,	  S.;	  Uno,	  B.	  E.;	  Wildeman,	  E.	  L.;	  Gonen,	  	  	  	  
	  	  	  	  	  T.;	  Rienstra,	  C.	  M.;	  Burke,	  M.	  D.	  Nat.	  Chem.	  Bio.	  2014,	  published	  online	  March	  30,	  2014	  
9.	  (a)	  Silberstein,	  A.	  J.	  Membr.	  Biol.	  1998,	  162,	  117.	  	  (b)	  Matsumori,	  N.;	  Sawada,	  Y.;	  Murata,	  	  
	  	  	  	  	  	  	  M.	  J.	  Am.	  Chem.	  Soc.	  2005,	  127,	  10667.	  	  (c)	  Neumann,	  A.;	  Czub,	  J.;	  Baginski,	  M.	  J.	  Phys.	  	  	  	  
 76 
	  	  	  	  	  	  	  Chem.	  B	  2009,	  113,	  15875.	  (d)	  Czub,	  J.;	  Neumann,	  A.;	  Borowski,	  E.;	  Baginski,	  M.	  Biophys.	  	  	  	  
	  	  	  	  	  	  	  Chem.	  2009,	  141,	  105.	  (e)	  Croatt,	  M.	  P.;	  Carreira,	  E.	  M.	  Org.	  Lett.	  2011,	  13,	  1390.	  
10.	  Wilcock,	  B.	  C.;	  Uno,	  B.	  E.;	  Bromann,	  G.	  L.;	  Clark,	  M.	  J.;	  Anderson,	  T.	  M.;	  Burke,	  M.	  D.	  Nat.	  	  
	  	  	  	  	  	  	  Chem.	  2012,	  4,	  996.	  
11.	  Wilcock,	  B.	  C.;	  Endo,	  M.	  M.;	  Uno,	  B.	  E.;	  Burke,	  M.	  D.	  J.	  Am.	  Chem.	  Soc.	  2013,	  135,	  	  
	  	  	  	  	  	  	  8488-­‐8491.	  
12.	  Overend,	  W.	  G.;	  Rees,	  C.	  W.;	  Sequeria,	  J.S.;	  J.	  Am.	  Chem.	  Soc.	  1962,	  3429-­‐40	  
13.	  Hammond,	  G.	  S.	  J.	  Am.	  Chem.	  Soc.	  1955,	  77,	  334-­‐338.	  
14.	  Mensah,	  E.	  A.;	  Azzarelli,	  J.	  A.;	  Nguyen,	  H.	  M.	  J.	  Org.	  Chem.	  2009,	  74,	  1650-­‐1657	  
15.	  Nicolaou,	  K.	  C.;	  Daines,	  R.	  A.;	  Chakraborty,	  T.	  K.;	  Ogawa,	  Y.	  J.	  Am.	  Chem.	  	  
	  	  	  	  	  	  	  Soc.1987,	  109,	  2821-­‐2822.	  
16.	  Szpilman,A.	  M.;	  Cereghetti,	  D.	  M.;	  Manthrope,	  j.	  M.;	  Wurtz,	  N.	  R.;	  Carreira,	  E.	  M.	  	  
	  	  	  	  	  	  	  Chem.Eur.	  J.	  2009,	  15,	  7117-­‐7128.	  
17.	  Guo,	  H.;	  O’	  Doherty,	  G.	  A.	  Angew.	  Chem.,	  Int.	  Ed.	  2007,	  46,	  5206.	  
18.	  Lepak	  A	  Castanheira	  M	  Diekema	  D	  Pfaller	  M	  Andes	  D	  .	  Antimicrob	  Agents	  	  
	  	  	  	  	  	  	  Chemother.	  2012,	  56(11):5875-­‐82	  
19.	  Examples	  of	  ligand-­‐selective	  allosteric	  effects	  in	  proteins:	  (a)	  Duggan,	  K.	  C.;	  Hermanson,	  	  
	  	  	  	  	  	  	  	  D.	  J.;	  Musee,	  J.;	  Prusakiewicz,	  J.	  J.;	  Scheib,	  J.	  L.;	  Carter,	  B.	  D.;	  Banerjee,	  S.;	  Oates,	  J.	  A.;	  	  
	  	  	  	  	  	  	  	  Marnett,	  L.	  J.	  Nat.	  Chem.	  Biol.	  2011,	  7,	  803.	  (b)	  Neant-­‐Fery,	  M.;	  Garcia-­‐Ordonez,	  R.	  D.;	  	  
	  	  	  	  	  	  	  	  Logan,	  T.	  P.;	  Selkoe,	  D.	  J.;	  Li,	  L.;	  Reinstatler,	  L.;	  Leissring,	  M.	  A.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  
	  	  	  	  	  	  	  	  2008,	  105,	  9582.	  (c)	  Knight,	  Z.	  A.;	  Shokat,	  K.	  M.	  Chem.	  Biol.	  2005,	  12,	  621.	  (d)	  Koike,	  K.;	  	  
	  	  	  	  	  	  	  	  Oleschuk,	  C.	   J.;	  Haimeur,	  A.;	  Olsen,	  S.	  L.;	  Deeley,	  R.	  G.;	  Cole,	  S.	  P.	  C.	  J.	  Biol.	  Chem.	  2002,	  	  
	  	  	  	  	  	  	  	  277,	  49495.	  (e)	  Changeux,	  J.	  P.;	  Edelstein,	  S.	  J.	  Neuron	  1998,	  21,	  959.	  
20.	  	  a)	  Ganis,	  P.;	  Avitabile,	  G.;	  Mechlinski,	  W.;	  Schaffner,	  C.	  P.	  J.	  Am.	  Chem.	  Soc.	  1971,	  93,	  	  
	  	  	  	  	  	  	  	  4560.	  	  (b)	  Jarzembska,	  K.	  N.;	  Kaminski,	  D.;	  Hoser,	  A.	  A.;	  Malinska,	  M.;	  Senczyna,	  B.;	  	  	  	  
	  	  	  	  	  	  	  	  Wozniak,	  K.;	  Gagos,	  M.	  Cryst.	  Growth	  Des.	  2012,	  12,	  2336.	  
21.	  Pangborn,	  A.B.;	  Giardello,	  M.A.;	  Grubbs,	  R.H.;	  Rosen,	  R.K.;	  Timmers,	  F.J.	  	  	  	  	  	  




CHAPTER	  4:	  THE	  C3’-­‐AMMONIUM	  OF	  AMB	  IS	  ANOTHER	  POTENTIAL	  SITE	  OF	  ALLOSTERIC	  
MODIFICATION,	  LEADING	  TO	  LIGAND	  SELECTIVE-­‐BINDING	  OF	  ERGOSTEROL	  OVER	  
CHOLESTEROL	  
	  
4-­‐1:	  UNDERSTANDING	  THE	  ROLE	  OF	  THE	  C3’-­‐NH3+	  
	  
	   A	  major	   contributor	   to	   the	   lack	   of	   progress	   toward	   a	   clinically	   viable	   therapeutic	  
replacement	   for	   AmB	   has	   been	   poor	   understanding	   of	   the	  mechanism(s)	   by	  which	   AmB	  
impacts	  yeast	  and	  human	  cells.	   	   It	  has	   for	  half	   a	   century	  been	  widely	  accepted	   that	  AmB	  
kills	  both	  types	  of	  cells	  primarily	  via	  ion	  channel	  mediated	  membrane	  permeabilization.1,2,3	  	  
Guided	   by	   this	   model,	   extensive	   efforts	   have	   focused	   on	   the	   challenging	   problem	   of	  
selectively	  forming	  ion	  channels	  in	  yeast	  vs.	  human	  cells.2,3	  
	   In	   contrast	   to	   this	   classic	  model,	  we	   recently	   discovered	   that	   AmB	   primarily	   kills	  
yeast	   cells	   by	   simply	   binding	   ergosterol	   (Erg);	   channel	   formation	   is	   not	   required.4	   	   This	  
suggests	  that	  binding	  cholesterol	  (Chol)	  may	  account	  primarily	   for	  the	  toxicity	  of	  AmB	  to	  
human	   cells	   and	   that	   efforts	   to	   improve	   AmB	   can	   focus	   on	   the	   simpler	   problem	   of	  
maximizing	  the	  relative	  binding	  affinity	  for	  Erg	  vs.	  Chol.	  	  	  
As	  we	  have	  discussed	  in	  the	  previous	  chapters	  when	  the	  mycosamine	  appendage	  is	  
deleted,	   the	   resulting	  derivative	   can	  no	   longer	  bind	  either	  Erg	  or	  Chol.4	   	  This	   inability	   to	  
bind	  sterols	  leads	  to	  a	  derivative	  that	  is	  nontoxic	  to	  both	  yeast	  and	  human	  cells.5	  	  	  With	  the	  
mycosamine	  highlighted	  as	  being	  critical	  for	  AmB’s	  ability	  to	  bind	  sterols,	  we	  hypothesized	  
that	  one	  or	  more	  of	  the	  heteroatoms	  contained	  on	  it	  was	  responsible	  for	  this	  phenomenon.	  
In	  the	  leading	  structural	  model,	  AmB	  interacts	  
with	  both	  Erg	  and	  Chol	  via	  a	  similar	  binding	  mode	  in	  
which	  the	  C2’-­‐hydroxyl	  group	  of	  AmB	  forms	  a	  critical	  
H-­‐bond	   to	   the	  3β-­‐hydroxyl	  group	  on	  each	  sterol	   (fig	  
4.1).6	  	  However,	  in	  contrast	  to	  this	  leading	  model,	  we	  
recently	  discovered	  that	  the	  C2’-­‐OH	  of	  AmB	  plays	  an	  
important	  role	  in	  binding	  Chol	  but	  not	  Erg.7	  	  Because	  





























Figure 4.1: Previous leading model of AmB sterol binding 




of	  AmB	  that	  readily	  binds	  both	  Erg	  and	  Chol.	  Deletion	  of	  this	  hydroxyl	  group,	  we	  propose,	  
favors	   a	   shift	   to	   a	   different	   conformer	   or	   set	   of	   conformers	  which	   retain	   the	   capacity	   to	  
bind	  Erg	  but	  not	  Chol.	  	  	  Alternatively	  stated,	  this	  model	  predicts	  that	  deletion	  of	  the	  C2’-­‐OH	  
of	   AmB	   causes	   a	   small-­‐molecule-­‐based	   allosteric	   effect	   that	   results	   in	   ligand-­‐selective	  
binding.	  
	   However,	   it	   is	   still	   possible	   that	  AmB	   interacts	  with	   these	   two	   sterols	   via	   distinct	  
binding	   modes.	   It	   is	   possible	   that	   the	   C2’-­‐OH	   uniquely	   participates	   in	   a	   direct	   binding	  
interaction	   with	   Chol,	   and	   that	   the	   C3’-­‐NH3+	   uniquely	   participates	   in	   a	   direct	   binding	  
interaction	  with	  Erg.	  	  This	  model	  could	  explain	  the	  observed	  difference	  in	  binding	  between	  
the	  sterols	  for	  C2’deOAmB.	  	  Furthermore	  it	  has	  been	  previously	  proposed	  in	  the	  literature	  
that	   the	   C3’-­‐NH3+	   is	   “indispensable	   for	   [AmB’s]	   biological	   activity	   and	   antibiotic-­‐sterol	  
interaction”.8c	   Additionally,	   other	   reports	   have	   indicated	   that	   the	   C3’-­‐NH3+	   is	   critical	   for	  
channel	  formation.9	  	  	  
	   In	   order	   to	   differentiate	   between	   the	   proposed	   mycosamine	   mediated	   binding	  
models—a	  direct	  binding	  model	  or	  an	  allosteric	  binding	  model—we	  needed	  to	  synthesize	  a	  
derivative	  lacking	  the	  C3’-­‐NH3+.	  	  Furthermore,	  we	  would	  also	  be	  in	  a	  position	  to	  investigate	  
the	  C3’-­‐NH3+’s	  role	  in	  ion	  channel	  formation.	  	  
	  
4-­‐2:	  SYNTHESIS	  AND	  STUDY	  OF	  C3’-­‐DEAMINO	  AMB	  
	  
I	   realized	   that	   a	   simmilar	   hybrid	   synthetic	   strategy	   successfully	   employed	   in	   the	  
synthesis	   of	   C2’deOAmB7	   would	   be	   amenable	   for	   the	   construction	   of	   C3’deNHAmB.	  
Additionally	   the	   common	   intermediate,	   epoxy-­‐alcohol10	   4.1—identical	   to	   3.16—would	  
readily	   lead	  to	  a	  C3’deamino	  sugar	  donor	  (Scheme	  4.1).	   	  From	  epoxy-­‐alcohol	   4.1,	   lithium	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from	  LiEt3BH	  opening	  at	  the	  C2’-­‐position)	  with	  yielding	  2,4-­‐diol	  4.2	  in	  70%	  yield.	  	  With	  an	  
equatorial	   hydroxyl	   group	   at	   the	   C2’-­‐position	   we	   could	   now	   take	   advantage	   of	   well	  
precedented	   anchimeric	   assistance	   methodology	   to	   selectively	   favor	   β	  over	  α	   glycoside	  
formation.11,12	  	  	  
We	   contemporaneously	   developed	   a	   pivolate-­‐like	   directing	   group	  with	   a	   primary	  
azide	   on	   the	   end	   of	   an	   ethyl	  
tail.	   The	   azido-­‐dimethyl	  
butyrate	   (AzDMB)	   group	   is	  
designed	   to	   maximize	   the	  
formation	   of	   the	   β-­‐glycoside,	  
prevent	   orthoester	   formation	  
and	  be	  readily	  removed	  under	  mild	  Staudinger	  deprotection	  conditions	  (Fig.	  4.2).13	  	  As	  the	  
acid	  chloride,	   the	  AzDMB	  group	  was	   installed	   to	  afford	  4.3	   in	  89%	  yield	  with	  93:7	  C2:C4	  
hydroxyl	   selectivity.	   	   Subsequent	  silylation	  at	   the	  C4-­‐OH	  with	  TBSCl	  afforded	  4.4	   in	  91%	  
yield.	  DDQ	  mediated	  PMB	  hydrolysis	  (4.5)	  and	  2,2,2-­‐trichloroacetimidate	  activation	  at	  C1	  
provided	  a	  robust	  and	  scalable	  route	  to	  the	  C3’deNH2	  sugar	  donor	  4.64	  (Scheme	  4.2).	  
	  
	  
	   	  
The	  persylilated	  macrolide	  acceptor	  4.7,	   previously	   reported	  by	  Palacios	  et	   al.,5	   is	  
similar	  to	  the	  macrolide	  acceptor	  3.13.7	  We	  envisioned	  the	  more	  robust	  allyl	  ester	  would	  
be	  required	  since	  an	  inversion	  of	  stereochemistry	  at	  C2’	  via	  a	  tandem	  oxidation	  reduction	  
sequence	  was	  needed	  to	  complete	  the	  synthesis	  of	  C3’deNHAmB.	  	  Glycosylation	  of	  aglycone	  
4.7	   with	   sugar	   donor	   4.6	   proceeded	   under	   2-­‐chloro-­‐6-­‐methyl	   pyridine	   and	   2-­‐chloro-­‐6-­‐
methyl	   pyridine	   triflic	   acid	   salt	   buffered	   conditions12	   and	   resulted	   in	   a	   65%	  yield	   of	  4.8	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Scheme 4.2: Synthesis of C3'deamino sugar donor, highlighting selective acylation of C2'-OH over C4'OH with AzDMB acid chloride.

































was	   readily	   removed	   with	   a	   two-­‐step	   reduction,	   hydrolysis	   procedure.	   	   Staudinger-­‐like	  
conditions	  using	  PMe3	  with	  100	  equivalents	  of	  water	  at	  55	  °C	  completely	  reduced	  the	  azide	  
(74%	   yield)	   and	   resulted	   in	   a	  minimal	   formation	   of	  4.9	   (25%)	  where	   the	   auxiliary	  was	  
removed.	  	  The	  free	  amine	  was	  converted	  to	  4.9	  with	  a	  sub-­‐stoichiometric	  amount	  of	  KOH	  in	  
THF	  water	  at	  ambient	  temperature.13	  	  This	  hydrolysis	  step	  was	  cycled	  an	  additional	  time	  to	  
afford	  4.9	  in	  57%	  yield	  (yield	  reported	  over	  two	  steps	  from	  azido-­‐β-­‐glycoside	  4.8)	  (Scheme	  
4.3).	  	  
It	  is	  noteworthy	  that,	  in	  the	  context	  of	  the	  total	  synthesis,	  if	  the	  AzDMB-­‐mycosamine	  
donor	  was	  selectively	  glycosylated	  to	  the	  aglycone,	  the	  AzDMB	  group	  could	  not	  be	  removed	  
from	  the	  C2’-­‐OH	  if	  the	  C3’-­‐N3	  was	  present.	  	  We	  hypothesized	  that	  the	  bulky	  AzDMB	  group	  
cannot	  achieve	  the	  required	  conformation	  for	  lactam	  formation	  if	  a	  neighboring	  equatorial	  
substituent	  is	  present.	  	  	  Therefore,	  other	  mycosamine	  modified	  AmB	  derivatives	  where	  the	  
C3’-­‐amine	  is	  present,	  should	  be	  synthesized	  through	  other	  means—either	  with	  a	  different	  
anchimeric	  assistance	  auxiliary,12	  or	  a	  degeradative	  strategy.7b	  	  
The	   inversion	   of	   the	   C2’-­‐stereocenter	   of	   4.9	   was	   achieved	   only	   after	   some	  
optimization.	   	   In	  Nicolaou’s	   total	   synthesis	   of	   AmB,	   inversion	   of	   the	   equatorial	   C2-­‐OH	   to	  
axial	   C2’-­‐OH	  proceeded	   in	   good	   yields	   and	   >20:1	   selectivity,	   employing	   a	   tandem	   Swern	  
oxidation	   -­‐	   sodium	  borohydride	   reduction.14	   	   However,	   in	   the	   absence	   of	   a	   C3’-­‐N3,	   these	  
conditions	  resulted	  in	  no	  selectivity	  for	  the	  desired	  axial	  C2’-­‐OH.	  	  Furthermore,	  upon	  global	  
deprotection,	  the	  two	  C2’-­‐OH	  epimers	  were	  completely	  inseparable	  by	  HPLC.	  	  Fortuitously,	  
stereoselective	   hydride	   reductions	   of	   conformationally	   rigid	   cyclic	   ketones	   have	   been	  
previously	  addressed	  in	  the	  literature.	  In	  1956,	  Noyce	  and	  coworkers	  described	  how	  bulky	  
hydrides	  attack	  cyclic	  ketones	  from	  the	  more	  sterically	  accessible	  equatorial	  trajectory	  and	  
override	  torsional	  strain,	  thus	  favoring	  the	  axial	  product.15	  	  Based	  on	  this	  well	  established	  
rational,	   the	   bulky	   L-­‐selectride	   was	   employed	   to	   afford	   4.10	   in	   >20:1	   axial:equatorial	  
selectivity	  in	  30%	  over	  two	  steps.	  	  	  
	   Since	   our	   strategy	   was	   informed	   by	   the	   successful	   synthesis	   of	   C2’deOAmB,	   we	  
employed	   labile	   TES	   groups	   that	   were	   removed	   under	   mild	   HF-­‐pyridine	   conditions	   to	  
afforded	   4.11	   in	   27%	   yield.	   	   Subsequent	   hydrolysis	   of	   the	   C41-­‐allylester	   under	   mild	  
Pd(PPh3)4	  with	   thiosalysilic	   acid	   in	  DMF	   for	   1	   hour,	   afforded	  C3’deNHAmB	   in	   47%	  yield	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after	  HPLC	  purification(MeCN:	  H2O	  with	  0.1%	  formic	  acid).4	  Fortuitously,	  the	  hydrolysis	  to	  
the	   hemiketal—the	   actual	   final	   step—was	   carried	   out	   cleanly	   and	   quantitatively	   while	  
concentrating	  aqueous	  acidic	  HPLC	  fractions	  containing	  the	  penultimate	  methylketal.	  	  	  
	  
In	  our	  MIC	  assays,	  C3’deNHAmB	  is	  active	  against	  two	  yeast	  strains	  S.	  cerevisiae	  and	  
C.	   albicans	   at	   3	   uM	   and	   4	   uM	   respectively4.	   These	   data	   reveal	   that,	   in	   contrast	   to	   prior	  
predictions,	  the	  C3’-­‐NH3+	  group	  is	  in	  fact	  not	  required	  for	  biological	  activity.8,9	  	  Additionally,	  
we	  have	  assayed	  C3’deNHAmB	  against	  human	  red	  blood	  cells	  and	  have	  observed	  that	  this	  
compound—like	   C2’deOAmB—shows	   no	   hemolytic	   activity	   up	   to	   the	   limits	   of	   solubility	  
(MHC:	   >500	   mM).16a	   Based	   on	   our	   previous	   work	   that	   establishes	   a	   strong	   correlation	  
between	  sterol	  binding	  and	  biological	  activity,	  these	  preliminary	  biological	  data4,7	  suggests	  
that	   C3’deNHAmB	   will	   still	   bind	   Erg	   but	   not	   bind	   Chol.	   	   My	   colleague	   is	   currently	  
concluding	   the	   ITC	   experiments	   to	   test	   this	   prediction	   along	   with	   potassium	   efflux	  
experiments	  to	  confirm	  that	  C3’deNHAmB	  still	  capable	  of	  permeablizing	  membranes.	  	  
Collectively	   these	   findings	   suggest	   that	   neither	   the	   C2’-­‐OH	   nor	   the	   C3’-­‐NH3+	   are	  
directly	   responsible	   for	   AmB’s	   ability	   to	   bind	   sterols.	   	   Although	   ITC	   data	   is	   needed	   to	  
determine	  C3’-­‐NH3+’s	  ability	  to	  bind	  sterols,	  we	  can	  infer	  from	  these	  preliminary	  biological	  
data	  that	  these	  residues	  could	  be	  involved	  in	  stabilizing	  a	  conformation	  of	  AmB	  that	  binds	  
both	  Erg	  and	  Chol.	  	  If	  either	  of	  these	  intramolecular	  polar	  interactions	  were	  removed,	  such	  
an	   allosteric	   modification	   would	   change	   the	   shape	   of	   the	   binding	   site	   on	   the	   molecule,	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    CDCl3, 0 oC, 2h 
2. L-selectride
   THF, -78 oC 0.5 h
   26% over 2 steps
   >20:1 !:" C2'-OH
1. HF-pyr, pyridine
    THF, MeOH, 0 oC 
    to 23 oC, 18 h 27% 
2. Pd(PPh3)4
    thiosalicylic acid
    DMF, 23 oC, 1h;
    HPLC purification
    47% over 2 steps
Scheme 4.3: Synthesis of C3'deNHAmB via "-selective glycosylation mediated by the AzDMB auxiliary. L-selectride facilitated >20:1 selectivity for 
the !-C2'OH
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magnifying	   Erg	   selectivity,	   and	   in	   effect,	   reducing	   human	   toxicity.	   This	   realization	   helps	  




4-­‐3:	  EXPERIMENTAL	  SECTION	  
	  
Materials.	   Commercial	   reagents	   were	   purchased	   from	   Sigma-­‐Aldrich,	   Strem,	   Alfa	   Aesar,	  
and	  Fisher	  Scientific	  and	  used	  without	  further	  purification	  unless	  otherwise	  noted.	  Solvents	  
were	   purified	   by	   passage	   through	   packed	   columns	   by	   the	   method	   of	   Pangborn	   and	  
coworkers17	  (THF,	  Et2O,	  CH3CN,	  CH2Cl2:	  dry	  neutral	  alumina;	  benzene,	  toluene:	  dry	  neutral	  
alumina	   and	   Q5	   reactant;	   DMSO,	   DMF,	   CH3OH:	   activated	   molecular	   sieves).	   Water	   was	  
obtained	   from	  a	  Millipore	   (Billerica,	  MA)	  MilliQ	  water	  purification	   system.	  Triethylamine	  
was	  freshly	  distilled	  under	  an	  atmosphere	  of	  nitrogen	  from	  CaH2.	  (±)-­‐10-­‐Camphorsulfonic	  
acid	  was	  recrystallized	  from	  EtOAc.	  	  
	  
General	  Experimental	  Procedures.	  All	  reactions	  were	  performed	  in	  flame-­‐	  or	  oven	  (125	  
°C)-­‐dried	  glassware	  under	  an	  atmosphere	  of	  dry	  nitrogen	  or	  argon	  unless	  otherwise	  stated.	  
Reactions	  were	  monitored	  by	  analytical	   thin	   layer	  chromatography	  (TLC)	  on	  Merck	  silica	  
gel	   60	   F254	   plates	   (0.25	   mm)	   using	   the	   indicated	   solvent	   system.	   Compounds	   were	  
visualized	   by	   exposure	   to	   UV	   light	   (254	   nm),	   or	   by	   an	   acidic	   solution	   of	  p-­‐anisaldehyde	  
followed	   by	   heating	   with	   a	   Varitemp	   heat	   gun.	   Flash	   column	   chromatography	   was	  
performed	  as	  described	  by	  Still	  and	  coworkers2	  using	  Merck	  silica	  gel	  60	  (230-­‐400	  mesh).	  	  
	  
Structural	  Analysis.	  1H	  NMR	  spectra	  were	  recorded	  at	  ambient	  temperature	  using	  one	  of	  
the	   following	   instruments:	   Varian	   Unity	   500	   (500	  MHz),	   Varian	   VXR	   500	   (500	  MHz),	   or	  
Varian	   Unity	   Inova	   500NB	   (500	  MHz).	   Chemical	   shifts	   are	   reported	   in	   parts	   per	  million	  
(ppm)	  downfield	   from	   tetramethylsilane	   and	   referenced	   to	   residual	   protium	   in	   the	  NMR	  
solvent	   (CDCl3,	   δ	   =	   7.26;	   (CD3)2CO,	   δ	   =	   2.05,	   center	   line).	   Spectral	   data	   are	   presented	   as	  
follows:	  chemical	  shift,	  multiplicity	  (s	  =	  singlet,	  d	  =	  doublet,	  t	  =	  triplet,	  q	  =	  quartet,	  sext	  =	  
sextet,	   dd	   =	   doublet	   of	   doublets,	   dt	   =	   doublet	   of	   triplets,	   ddd	   =	   doublet	   of	   doublet	   of	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doublets,	  m	  =	  multiplet,	  b	  =	  broad,	  app	  =	  apparent),	  coupling	  constant	  (J),	  and	  integration.	  
13C	   NMR	   spectra	   were	   recorded	   at	   ambient	   temperature	   using	   one	   of	   the	   following	  
instruments:	  Varian	  VXR	  500	  (125	  MHz),	  Varian	  Unity	  500	  (125	  MHz),	  or	  Varian	  Unity	  400	  
(101	   MHz)	   instrument.	   Chemical	   shifts	   are	   reported	   in	   ppm	   downfield	   from	  
tetramethylsilane	   and	   referenced	   to	   carbon	   resonances	   in	   the	   NMR	   solvent	   (CDCl3,	   δ	   =	  
77.16,	  center	  line;	  (CD3)2CO,	  δ	  =	  29.84,	  center	  line).	  High-­‐resolution	  mass	  spectra	  (HRMS)	  
were	  acquired	  by	  Mr.	  Pulin	  Wang,	  Mr.	  Furong	  Sun,	  or	  Dr.	  Haijun	  Yao	  at	   the	  University	  of	  
Illinois	   School	   of	   Chemical	   Sciences	  Mass	   Spectrometry	   Laboratory.	  Data	   are	   reported	   in	  
the	  form	  of	  m/z.	  Gas	  chromatography	  analysis	  was	  conducted	  on	  an	  Agilent	  Technologies	  
7890A	  instrument.	  The	  diastereoselectivity	  of	  lactonization	  was	  determined	  by	  GC	  analysis	  
with	   an	   Agilent	   Technologies	   chiral	   β-­‐cyclodextrin	   stationary	   phase	   (part	   number	   112-­‐
2532).	  X-­‐ray	  crystallographic	  analysis	  was	  carried	  out	  by	  Dr.	  Danielle	  gray	  at	  the	  University	  
of	  Illinois	  George	  L.	  Clark	  X-­‐Ray	  facility.	  
	  
	  




Epoxy	  alcohol	  4.1	  (2.45	  g,	  9.21	  mmol,	  1.0	  equiv)	  was	  azeotropically	  dried	  with	  benzene	  (3x	  
5	  mL)	  and	  placed	  under	  high	  vac	  overnight	  in	  a	  250	  mL	  round	  bottom	  flask.	  A	  rigorously	  
dried	  500	  mL	  single-­‐neck	  round	  bottom	  flask	  under	  an	  nitrogen	  atmosphere	  was	  charged	  
with	   dry	   uninhibited	   THF	   (100	  mL)	   and	   subsequently	   cooled	   to	   0	   °C.	   Lithiumaluminum	  
hydride	  	  (700	  mg,	  18.42	  mmol,	  2.0	  equiv)	  was	  carefully	  added	  as	  a	  solid	  powder	  to	  the	  500	  
mL	  flask	  forming	  a	  dark	  grey	  slurry.	   	  4.1	  was	  then	  dissolved	  in	  dry	  THF	  (90	  mL)	  and	  the	  
subsequent	   solution	   was	   added	   drop	   wise	   via	   cannula	   to	   the	   cold	   stirring	   LiAlH4	   THF	  
slurry.	   	  The	  addition	  was	  complete	   in	  approximately	  10	  min	  whereupon	  the	   ice	  bath	  was	  
removed	  and	  the	  stirring	  solution	  was	  allowed	  to	  warm	  to	  23	  °C	  over	  20	  h.	   	  The	  reaction	  
was	   then	  cooled	   to	  0	  °C	   for	  10	  min	   followed	  by	  slow	  sequential	  addition	  of	  dry	  Et2O	  (60	  
















(3.0	  mL).	  The	  quenched	  reaction	  was	  allowed	  to	  warm	  up	  to	  23	  °C	  by	  removal	  of	   the	   ice	  
bath	  and	  stirred	  for	  an	  additional	  30	  min	  followed	  by	  excess	  solid	  sodium	  sulfate	  powder.	  	  
The	   slurry	  was	   filtered,	   filter	   cake	  was	  washed	  with	   Et2O,	   and	   the	   resulting	   filtrate	  was	  
concentrated	   under	   reduced	   pressure.	   Purification	   via	   flash	   chromatography	   (SiO2,	  
gradient	  elution:	  1:1	  Hex:EtOAc	   to	  1:2	  Hex:EtOAc	   to	  100%	  EtOAc)	  afforded	  PMB-­‐diol	  4.2	  
(1.79	  g,	  6.67	  mmol,	  72%)	  as	  a	  clear	  colorless	  oil.	  
	  
	  
Rf	  =	  0.25	  (1:1	  Hex:EtOAc,	  CAM	  stain)	  
	  
1H	  NMR	  (500	  MHz,	  CDCl3)	  δ	  7.27	  (dd,	  J	  =	  9.4,	  2.8	  Hz,	  2H),	  6.92	  –	  6.86	  (m,	  2H),	  4.79	  (d,	  J	  =	  3.7	  
Hz,	  1H),	  4.70	  (d,	  J	  =	  11.4	  Hz,	  1H),	  4.47	  (d,	  J	  =	  11.4	  Hz,	  1H),	  3.81	  (d,	  J	  =	  0.8	  Hz,	  3H),	  3.73	  –	  
3.65	  (m,	  1H),	  3.57	  (dq,	  J	  =	  9.0,	  6.2	  Hz,	  1H),	  3.28	  (dddd,	  J	  =	  10.6,	  9.2,	  5.9,	  4.5	  Hz,	  1H),	  2.17	  (dt,	  
J	  =	  11.5,	  4.6	  Hz,	  1H),	  2.07	  (dd,	  J	  =	  11.0,	  1.1	  Hz,	  1H),	  1.78	  (dd,	  J	  =	  5.9,	  1.8	  Hz,	  1H),	  1.66	  (q,	  J	  =	  
11.4	  Hz,	  1H),	  1.24	  (dd,	  J	  =	  6.3,	  0.8	  Hz,	  3H).	  
	  
13C	   NMR	   (126	  MHz,	   CDCl3)	   δ	   159.53,	   129.70,	   114.03,	   96.54,	   70.90,	   69.27,	   69.11,	   67.64,	  
55.43,	  37.11,	  17.47	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C14H20O5	  (M	  +	  Na)+:	  	  291.1208	  




















AzDMB	  acid	  (4.72	  g,	  30.04	  mmol,	  2.0	  equiv)	  was	  azeotropically	  dried	  with	  benzene	  (3x	  5	  
mL)	   in	  a	  100	  mL	  round	  bottom	  flask	  equipped	  with	  a	  reflux	  condenser.	  Dry	  benzene	  (12	  
mL)	   was	   then	   added	   under	   inert	   atmosphere	   followed	   by	   oxallylchloride	   (9.5	   mL,	   75.1	  
mmol,	  5.0	  equiv)	  and	  heated	  to	  50	  °C	  for	  15	  min	  (until	  gas	  formation	  ceases).	  	  The	  excess	  
oxallychloride	  was	  then	  removed	  under	  reduced	  pressure	  followed	  by	  azeotropic	  removal	  
with	  benzene	  (3x	  10	  mL)	  to	  yield	  a	  yellow	  oil.	  	  Pyridine	  (60	  mL,	  0.5	  M	  relative	  to	  AzDMB)	  
was	  then	  added	  to	  the	  AzDMB	  acid	  chloride	  and	  stirred	  at	  23	  °C	  while	   the	  substrate	  was	  
prepared.	  	  To	  a	  separate	  100	  mL	  round	  bottom	  flask,	  PMB-­‐diol	  4.2	  (4.0	  g,	  15.02	  mmol,	  1.0	  
equiv)	  was	   added	  and	  azeotropically	  dried	  with	  benzene	   (3x	  10	  mL),	   placed	  under	   inert	  
atmosphere,	  then	  charged	  with	  pyridine	  (40	  mL,	  0.375M)	  and	  cooled	  to	  0	  °C.	  	  The	  AzDMB	  
acid	   chloride	   pyridine	   solution	  was	   then	   added	   to	   the	   solution	   containing	   the	   substrate	  
drop	  wise	  via	  cannula	  at	  0	  °C	  over	  15	  min.	  	  The	  reaction	  was	  stirred	  for	  an	  additional	  3	  h	  at	  
0	  °C	  then	  transferred	  to	  a	  seperatory	  funnel	  containing	  saturated	  aqueous	  NH4Cl	  and	  Et2O.	  
Organics	  were	  washed	  2	  more	  times	  with	  NH4Cl	  then	  aqueous	  phases	  were	  back	  extracted	  

















toluene, 50 oC, 10 min;
pyridine, 0 oC
3 h, 89% 
93:7 2':4'4.2 4.3
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then	  the	  resulting	  aqueous	  phases	  were	  back	  extracted	  with	  Et2O.	  	  The	  combined	  organics	  
were	  washed	  with	   saturated	   brine,	   dried	  with	   sodium	   sulfate,	   filtered	   and	   concentrated	  
under	  reduced	  pressure.	  	  Purification	  via	  flash	  chromatography	  (SiO2,	  gradient	  elution:	  3:1	  
Hex:EtOAc	   to	   1:1	   Hex:EtOAc	   to	   100%	   EtOAc)	   yielded	   C2’-­‐AzDMB-­‐alcohol	   4.3	   (5.432	   g,	  




Rf	  =	  0.22	  (3:1	  Hex:EtOAc,	  CAM	  stain)	  
	  
1H	  NMR:	  (500	  MHz,	  CDCl3)	  δ	  7.26	  –	  7.24	  (m,	  2H),	  6.88	  –	  6.84	  (m,	  2H),	  4.89	  (d,	  J	  =	  3.5	  Hz,	  
1H),	  4.75	  (ddd,	  J	  =	  12.3,	  4.9,	  3.5	  Hz,	  1H),	  4.64	  (d,	  J	  =	  11.7	  Hz,	  1H),	  4.44	  (d,	  J	  =	  11.7	  Hz,	  1H),	  
3.62	  (dq,	  J	  =	  9.2,	  6.2	  Hz,	  1H),	  3.37	  (ddd,	  J	  =	  11.2,	  9.3,	  4.6	  Hz,	  1H),	  3.26	  –	  3.13	  (m,	  2H),	  2.11	  
(dt,	  J	  =	  11.3,	  4.7	  Hz,	  1H),	  1.98	  –	  1.89	  (m,	  1H),	  1.79	  (ddd,	  J	  =	  8.2,	  7.1,	  1.2	  Hz,	  2H),	  1.25	  (d,	  J	  =	  
6.0	  Hz,	  4H),	  1.16	  (s,	  6H).	  
	  
13CNMR:	   (126	  MHz,	   CDCl3)	   δ	   176.37,	   159.46,	   129.73,	   113.91,	   93.94,	   71.03,	   69.27,	   68.88,	  
68.87,	  55.43,	  47.95,	  38.75,	  32.85,	  25.35,	  17.50.	  
	  
	  




To	  a	  stirring	  solution	  of	  alcohol	  4.3	   (5.4	  g,	  13.25	  mmol,	  1.0	  equiv)	   in	  DMF	  (26.5	  mL)	  in	  a	  
100	  mL	  round	  bottom	  flask	  at	  23	  °C,	  was	  added	  sequentially	  imidazole	  (2.95	  g,	  46.4	  mmol,	  





























h	   then	   transferred	   to	   a	   seperatory	   funnel	   containing	   Et2O	   and	   saturated	   aqueous	  
bicarbonate	  and	  extracted	  with	  more	  Et2O.	  	  The	  combined	  organics	  were	  then	  washed	  with	  
deionized	  water,	  back	  extracted	  with	  Et2O,	  and	  washed	  with	  brine.	  	  The	  combined	  organics	  
were	  dried	  over	  sodium	  sulfate,	  filtered	  concentrated	  under	  reduced	  pressure.	  Purification	  
via	   flash	   chromatography	   (SiO2,	   gradient	   elution:	   10:1	  Hex:EtOAc	   to	   5:1	  EtOAc)	   afforded	  
C2’AzDMB-­‐TBS	  ether	  4.4	  (6.32	  g,	  12.06	  mmol,	  91%)	  as	  a	  clear	  colorless	  oil.	  
	  
	  
Rf	  =	  0.93	  (3:1	  Hex:EtOAc,	  CAM	  stain)	  
	  
1H	  NMR:	  (500	  MHz,	  CDCl3)	  δ	  7.29	  –	  7.24	  (m,	  2H),	  6.90	  –	  6.82	  (m,	  2H),	  4.88	  (d,	  J	  =	  3.6	  Hz,	  
1H),	  4.77	  –	  4.69	  (m,	  1H),	  4.64	  (d,	  J	  =	  11.7	  Hz,	  1H),	  4.41	  (d,	  J	  =	  11.7	  Hz,	  1H),	  3.78	  (s,	  3H),	  3.64	  
(dq,	  J	  =	  9.0,	  6.2	  Hz,	  1H),	  3.33	  (td,	  J	  =	  8.9,	  6.9	  Hz,	  1H),	  3.29	  –	  3.14	  (m,	  2H),	  2.33	  (s,	  1H),	  2.15	  
(s,	  2H),	  1.95	  (td,	  J	  =	  8.8,	  2.1	  Hz,	  2H),	  1.82	  –	  1.76	  (m,	  2H),	  1.18	  (d,	  J	  =	  2.0	  Hz,	  3H),	  1.16	  (d,	  J	  =	  
1.2	  Hz,	  6H),	  0.86	  (s,	  9H).	  	  
	  
13CNMR:	   (126	  MHz,	   CDCl3)	   δ	   176.35,	   159.38,	   129.67,	   113.84,	   93.85,	   71.59,	   69.26,	   68.95,	  
68.69,	  55.36,	  47.93,	  38.73,	  33.40,	  25.82,	  25.32,	  25.30,	  17.99,	  17.83,	  -­‐4.03,	  -­‐4.66.	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C26H43N3O6Si	  (M	  +	  Na)+:	  	   544.2819	  

























To	  a	  stirring	  biphasic	  solution	  of	  C2’AzDMB-­‐TBS	  ether	  4.4	  (2.34	  g,	  4.5	  mmol,	  1.0	  equiv)	  in	  
DCM:H2O	  (41	  mL:	  4.5	  mL)	  in	  a100	  mL	  round	  bottom	  flask	  	  at	  23°C	  was	  added	  DDQ	  (2.0	  g,	  
9.0	  mmol,	  2.0	  equiv).	  The	  reaction	  was	  sealed	  and	  heated	  to	  40	  °C	  for	  4	  h	  then	  transferred	  
to	  a	  separatory	   funnel	  containing	  saturated	  aqueous	  bicarbonate	  and	  Et2O.	   	  The	  aqueous	  
phase	   was	   extracted	   with	   Et2O	   until	   the	   resulting	   Et2O	   layer	   was	   clear.	   	   The	   combined	  
organic	   fractions	  were	  washed	  with	   saturated	   aqueous	   brine,	   dried	   over	   sodium	   sulfate,	  
filtered	  and	  concentrated	  under	  reduced	  pressure.	   	  Purification	  via	  flash	  chromatography	  
(SiO2,	  gradient	  elution:	  9:1	  Hex:EtOAc	  isocratic)	  afforded	  hemiketal	  4.5	  (1.61	  g,	  4.01	  mmol,	  
~1:1	  mixture	  of	  annomers,	  89%)	  as	  a	  slightly	  yellow	  clear	  oil.	  
	  
	  
Rf	  =	  0.13	  (9:1	  Hex:EtOAc,	  CAM	  stain)	  
	  
1H	  NMR:	   (500	  MHz,	  CDCl3)	  δ	  5.25	  (t,	   J	  =	  3.5	  Hz,	  2H),	  4.80	  –	  4.72	  (m,	  2H),	  4.69	  –	  4.58	  (m,	  
5H),	  3.81	  (dq,	  J	  =	  9.0,	  6.2	  Hz,	  2H),	  3.44	  –	  3.23	  (m,	  21H),	  2.72	  (d,	  J	  =	  3.4	  Hz,	  2H),	  2.20	  (dt,	  J	  =	  
12.4,	  4.1	  Hz,	  2H),	  2.02	  –	  1.78	  (m,	  16H),	  1.58	  (s,	  7H),	  1.36	  –	  1.14	  (m,	  65H),	  0.94	  –	  0.85	  (m,	  
60H),	  0.07	  (t,	  J	  =	  2.3	  Hz,	  32H).	  
	  
13CNMR:	   (126	   MHz,	   CDCl3)	   δ	   177.30,	   176.38,	   97.15,	   89.27,	   71.76,	   71.39,	   71.22,	   	   69.61,	  
68.95,	   48.13,	   48.02,	   41.18,	   40.99,	   38.99,	   38.92,	   37.43,	   32.68,	   31.74,	   25.84,	   25.83,	   25.61,	  




























Calculated	  for	  C18H35N3O5Si	  (M	  +	  Na)+:	  	   424.2244	  
	   Found:	   	   	   	   	   424.2242	  
	  
	  




Hemiketal	  4.5	  (1.60	  g,	  3.99	  mmol,	  1.0	  equiv)	  was	  azeotropically	  dried	  with	  benzene	  (3x	  10	  
mL)	  and	  left	  on	  the	  high	  vac	  over	  night	  in	  a	  100	  mL	  round	  bottom	  flask.	  	  	  DCM	  (40	  mL)	  was	  
then	  added	   to	   the	   flask	  containing	  3.5	   followed	  by	  Cs2CO3	   (651	  mg,	  2.0	  mmol,	  0.5	  equiv)	  
and	  lastly	  trichloroacetonitrile	  (4.01	  mL,	  40.0	  mmol,	  10.0	  equiv)	  at	  23	  °C	  and	  stirred	  for	  1h.	  	  
The	   reaction	   was	   then	   transferred	   to	   a	   separatory	   funnel	   containing	   saturated	   aqueous	  
bicarbonate	   and	   Et2O.	   	   The	   aqueous	   phase	   was	   extracted	   with	   Et2O	   and	   the	   combined	  
organic	   fractions	  were	  washed	  with	   saturated	   aqueous	   brine,	   dried	   over	   sodium	   sulfate,	  
filtered	  and	  concentrated	  under	  reduced	  pressure.	   	  Purification	  via	  flash	  chromatography	  
(SiO2,	   gradient	   elution:	   95:5	   Hex:EtOAc	   isocratic)	   afforded	   hemiketal	   4.6	   (1.91	   g,	   3.52	  




Rf	  =	  0.95	  (95:5	  Hex:EtOAc,	  w/0.1%	  Et3N	  CAM	  stain)	  
	  
Cl3CCN, Cs2CO3



























1H	  NMR:	  (500	  MHz,	  CDCl3)	  δ	  8.64	  (s,	  1H),	  4.95	  (tdd,	  J	  =	  7.9,	  6.0,	  4.8	  Hz,	  1H),	  3.49	  (ddddd,	  J	  =	  
18.8,	  9.7,	  8.2,	  5.8,	  4.6	  Hz,	  2H),	  3.26	  (td,	  J	  =	  7.7,	  1.2	  Hz,	  3H),	  2.49	  –	  2.33	  (m,	  1H),	  1.83	  (pd,	  J	  =	  
7.6,	  6.9,	  1.3	  Hz,	  2H),	  1.66	  –	  1.52	  (m,	  3H),	  1.34	  –	  1.25	  (m,	  4H),	  1.25	  –	  1.11	  (m,	  9H),	  0.97	  –	  
0.78	  (m,	  14H),	  0.19	  –	  -­‐0.03	  (m,	  9H).	  
	  
13CNMR:	  (126	  MHz,	  CDCl3)	  δ	  175.65	  ,	  161.33	  ,	  128.45	  ,	  97.28	  ,	  77.47	  ,	  70.50	  ,	  69.11	  ,	  47.91	  ,	  
41.09	  ,	  38.66	  ,	  37.35	  ,	  25.83	  (d,	  J	  =	  4.2	  Hz),	  25.39	  ,	  25.15	  ,	  17.99	  ,	  -­‐4.07	  ,	  -­‐4.68	  
	  
	  
Synthesis	  of	  intermediate	  4.8	  
	  
	  
Previously	  reported	  protected	  AmdeB	  4.7	  (1.45	  g,	  2.66	  mmol,	  2.0	  equiv)	  was	  azeotropically	  
dried	  with	  benzene	  (3x	  5	  mL)	  and	  placed	  under	  high	  vac	  overnight.	  The	  frozen	  Ar	  benzene	  
matrix	   containing	   trichloroacetimidate	  4.6	   (2.17	  g,	  1.33	  mmol,	  1.0)	  was	   thawed	  at	  23	  °C	  
then	   concentrated	   under	   reduced	   pressure	   and	   added	   to	   a	   250	   mL	   round	   bottom	   flask	  
containing	  4.7	   and	   the	   two	  were	   azeotropically	   dried	   together	  with	   benzene	   (3x	   5	  mL).	  	  
The	   flask	  was	   then	  placed	  under	  an	   inert	  atmosphere	  and	  charged	  with	  dry	  hexanes	   (67	  
mL)	   and	   2-­‐chloro-­‐6-­‐methylpyridine	   (145	  mL,	   1.33	  mmol,	   1.0	   equiv)	   and	   cooled	   to	   0	   °C.	  	  
Once	  the	   flask	  was	  at	  0	  °C,	  2-­‐chloro-­‐6-­‐methylpyridinium	  triflate	  (185	  mL,	  0.66	  mmol,	  0.5	  
equiv)	   was	   added	   as	   a	   solid	   in	   one	   portion.	   	   After	   10	  min	   the	   reaction	   turned	   greenish	  
yellow	  from	  bright	  yellow.	  	  The	  reaction	  was	  stirred	  for	  1	  h	  total	  at	  0	  °C,	  then	  transferred	  to	  
a	   separatory	   funnel	   containing	   saturated	  aqueous	  bicarbonate	  and	  hexane.	   	  The	  aqueous	  
phase	  was	  extracted	  with	  hexanes	  and	  the	  combined	  organic	  fractions	  were	  washed	  with	  
saturated	   aqueous	   brine,	   dried	   over	   sodium	   sulfate,	   filtered	   and	   concentrated	   under	  
reduced	   pressure.	   	   Purification	   via	   flash	   chromatography	   (SiO2,	   gradient	   elution:	   95:5	  
Hex:EtOAc	   isocratic)	   afforded	   AzDMB-­‐glycoside	   4.8	   (1.72	   g,	   0.88	   mmol,	   66%)	   as	   a	  
yellow/orange	  glassy	  solid.	  
NCl Me
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Rf	  =	  0.79	  (5:1	  Hex:EtOAc,	  w/0.1%	  Et3N	  CAM	  stain)	  
	  
1H	  NMR:	  (500	  MHz,	  CDCl3)	  δ	  6.38	  –	  6.10	  (m,	  14H),	  6.10	  –	  5.92	  (m,	  3H),	  5.80	  (dd,	  J	  =	  14.2,	  
7.5	  Hz,	  1H),	  5.45	  –	  5.36	  (m,	  2H),	  5.28	  (dq,	  J	  =	  10.5,	  1.2	  Hz,	  1H),	  4.94	  (s,	  1H),	  4.62	  (ddtd,	  J	  =	  
10.9,	  7.1,	  5.8,	  2.1	  Hz,	  4H),	  4.52	  –	  4.45	  (m,	  1H),	  4.42	  (d,	  J	  =	  7.9	  Hz,	  1H),	  4.29	  (ddd,	  J	  =	  10.4,	  
8.6,	  4.5	  Hz,	  2H),	  3.90	  (t,	  J	  =	  10.3	  Hz,	  1H),	  3.86	  –	  3.78	  (m,	  1H),	  3.74	  (q,	  J	  =	  6.0	  Hz,	  1H),	  3.52	  (t,	  
J	  =	  6.9	  Hz,	  2H),	  3.46	  (dd,	  J	  =	  10.4,	  4.3	  Hz,	  1H),	  3.34	  (ddt,	  J	  =	  12.7,	  7.0,	  3.3	  Hz,	  1H),	  3.26	  (tdd,	  J	  
=	  15.0,	  6.5,	  2.8	  Hz,	  4H),	  3.03	  (s,	  4H),	  2.48	  –	  2.30	  (m,	  5H),	  2.26	  (dt,	  J	  =	  12.0,	  5.0	  Hz,	  1H),	  2.12	  
(dd,	  J	  =	  13.1,	  4.7	  Hz,	  1H),	  1.95	  –	  1.78	  (m,	  6H),	  1.73	  (ddd,	  J	  =	  7.8,	  5.5,	  2.5	  Hz,	  4H),	  1.70	  –	  1.56	  
(m,	  5H),	  1.55	  –	  1.34	  (m,	  6H),	  1.33	  –	  1.14	  (m,	  22H),	  1.07	  –	  0.78	  (m,	  113H),	  0.74	  –	  0.47	  (m,	  
60H).	  
	  
13CNMR:	   NMR	   (126	  MHz,	   CDCl3)	   δ	   175.83	   ,	   172.54	   ,	   170.93	   ,	   137.94	   ,	   135.53	   ,	   133.80	   ,	  
133.70	   ,	   133.13	   ,	   132.93	   ,	   132.66	   ,	   132.57	   ,	   132.26	   ,	   132.17	   ,	   132.07	   ,	   131.97	   ,	   131.01	   ,	  
130.40	  ,	  130.16	  ,	  119.07	  ,	  100.86	  ,	  100.21	  ,	  76.27	  ,	  75.87	  ,	  73.34	  ,	  71.06	  ,	  70.33	  ,	  70.12	  ,	  68.33	  
,	  67.25	  ,	  67.07	  ,	  66.46	  ,	  65.54	  ,	  55.92	  ,	  47.99	  ,	  47.79	  ,	  46.40	  ,	  43.53	  ,	  42.93	  ,	  42.53	  ,	  41.14	  ,	  
40.31	   ,	  38.88	   ,	  37.77	   ,	  37.21	   ,	  35.95	   ,	  26.25	   ,	  25.85	   ,	  25.50	   ,	  25.20	   ,	  19.20	   ,	  18.27	   ,	  18.05	   ,	  
18.00	  ,	  11.86	  ,	  7.36	  ,	  7.23	  ,	  7.18	  ,	  7.06	  ,	  6.96	  ,	  5.74	  ,	  5.58	  ,	  5.50	  ,	  5.43	  ,	  5.25	  ,	  5.16	  .	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C105H199N3O18Si8	  (M	  +	  Na)+:	  2037.2801	  































To	  a	  stirred	  solution	  of	  AzDMB-­‐glycoside	  4.8	  (1.77	  g,	  0.88	  mmol,	  1.0	  equiv)	  in	  THF	  (30	  mL)	  
and	   H2O	   (1.58	   mL,	   87.8	   mmol,	   100.0	   equiv)	   at	   50	   °C	   in	   a	   100	   mL	   round	   bottom	   flask	  
equipped	  with	  a	  septum	  was	  added	  PMe3	  (1.0	  M	  in	  THF:	  2.63	  mL,	  2.63	  mmol,	  3.0	  equiv).	  	  
The	   reaction	  was	   sealed	  and	  not	   submerged	   in	   the	  oil	  bath	  above	   the	   solution	   level.	  The	  
reaction	   was	   stirred	   for	   4	   h	   total	   at	   50	   °C,	   then	   transferred	   to	   a	   separatory	   funnel	  
containing	  saturated	  aqueous	  bicarbonate	  and	  hexane.	   	  The	  aqueous	  phase	  was	  extracted	  
with	   hexanes	   and	   the	   combined	   organic	   fractions	   were	   washed	  with	   saturated	   aqueous	  
brine,	   dried	   over	   sodium	   sulfate,	   filtered	   and	   concentrated	   under	   reduced	   pressure.	  	  
Purification	   via	   flash	   chromatography	   (SiO2,	   gradient	   elution:	   95:5	   Hex:EtOAc	   isocratic)	  
afforded	  C3’deNH-­‐C2’bOH	  4.9	   (397	  mg,	  0.21	  mmol,	  24%)	  and	  aminoDMB-­‐glycoside	  SI4.1	  
(1.286	  g,	  0.65	  mmol,	  74%)	  	  a	  yellow/orange	  glassy	  solid.	  
	  
	  
Rf	  =	  0.23	  (9:1	  Hex:EtOAc,	  w/0.1%	  Et3N	  CAM	  stain)	  
	  
1H	  NMR:	  (500	  MHz,	  CDCl3)	  δ	  6.37	  –	  5.90	  (m,	  13H),	  5.81	  (dd,	  J	  =	  14.0,	  7.7	  Hz,	  1H),	  5.45	  –	  5.33	  
(m,	  2H),	  5.29	  (dd,	  J	  =	  10.3,	  1.5	  Hz,	  1H),	  4.95	  (s,	  1H),	  4.69	  –	  4.55	  (m,	  3H),	  4.46	  (t,	  J	  =	  8.4	  Hz,	  
1H),	  4.42	  (d,	  J	  =	  8.0	  Hz,	  1H),	  4.28	  (td,	  J	  =	  10.2,	  4.4	  Hz,	  2H),	  3.88	  (d,	  J	  =	  10.2	  Hz,	  1H),	  3.86	  –	  
3.79	  (m,	  1H),	  3.72	  (d,	  J	  =	  7.3	  Hz,	  1H),	  3.51	  (s,	  2H),	  3.46	  (dd,	  J	  =	  10.4,	  4.3	  Hz,	  1H),	  3.38	  –	  3.28	  
(m,	  2H),	  3.27	  –	  3.20	  (m,	  1H),	  3.03	  (d,	  J	  =	  2.9	  Hz,	  3H),	  2.73	  (s,	  1H),	  2.49	  –	  2.30	  (m,	  4H),	  2.26	  
1. PMe3, H2O
   THF, 50 oC, 4h
2. KOH, THF,H2O
    23 oC, 2 h 



























































(dt,	  J	  =	  10.7,	  5.0	  Hz,	  1H),	  2.12	  (dd,	  J	  =	  13.1,	  4.6	  Hz,	  1H),	  1.96	  –	  1.70	  (m,	  8H),	  1.70	  –	  1.35	  (m,	  




Calculated	  for	  C105H202N1O18Si8	  (M	  +	  H)+:	  	   1989.3	  	  
	   Found:	   	   	   	   	   1989.3	  	   	  
	  
	  
To	  a	  stirred	  solution	  of	  intermediate	  aminoDMB-­‐glycoside	  SI4.1	  (1.281	  g,	  0.643	  mmol,	  1.0	  
equiv)	  in	  THF	  (20.8	  mL)	  in	  a	  40	  mL	  iChem	  vial	  at	  23	  °C	  was	  added	  KOH	  (0.0167	  M	  solution	  
in	  DI	  water:	  3.9	  mL,	  0.064	  mmol,	  0.1	  equiv)	  and	  stirred	  for	  2	  h	  at	  23	  °C	  then	  transferred	  to	  
a	   separatory	   funnel	   containing	   saturated	  aqueous	  bicarbonate	  and	  hexane.	   	  The	  aqueous	  
phase	  was	  extracted	  with	  hexanes	  and	  the	  combined	  organic	  fractions	  were	  washed	  with	  
saturated	   aqueous	   brine,	   dried	   over	   sodium	   sulfate,	   filtered	   and	   concentrated	   under	  
reduced	   pressure.	   	   Purification	   via	   flash	   chromatography	   (SiO2,	   gradient	   elution:	   95:5	  
Hex:EtOAc	   isocratic)	   afforded	   C3’deNH-­‐C2’bOH	   4.9	   (248	   mg,	   0.21	   mmol,	   20%)	   a	  
yellow/orange	   glassy	   solid	   and	   recovered	   aminoDMB-­‐glycoside	   SI4.1starting	   material	  
(650	  mg,	   0.326	  mmol,	   51%)	   	   a	   yellow/orange	   glassy	   solid.	   The	   recovered	  SI4.1	   starting	  
material	  was	  recycled	  under	  proportionally	  identical	  conditions	  to	  afford	  C3’deNH-­‐alcohol	  
4.9	  (289	  mg,	  0.15	  mmol,	  47%)	  and	  recovered	  aminoDMB-­‐glycoside	  SI4.1	  starting	  material	  
(248	  mg,	  0.125	  mmol,	  38%).	  	  C3’deNH-­‐C2’bOH	  4.9	  (total	  of	  933	  mg,	  0.497	  mmol,	  57%	  over	  
























1H	  NMR:	  (500	  MHz,	  CD3C(O)CD3)	  δ	  6.60	  –	  5.97	  (m,	  15H),	  5.51	  (dd,	  J	  =	  14.9,	  9.4	  Hz,	  1H),	  5.41	  
(dt,	  J	  =	  17.2,	  1.6	  Hz,	  1H),	  5.33	  –	  5.23	  (m,	  1H),	  4.74	  –	  4.58	  (m,	  3H),	  4.57	  –	  4.49	  (m,	  1H),	  4.42	  
(dt,	  J	  =	  10.5,	  5.3	  Hz,	  1H),	  4.21	  (d,	  J	  =	  7.5	  Hz,	  2H),	  4.14	  (t,	  J	  =	  9.7	  Hz,	  1H),	  4.04	  (ddd,	  J	  =	  17.2,	  
11.3,	  5.6	  Hz,	  2H),	  3.86	  (dd,	  J	  =	  8.9,	  2.9	  Hz,	  1H),	  3.70	  (dt,	  J	  =	  9.0,	  4.0	  Hz,	  1H),	  3.62	  (dd,	  J	  =	  10.6,	  
4.6	  Hz,	  1H),	  3.44	  –	  3.28	  (m,	  2H),	  3.23	  (dq,	  J	  =	  8.7,	  6.1	  Hz,	  1H),	  3.12	  (s,	  3H),	  2.59	  (dd,	  J	  =	  6.5,	  
3.8	  Hz,	  2H),	  2.43	  (td,	  J	  =	  9.2,	  6.5	  Hz,	  1H),	  2.38	  –	  2.31	  (m,	  1H),	  2.22	  (dt,	  J	  =	  12.2,	  4.8	  Hz,	  1H),	  
2.12	  –	  1.98	  (m,	  45H),	  1.98	  –	  1.86	  (m,	  5H),	  1.86	  –	  1.70	  (m,	  6H),	  1.70	  –	  1.57	  (m,	  4H),	  1.52	  (d,	  J	  
=	  12.4	  Hz,	  1H),	  1.42	  (d,	  J	  =	  11.1	  Hz,	  1H),	  1.29	  (s,	  6H),	  1.17	  (dd,	  J	  =	  6.1,	  3.3	  Hz,	  7H),	  1.11	  –	  
0.81	  (m,	  86H),	  0.80	  –	  0.54	  (m,	  48H),	  0.11	  (d,	  J	  =	  5.0	  Hz,	  7H).	  
	  
13CNMR:	   (126	   MHz,	   CDCl3)	   δ	   173.93,	   170.18,	   138.21,	   134.53,	   134.18,	   133.65,	   133.49,	  
132.05,	  131.80,	  131.54,	  131.50,	  130.75,	  129.99,	  119.21,	  104.97,	  100.76,	  77.54,	  76.33,	  75.78,	  
73.25,	  72.54,	  71.50,	  70.19,	  68.79,	  68.29,	  66.66,	  66.6,	  66.5,	  65.81,	  56.44,	  53.48,	  47.82,	  47.08,	  
43.39,	   43.02,	   41.53,	   40.54,	   39.45,	   37.04,	   35.16,	   34.29,	   30.39,	   29.80,	   26.59,	   25.79,	   19.50,	  
18.75,	  18.07,	  17.99,	  11.27,	  7.28,	  7.25,	  7.17,	  7.13,	  7.13,	  7.08,	  7.01,	  6.87,	  5.73,	  5.52,	  5.35,	  5.30,	  
5.28,	  5.21,	  5.03,	  1.09,	  -­‐4.19,	  -­‐4.74.	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C99H19O17Si8	  (M	  +	  Na)+:	  	   1898.2055	  









To	  a	  stirred	  solution	  of	  C3’deNH-­‐C2’bOH	  4.9	  (70.5	  mg,	  37.6	  mmol,	  1.0	  equiv)	  in	  CDCl3	  (1.25	  
































    CDCl3, 0 oC, 2h 
2. L-selectride
   THF, -78 oC 0.5 h






bicarbonate	  (63	  mg,	  750	  mmol,	  20.0	  equiv)	  Dess-­‐Martin	  periodinane	  (32	  mg,	  75	  mmol,	  2.0	  
equiv).	   After	   1	   h	   at	   0	   °C	   the	   reaction	   was	   checked	   for	   conversion	   by	   monitoring	   the	  
disappearance	  of	  the	  C1’	  proton	  (5.1	  ppm,	  d	  1H)	  by	  1HNMR.	  	  	  The	  reaction	  was	  transferred	  
to	  a	  separatory	  funnel	  containing	  saturated	  aqueous	  bicarbonate	  and	  hexane.	  	  The	  aqueous	  
phase	  was	  extracted	  with	  hexanes	  and	  the	  combined	  organic	  fractions	  were	  washed	  with	  
saturated	   aqueous	   brine,	   dried	   over	   sodium	   sulfate,	   filtered	   and	   concentrated	   under	  
reduced	  pressure.	  	  Due	  to	  the	  sensitive	  nature	  of	  ketone	  SI4.2,	  after	  azeotropic	  drying	  with	  
benzene	  (3x	  2	  mL),	  it	  was	  taken	  on	  to	  the	  subsequent	  reaction	  without	  further	  purification.	  
	  
	  	  	  	  	  	  	  	  	  	   	   	   	   	  
Rf	  =	  0.55	  (9:1	  Hex:EtOAc,	  CAM	  stain)	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C97H190O17Si8	  (M	  +	  Na)+:	  	   1874.2055	  
	   Found:	   	   	   	   	   1874.2053	  
	  
To	   a	   stirred	   solution	   of	   ketone	   SI4.2	   (assumed	   37	   mmol,	   1.0	   equiv)	   in	   THF	   (1.25	   mL)	  
cooled	  to	  -­‐78	  °C	  in	  a	  dry-­‐ice/acetone	  bath	  was	  slowly	  added	  L-­‐selectride	  (1.0	  M	  in	  THF:	  40	  
mL,	  40	  mmol,	  1.05	  equiv).	   	  After	  30	  min	  stirring	  at	  -­‐78	  °C,	  TLC	  showed	  full	  conversion	  to	  
the	   reduced	   product	   and	   was	   transferred	   to	   a	   separatory	   funnel	   containing	   saturated	  
aqueous	  bicarbonate	  and	  hexane.	  	  The	  aqueous	  phase	  was	  extracted	  with	  hexanes	  and	  the	  
combined	  organic	  fractions	  were	  washed	  with	  saturated	  aqueous	  brine,	  dried	  over	  sodium	  
sulfate,	   filtered	   and	   concentrated	   under	   reduced	   pressure.	   	   Purification	   via	   flash	  
chromatography	   (SiO2,	   gradient	   elution:	   95:5	   Hex:EtOAc	   isocratic)	   afforded	   C3’deNH-­‐





















Rf	  =	  0.85	  (9:1	  Hex:EtOAc,	  w/0.1%	  Et3N	  CAM	  stain)	  
	  
1H	  NMR:	  (500	  MHz,	  CD3C(O)CD3)	  δ	  6.60	  –	  5.95	  (m,	  14H),	  5.51	  (dd,	  J	  =	  14.9,	  9.4	  Hz,	  1H),	  5.41	  
(dq,	  J	  =	  17.2,	  1.6	  Hz,	  1H),	  5.28	  (dq,	  J	  =	  10.4,	  1.3	  Hz,	  1H),	  4.75	  –	  4.57	  (m,	  4H),	  4.50	  (d,	  J	  =	  1.3	  
Hz,	  1H),	  4.43	  (td,	  J	  =	  10.4,	  4.8	  Hz,	  1H),	  4.21	  (qd,	  J	  =	  8.6,	  8.1,	  3.2	  Hz,	  1H),	  4.14	  (td,	  J	  =	  8.2,	  4.1	  
Hz,	  1H),	  4.00	  (dddd,	  J	  =	  12.8,	  10.3,	  8.7,	  2.6	  Hz,	  2H),	  3.87	  (dd,	  J	  =	  9.0,	  2.9	  Hz,	  1H),	  3.81	  (p,	  J	  =	  
2.7,	  2.3	  Hz,	  1H),	  3.66	  (dddd,	  J	  =	  28.5,	  15.3,	  7.7,	  3.7	  Hz,	  3H),	  3.27	  (dq,	  J	  =	  8.4,	  6.1	  Hz,	  1H),	  3.12	  
(s,	  3H),	  2.78	  (d,	  J	  =	  15.9	  Hz,	  1H),	  2.65	  –	  2.52	  (m,	  2H),	  2.44	  (ddt,	  J	  =	  16.1,	  9.3,	  7.0	  Hz,	  1H),	  2.35	  
(t,	  J	  =	  10.4	  Hz,	  1H),	  2.18	  –	  2.02	  (m,	  4H),	  2.02	  –	  1.81	  (m,	  6H),	  1.81	  –	  1.68	  (m,	  5H),	  1.68	  –	  1.59	  
(m,	  3H),	  1.52	  (dddd,	  J	  =	  19.0,	  14.5,	  8.7,	  2.9	  Hz,	  3H),	  1.30	  (dt,	  J	  =	  12.3,	  7.6	  Hz,	  5H),	  1.18	  (dd,	  J	  
=	  8.0,	  6.0	  Hz,	  7H),	  1.14	  –	  0.82	  (m,	  96H),	  0.82	  –	  0.48	  (m,	  53H),	  0.09	  (t,	  J	  =	  2.6	  Hz,	  6H).	  
	  
13CNMR:	  (126	  MHz,	  CD3C(O)CD3)	  δ	  173.40,	  170.65,	  139.43,	  135.68,	  135.59,	  135.42,	  135.07,	  
134.24,	   133.65,	   133.37,	   132.95,	   132.87,	   132.72,	   132.63,	   131.59,	   130.88,	   130.70,	   119.14,	  
101.60,	   99.15,	   77.01,	   76.93,	   74.67,	   74.23,	   73.76,	   71.40,	   69.77,	   69.31,	   69.01,	   67.75,	   67.51,	  
67.40,	   66.16,	   57.94,	   48.36,	   48.28,	   44.44,	   43.71,	   42.14,	   41.56,	   36.36,	   35.72,	   35.45,	   32.51,	  
27.81,	   26.37,	   23.50,	   20.21,	   19.56,	   19.02,	   18.69,	   14.57,	   11.35,	   7.90,	   7.88,	   7.75,	   7.56,	   7.53,	  




Calculated	  for	  C99H190O17Si8	  (M	  +	  Na)+:	  	   1898.2055	  



























C3’deNH-­‐C2’aOH	  4.10	   (130	  mg,	  69	  mmol,	  1.0	  equiv)	  was	  azeotropically	  dried	  and	  placed	  
on	  the	  high	  vac	  over	  night	  in	  a	  7	  mL	  vial.	  	  To	  a	  stirred	  solution	  of	  freshly	  distilled	  pyridine	  
(690	  mL,	  0.1	  M)	  in	  MeOH	  (300	  mL)	  at	  0	  °C	  in	  a	  40	  mL	  Teflon	  vial	  was	  added	  HF-­‐pyridine	  
70%	  complex	  (690	  mL,	  0.1	  M).	  	  C3’deNH-­‐C2’aOH	  4.10	  was	  then	  dissolved	  in	  THF	  (1.0	  mL)	  
and	   transferred	   via	   cannula	   to	   the	   HF-­‐pyridine/pyridine	   solution	   at	   0	   °C.	   	   The	   vial	  
containing	  3.10	  was	  then	  rinsed	  with	  THF	  (2x	  500	  mL)	  and	  then	  allowed	  to	  warm	  to	  23	  °C	  
for	  18	  h.	  	  The	  reaction	  was	  quenched	  at	  0	  °C	  by	  the	  slow	  addition	  of	  excess	  TMSOMe	  (~25	  
mL)	  and	  allowed	  to	  warm	  to	  23	  °C	  by	  the	  removal	  of	  the	  ice	  bath	  and	  stirred	  for	  1	  h.	  The	  
reaction	  was	   then	   transferred	   to	   a	   100	  mL	   round	   bottom	   flask	   and	   concentrated	   under	  
reduced	   pressure.	   	   Pyridine	   was	   removed	   azeotropically	   with	   benzene	   (5x	   2	   mL).	  	  
Preparative	  HPLC	  purification	  (C18SiO2,	  gradient	  elution:	  5:95	  MeCN:H2O	  to	  95:5	  MeCN:H2O	  
over	  25	  min	  at	  25	  mL/min)	  afforded	  C3’deNH-­‐methylketal-­‐Allylester	   4.11	   (18.1	  mg,	  18.6	  






Calculated	  for	  C51H78O17	  (M	  +	  Na)+:	  	   985.5137	  






























































C3’deNH-­‐methylketal-­‐Allylester	  4.11	  (7	  mg,	  7.3	  mmol,	  1.0	  equiv)	  was	  azeotropically	  dried	  
with	  benzene	  (3x	  1	  mL)	  in	  a	  7	  mL	  vial,	  taken	  into	  the	  glove	  box	  where,	  Pd(PPh3)4	  (2.5	  mg,	  
2.2	  mmol,	  30	  mol%)was	  added	  followed	  by	  thiosalicylic	  acid	  (3.36	  mg,	  22	  mmol,	  3.0	  equiv)	  
then	  dissolved	  in	  DMF	  (240	  mL,	  0.03M)	  and	  stirred	  for	  1	  h	  at	  23	  °C.	  	  The	  reaction	  was	  then	  
added	   drop-­‐wise	   to	   rapidly	   stirring	   Et2O	   (7	   mL)	   and	   the	   precipitate	   was	   filtered.	   	   The	  
resulting	  filtrate	  was	  concentrated	  under	  reduced	  pressure	  to	  yield	  a	  dark	  orange/red	  oil	  
that	  was	  diluted	  with	  Et2O	  and	  filtered	  again.	  	  The	  filtered	  precipitates	  were	  then	  dissolved	  
in	  a	  minimal	  amount	  of	  DMSO	  and	  preparatively	  HPLC	  purified	  (C18SiO2,	  gradient	  elution:	  
5:95	  to	  95:5	  MeCN:H2O	  with	  0.3%	  formic	  acid	  over	  25	  min	  at	  25	  mL/min).	  	  Concentration	  
of	   the	   product	   containing	   aqueous	   acidic	   fractions	   afforded	   C3’deNHAmB	   (3.1	   mg,	   3.4	  





RT=	  16.7	  min;	  flow	  rate	  =	  1mL/min,	  gradient	  =	  0→5%	  MeCN	  in	  0.1%	  aqueous	  formic	  acid	  at	  
2	  min,	  5	  →	  95	  %	  MeCN	  in	  0.1%	  aqueous	  formic	  acid	  at	  30	  min.	  
	  
1H	  NMR:	  (500	  MHz,	  CD3S(O)CD3)	  δ	  6.52	  –	  6.03	  (m,	  6H),	  5.86	  (s,	  0H),	  5.40	  (d,	  J	  =	  7.5	  Hz,	  1H),	  
5.23	  (d,	  J	  =	  6.2	  Hz,	  1H),	  4.80	  (dd,	  J	  =	  17.6,	  4.5	  Hz,	  2H),	  4.66	  (s,	  1H),	  4.44	  (s,	  1H),	  4.37	  (d,	  J	  =	  

































DMF, 23 oC, 1h;
HPLC purification



















(m,	  1H),	  1.93	  –	  1.81	  (m,	  2H),	  1.71	  (s,	  1H),	  1.56	  (dd,	  J	  =	  22.1,	  11.8	  Hz,	  2H),	  1.50	  –	  1.37	  (m,	  
2H),	  1.37	  –	  1.19	  (m,	  3H),	  1.13	  (dd,	  J	  =	  13.8,	  6.3	  Hz,	  4H),	  1.04	  (dd,	  J	  =	  6.7,	  3.9	  Hz,	  2H),	  0.95	  –	  
0.89	  (m,	  2H).	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C47H72O17	  (M	  +	  Na)+:	  931.4667	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CHAPTER	  5:	  RATIONAL	  DESIGN	  OF	  A	  NON-­‐TOXIC	  AMPHOTERIC	  DERIVATIVE	  OF	  AMB	  
	  
5-­‐1:	  ROAD	  MAP	  FOR	  THE	  IMPROVEMENT	  OF	  AMB’S	  THERAPEUTIC	  INDEX	  
	  
	  	  	  	  	  	  	  	  AmB	   self	   assembles	   into	   an	   extramembranous	  
‘sterol-­‐sponge’1	   (Fig.	  5.1	  A)	   that	  primarily	  kills	  cells	  
by	  binding	  and	  extracting	  sterols2	  in	  a	  mycosamine-­‐
dependent	   fashion.3	   Evidence	   described	   in	   the	  
previous	   chapters	   supports	   a	   model	   in	   which	   the	  
C2’-­‐OH	   and	   C3’-­‐NH3+	   on	   the	   mycosamine	  
appendage4,5	   are	   involved	   in	   stabilizing	   a	   ground	  
state	   conformation	   of	   AmB	   that	   allows	   for	   the	  
binding	   of	   both	   ergosterol	   (Erg)	   and	   cholesterol	  
(Chol)	  (Fig.	  5.1.	  B).	   	  When	  either	   the	  C2’-­‐OH	  or	  C3’-­‐
NH3+	   is	   deleted,	   AmB	   still	   binds	   Erg	   but	   can	   no	  
longer	  bind	  Chol.4,5	  	  Furthermore,	  this	  shift	  in	  sterol	  
binding	   directly	   correlates	   to	   a	   substantial	   loss	   of	  
observed	   toxicity	   to	   human	   cells.4,5	   	   Alternatively	  
stated,	   these	   results	   are	   consistent	   with	   ligand-­‐
selective	  allosteric	  effects	  in	  these	  prototypical	  small	  
molecule-­‐small	  molecule	  interactions.	  (Fig.	  5.1	  C).	  	  	  
The	   relative	   exotherms	   observed	   in	   ITC	   assays	   and	   MIC	   vs.	   MHC	   concentrations	  
suggest	  that	  AmB	  preferentially	  binds	  Erg	  over	  Chol.	  It	  is	  suggested	  that	  this	  predisposition	  
is	  due	  to	  Chol	  being	  slightly	  bulkier	  than	  Erg.	  Furthermore,	  when	  allosteric	  modifications	  
are	  made	   to	   AmB	   (i.e.	   deletion	   of	   either	   the	   C2’-­‐OH	   or	   the	   C3’-­‐NH3+)	   this	   natural	   sterol	  
selectivity	   is	  magnified	   to	   only	   favor	  Erg	   binding	   (Fig.	   5.2	  B).	   	   	  With	   these	   two	  potential	  
sites	   of	   allostery	   identified,	  we	  proceeded	   to	   investigate	   how	   subtle	  modifications	   to	   the	  









































Figure 5.1 A) AmB primarily exists as a 'sterol sponge' sequestering 
Erg in green, B) N-IodoAmB X-ray crystal structure with water bridge. 
C) ChemDraw representation of B showing the two putative contact 











We	   hypothesized	   that	   epimerization	   of	  
the	   C2’-­‐OH	   would	   lead	   to	   a	   similar	  
magnification	  of	  Erg	  binding	  as	  observed	  when	  
the	  C2’-­‐OH	  is	  deleted.	  Specifically,	  based	  on	  our	  
understanding	   of	   a	   possible	   ground-­‐state	  
conformation	  of	  AmB	  (Fig.	  5.2	  A)—informed	  by	  
the	   N-­‐IodoacylAmB	   crystal	   structure8—we	  
proposed	   that	   a	   potential	   hydrogen	   bonding	  
interaction	   between	   the	   C2’-­‐OH,	   a	   molecule	   of	  
water,	   and	   the	   C13-­‐OH	   is	   implicated	   in	   AmB’s	  
ability	   to	   bind	   both	   Erg	   and	   Chol.	   Similar	   to	  
deletion	  of	  the	  C2’	  hydroxyl	  group,	  we	  predicted	  
that	   epimerization	   at	   the	   C2’-­‐position	   would	  
potentially	   cause	   a	   disruption	   or	   alteration	   of	  
this	  putative	   ‘water	  bridge,’	  possibly	   leading	  to	  
a	   change	   in	   shape	   of	   the	   sterol	   binding	   pocket	  
that	   would	   result	   in	   a	   magnification	   of	   Erg	  
binding	  (5.2	  C).	  	  
The	   synthesis	   of	   doubly	   modified	   C2’epiAmB	   methyl	   ester	   (C2’epiAmE)	   was	  
previously	   reported	   by	   Carreira	   and	   coworkers	   in	   2011	   (Fig.	   5.3).9	   	   Interestingly,	   they	  
observed	   that	   C2’epiAmE	  was	   equipotent	   to	   AmB	   in	   their	   yeast	  MIC	   assays	   (Fig.	   5.3	   B).	  	  
They	   also	   observed	   that	   it	   caused	   efflux	   of	   potassium	   ions	   from	   both	   Erg	   and	   Chol	  
containing	   POPC	   liposomes	   at	  
1	   µM.	   From	   these	   data,	  
Carreira	   and	   coworkers	  
concluded	   that	   “the	  
configuration	   of	   C2’-­‐position	  
was	   inconsequential.”9	  
Carreira	   and	   coworkers	   did	   not	   assay	   C2’epiAmE	   for	   human	   toxicity	   or	   Chol	   binding.	  





































































































Figure 5.2 A) Chemdraw representation of the N-IodoAmB
crystal structure with Chol bound to the groung state conformation 
stabilized by two polar intramolecular contacts. B) C2'deOAmB 












































to	  test	  the	  hypothesis	  that	  the	  singly	  modified	  AmB	  derivative	  having	  only	  one	  sterogenic	  
center	  inverted,	  C2’epiAmB,	  would	  show	  little	  or	  no	  toxicity	  to	  human	  cells	  while	  retaining	  
potent	  antifungal	  activity.	  
	  
	  
5-­‐2:	  SYNTHESIS	  AND	  STUDY	  OF	  THE	  C2’-­‐EPIMER	  OF	  AMPHOTERICIN	  B	  
	  
In	  our	  first	  generation	  synthesis	  of	  C2’epiAmB,	  we	  adapted	  the	  previously	  reported	  
synthesis	   of	   C2’epiAmE	   with	   one	   key	   change	   that	   allowed	   us	   to	   access	   the	   targeted	  
deprotected	  material.	  Specifically,	  we	  employed	  a	  readily	  removable	  allyl	  ester	  at	  the	  C41-­‐
position.	   Employing	   our	   previously	   reported	   route	   to	   the	   fully	   protected	   aglycone	  5.5—
identical	   to	   4.73b,5	   with	   the	   mycosamine	   donor	   and	   glycosylation	   conditions	   previously	  
used	  in	  the	  construction	  of	  C3’deNHAmB,5	  I	  synthesized	  C2’epiAmB	  (Scheme	  5.1).	  	  	  	  	  	  
Although	  the	  synthesis	  of	  C2’epiAmB	  was	  possible	  from	  a	  hybrid	  glycosylation	  route	  
similar	   to	  C2’deOAmB4	  and	  C3’deNHAmB5,	  we	  realized	   that	  our	  previously	  reported	  site-­‐
selective	   acylation	   methodology	   of	   AmB	   could	   provide	   a	   more	   efficient	   and	   practical	  
synthesis	  of	  C2’epiAmB.11	  	  	  
In	   the	   second-­‐generation	   synthesis	   of	   C2’epiAmB,	   a	   different	   protecting	   group	  
strategy	  was	  employed	  based	  on	  all	  of	  the	  lessons	  learned	  from	  the	  previously	  synthesized	  
AmB	   derivatives.1-­‐5	   Alloc	   was	   installed	   as	   the	   protecting	   group	   on	   the	   amine.	   The	   C41	  
carboxylate	   was	   protected	   with	   an	   allyl	   group.	   Both	   of	   these	   groups	   would	   be	  
simultaneously	   removed	   in	   the	   penultimate	   step	   with	   Pd(PPh3)4	   and	   thiosaliscylic	   acid.	  	  
The	   PMP	   ketals	   were	   critical	   for	   the	   selective	   acylation	   methodology	   and	   could	   be	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conditions.	   	   Diethylisopropyl	   silyl	   (DEIPS)	   ether	   groups	  were	   also	   necessary	   as	   they	   are	  
robust	  enough	  to	  survive	  the	  KCN	  mediated	  hydrolysis	  of	  both	  C2’benzoate	  intermediates,	  
yet	  easily	  removed	  with	  HF-­‐pyridine	  conditions.11	  
	  	  	  	  
In	  the	  forward	  sense,	  the	  Alloc	  group,	  hemiketal,	  PMP	  ketals,	  and	  allyl	  groups	  were	  
installed	  in	  three	  steps	  from	  AmB	  with	  one	  chromatographic	  separation	  affording	  5.11	   in	  
30%	   yield.	   	   At	   this	   point	   the	   C2’-­‐OH	   of	   5.11	   was	   selectively	   acylated	   with	   p-­‐
tertbutylbenzoyl	  chloride	  under	  the	  previously	  reported	  conditions	  to	  generated	  4.12	  in	  a	  
preparatively	   useful	   45%	   yield.	   	   	   DEIPS	   groups	   were	   installed	   using	   the	   corresponding	  
triflate,	   affording	  5.13	   in	   72%	   yield.	   Subsequent	   KCN	  mediated	   hydrolysis	   of	   the	   C2’	   p-­‐
tertbutylbenzoate	  provided	   free	  C2’-­‐OH	  5.14	   in	  65%	  yield.	   	   Inverting	   the	  C2’-­‐OH	  of	  5.14	  
proceeded	   under	  Mitsunobu	   conditions	   affording	   C2’	   equatorial	   p-­‐nitrobenzoate	  5.15	   in	  
84%	   yield.	   The	   resulting	   C2’-­‐nitrobenzoate	   5.15	   was	   then	   cleaved	   with	   identical	   KCN	  
conditions	   to	   generate	   intermediate	   5.16.	   	   Global	   deprotection	   commenced	   with	   HF-­‐
pyridine	  mediated	  desilylation	  to	  yield	  intermediate	  5.17	  in	  68%	  yield.	  	  The	  Alloc	  and	  allyl	  
groups	  on	  the	  C3’-­‐amine	  and	  C41-­‐carboxylate	  respectively,	  were	  simultaneously	  removed	  
with	  Pd(PPh3)4	  and	  thiosalicylic	  acid	  to	  yield	  zwitterionic	  intermediate	  5.18	   in	  87%	  yield	  
as	   a	   single	   peak	   by	   HPLC.	   	   It	   is	   noteworthy	   that	   this	   reaction	   generates	   clean	   material	  
without	   chromatography.	   	   The	   two	   PMP	   ketals	   along	   with	   the	   methyl	   ketal	   at	   C13	   are	  
hydrolyzed	   in	   a	   single	   step	   with	   CSA	   in	   20:1	   mixture	   of	   MeCN	   to	   H2O	   at	   0	   oC.	   	   These	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With	  scalable	  access	  to	  this	  key	  probe,	  my	  colleague	  Matt	  Endo	  tested	  its	  biophysical	  
and	  biological	  properties.	  	  Gratifyingly,	  C2’epiAmB	  was	  able	  to	  bind	  Erg	  and	  not	  Chol	  within	  
the	   limits	   of	   our	   assays.	   These	   sterol-­‐binding	   results	   predicted	   the	   following	   biological	  
activity.	  C2’epiAmB	  has	  potent	  antifungal	  activity	  against	  S.	  cerevisiae	  (MIC	  =	  2	  µM)	  and	  C.	  
albicans	   (MIC	   =	   2	  µM)	   and	  within	   the	   limits	   of	   detection	   in	   our	   assays,	   complete	   lack	   of	  
toxicity	   to	   human	   cells	   in	   vitro	   (MHC	   >500	  µM,	  MTC	   >80	  µM).	   	   These	   results	   show	   that	  
C2’epiAmB	  is	  very	  similar	  to	  C2’deOAmB	  in	  vitro	  (Fig.	  5.4)	  10.	  	  
	   With	   these	   promising	   in	   vitro	   results	   in	   hand	  we	   are	   in	   the	   process	   of	   testing	   its	  
efficacy	   and	   toxicity	   in	   a	  mouse	   study	   against	   AmB	   and	   C2’deOAmB.	   	  We	   predicted	   that	  
C2’epiAmB	  will	   be	   equipotent	   to	   AmB	   yet	   substantially	   less-­‐toxic	   to	  mice.	   Furthermore,	  
since	   there	   is	   a	   hydroxyl	   group	   at	   the	   C2’-­‐position,	   we	   predict	   that	   C2’epiAmB	   should	  
behave	   otherwise	   similarly	   to	   AmB	   in	  
vivo.	  	  	  
	   These	   results	   lend	   further	  
evidence	   in	   support	   of	   our	   ligand	  
selective	  allosteric	  binding	  model4,5.	  More	  
importantly,	   we	   harnessed	   this	  
understanding	   to	   guide	   the	   rational	  
development	   of	   a	   new	   efficacious	   non-­‐
toxic	   derivative	   that	   has	   thus	   far	   shown	  
substantial	   potential	   as	   a	   clinically	   viable	   therapeutic	   replacement	   for	   AmB.	   C2’epiAmB	  
retains	   its	   zwitterionic	   character	   and	   is	   essentially	   identical	   to	   AmB	   with	   the	   only	  
difference	  being	  the	  inversion	  of	  a	  single	  stereogenic	  center.	  	  Based	  on	  our	  proposed	  ligand	  
selective	   allosteric	   binding	  model,	   C2’epiAmB	   adds	   to	   a	   growing	   list	   of	  rationally	   guided	  











Figure 5.4 A) ITC binding data, B) MIC data, C) MHC and MTC data against 
human red blood cells (RBC) and human renal epithelial cells (REC), 
















5-­‐3:	  EXPERIMENTAL	  SECTION	  
	  
General	  methods	  
Materials.	   Commercial	   reagents	   were	   purchased	   from	   Sigma-­‐Aldrich,	   Strem,	   Alfa	   Aesar,	  
and	  Fisher	  Scientific	  and	  used	  without	  further	  purification	  unless	  otherwise	  noted.	  Solvents	  
were	   purified	   by	   passage	   through	   packed	   columns	   by	   the	   method	   of	   Pangborn	   and	  
coworkers12	  (THF,	  Et2O,	  CH3CN,	  CH2Cl2:	  dry	  neutral	  alumina;	  benzene,	  toluene:	  dry	  neutral	  
alumina	   and	   Q5	   reactant;	   DMSO,	   DMF,	   CH3OH:	   activated	   molecular	   sieves).	   Water	   was	  
obtained	   from	  a	  Millipore	   (Billerica,	  MA)	  MilliQ	  water	  purification	   system.	  Triethylamine	  
was	  freshly	  distilled	  under	  an	  atmosphere	  of	  nitrogen	  from	  CaH2.	  (±)-­‐10-­‐Camphorsulfonic	  
acid	  was	  recrystallized	  from	  EtOAc.	  	  
	  
General	  Experimental	  Procedures.	  All	  reactions	  were	  performed	  in	  flame-­‐	  or	  oven	  (125	  
°C)-­‐dried	  glassware	  under	  an	  atmosphere	  of	  dry	  nitrogen	  or	  argon	  unless	  otherwise	  stated.	  
Reactions	  were	  monitored	  by	  analytical	   thin	   layer	  chromatography	  (TLC)	  on	  Merck	  silica	  
gel	   60	   F254	   plates	   (0.25	   mm)	   using	   the	   indicated	   solvent	   system.	   Compounds	   were	  
visualized	   by	   exposure	   to	   UV	   light	   (254	   nm),	   or	   by	   an	   acidic	   solution	   of	  p-­‐anisaldehyde	  
followed	   by	   heating	   with	   a	   Varitemp	   heat	   gun.	   Flash	   column	   chromatography	   was	  
performed	  using	  Merck	  silica	  gel	  60	  (230-­‐400	  mesh).	  	  
	  
Structural	  Analysis.	  1H	  NMR	  spectra	  were	  recorded	  at	  ambient	  temperature	  using	  one	  of	  
the	   following	   instruments:	   Varian	   Unity	   500	   (500	  MHz),	   Varian	   VXR	   500	   (500	  MHz),	   or	  
Varian	   Unity	   Inova	   500NB	   (500	  MHz).	   Chemical	   shifts	   are	   reported	   in	   parts	   per	  million	  
(ppm)	  downfield	   from	   tetramethylsilane	   and	   referenced	   to	   residual	   protium	   in	   the	  NMR	  
solvent	   (CDCl3,	   δ	   =	   7.26;	   (CD3)2CO,	   δ	   =	   2.05,	   center	   line).	   Spectral	   data	   are	   presented	   as	  
follows:	  chemical	  shift,	  multiplicity	  (s	  =	  singlet,	  d	  =	  doublet,	  t	  =	  triplet,	  q	  =	  quartet,	  sext	  =	  
sextet,	   dd	   =	   doublet	   of	   doublets,	   dt	   =	   doublet	   of	   triplets,	   ddd	   =	   doublet	   of	   doublet	   of	  
doublets,	  m	  =	  multiplet,	  b	  =	  broad,	  app	  =	  apparent),	  coupling	  constant	  (J),	  and	  integration.	  
13C	   NMR	   spectra	   were	   recorded	   at	   ambient	   temperature	   using	   one	   of	   the	   following	  
instruments:	  Varian	  VXR	  500	  (125	  MHz),	  Varian	  Unity	  500	  (125	  MHz),	  or	  Varian	  Unity	  400	  
(101	   MHz)	   instrument.	   Chemical	   shifts	   are	   reported	   in	   ppm	   downfield	   from	  
 107 
tetramethylsilane	   and	   referenced	   to	   carbon	   resonances	   in	   the	   NMR	   solvent	   (CDCl3,	   δ	   =	  
77.16,	   center	   line;	   CD3C(O)CD3,	   δ	   =	   29.84,	   center	   line).	   High-­‐resolution	   mass	   spectra	  
(HRMS)	   were	   acquired	   by	   Mr.	   Pulin	   Wang,	   Mr.	   Furong	   Sun,	   or	   Dr.	   Haijun	   Yao	   at	   the	  
University	  of	  Illinois	  School	  of	  Chemical	  Sciences	  Mass	  Spectrometry	  Laboratory.	  Data	  are	  
reported	   in	   the	   form	  of	  m/z.	   Gas	   chromatography	   analysis	  was	   conducted	   on	   an	  Agilent	  








To	  a	  stirred	  solution	  of	  azido	  alcohol	  5.1	  (1.14	  g,	  2.69	  mmol,	  1.0	  equiv)	  and	  pyridine	  (2.17	  
mL,	  26.87	  mmol,	  10.0	  equiv)	  in	  27	  mL	  DCM	  at	  0	  °C	  in	  a	  100	  mL	  round	  bottom	  flask	  were	  
sequentially	  added	  acetic	  anhydride	  (1.27	  mL,	  13.4	  mmol,	  5.0	  equiv)	  and	  DMAP	  (16.4	  mg,	  
0.135	  mmol,	   0.05	   equiv).	  After	  15	  min	   the	   solution	  was	  warmed	   to	  23	  °C,	   stirred	   for	  10	  
min,	  poured	  into	  a	  separatory	  funnel	  containing	  Et2O	  and	  saturated	  aqueous	  bicarbonate.	  	  
The	  aqueous	   layer	  was	  extracted	  with	  Et2O	   (3x	  20	  mL)	  and	   the	  combined	  organic	   layers	  
were	   dried	   over	   sodium	   sulfate,	   filtered	   and	   concentrated	   under	   reduced	   pressure.	   The	  
pyridine	   was	   removed	   azeotropically	   with	   benzene	   (3x15	   mL).	   Purified	   by	   flash	  
chromatography	  (gradient	  elution,	  5%	  EtOAc:Hex	  to	  10%	  EtoAc:Hex)	  afforded	  acetate	  5.2	  
(1.09	  g,	  2.34	  mmol,	  87%)	  as	  a	  clear,	  colorless	  oil.	  
	  
	  






















1H	  NMR:	  (500	  MHz,	  CD3C(O)CD3)	  δ	  7.33	  –	  7.28	  (m,	  2H),	  6.95	  –	  6.90	  (m,	  2H),	  4.97	  (d,	  J	  =	  3.7	  
Hz,	  1H),	  4.68	  (d,	  J	  =	  11.8	  Hz,	  1H),	  4.64	  (dd,	  J	  =	  10.6,	  3.7	  Hz,	  1H),	  4.47	  (d,	  J	  =	  11.7	  Hz,	  1H),	  
3.80	  (s,	  3H),	  3.77	  –	  3.72	  (m,	  2H),	  3.23	  (t,	  J	  =	  9.2	  Hz,	  1H),	  2.09	  (s,	  1H),	  2.07	  (s,	  3H),	  1.24	  (d,	  J	  =	  
6.2	  Hz,	  3H),	  0.93	  (s,	  11H).	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C22H35N3O6Si	  (M	  +	  Na)+:	  	   488.2193	  
	   Found:	   	   	   	   	   488.2193	  
	  
	  




To	  a	  stirred	  solution	  of	  acetate	  5.2	  (1.09	  g,	  2.34	  mmol,	  1.0	  equiv)	  in	  a	  mixture	  of	  DCM:H2O	  
(23.4	  mL,	  10:1)	  at	  0	  °C	  in	  a	  foil	  covered	  40	  mL	  iChem	  vial	  was	  added	  DDQ	  (623	  mg,	  2.81	  
mmol,	   1.2	   equiv).	   After	   5	  min,	   the	   reaction	  was	  warmed	   to	   23	   °C,	   stirred	   for	   12	   h,	   and	  
poured	   into	   a	   separatory	   funnel	   containing	   Et2O	   and	   saturated	   aqueous	   bicarbonate.	  
Organics	  were	  washed	  with	  saturated	  brine.	  	  The	  combined	  aqueous	  layers	  were	  extracted	  
with	   Et2O	   (3x	   20	  mL)	   and	   the	   combined	   organic	   layers	  were	   dried	   over	   sodium	   sulfate,	  
filtered	  and	  concentrated	  under	  reduced	  pressure.	  Purified	  by	  flash	  chromatography	  (SiO2,	  
gradient	  elution,	  10%	  EtoAc:Hex	  to	  15%	  EtoAc:Hex	  to	  20%	  EtoAc:Hex)	  afforded	  hemiketal	  
5.3	  (716	  mg,	  2.07	  mmol,	  89%)	  as	  a	  clear,	  colorless	  oil.	  	  
	  
	  


















1H	  NMR:	  1H	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  5.23	  (d,	  J	  =	  3.7	  Hz,	  1H),	  4.61	  (dd,	  J	  =	  10.5,	  3.6	  
Hz,	  1H),	  3.92	  (dq,	  J	  =	  9.2,	  6.3	  Hz,	  1H),	  3.77	  (dd,	  J	  =	  10.5,	  9.2	  Hz,	  1H),	  3.19	  (t,	  J	  =	  9.2	  Hz,	  1H),	  
2.09	  (s,	  3H),	  2.08	  (d,	  J	  =	  1.7	  Hz,	  1H),	  1.24	  (d,	  J	  =	  6.2	  Hz,	  0H),	  1.19	  (d,	  J	  =	  6.3	  Hz,	  4H),	  0.94	  (s,	  
10H),	  0.93	  (s,	  2H),	  0.21	  (d,	  J	  =	  3.3	  Hz,	  4H),	  0.15	  (s,	  4H).	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C14H27N3O5Si	  (M	  +	  Na)+:	  	   368.1618	  
	   Found:	   	   	   	   	   368.1620	  
	  
	  




To	  a	  stirred	  solution	  of	  Hemiketal	  5.3	  (716	  mg,	  2.07	  mmol,	  1.0	  equiv)	  in	  10.35	  mL	  DCM,	  at	  
23	  °C	  in	  a	  40	  mL	  iChem	  vial	  were	  sequentially	  added	  trichloroacetonitrile	  (1.04	  mL,	  10.35	  
mmol,	  5.0	  equiv)	  and	  cesium	  carbonate	  (337.2	  mg,	  1.03	  mmol,	  0.5	  equiv).	  	  After	  30	  min,	  the	  
reaction	  was	  poured	   into	   a	   separatory	   funnel	   containing	  hexanes	   and	  water.	   	   The	   layers	  
were	   separated,	   the	   aqueous	   phase	   was	   extracted	   with	   hexane	   (3x	   30	   mL)	   and	   the	  
combined	  organic	  layers	  were	  dried	  over	  sodium	  sulfate,	   filtered	  and	  concentrated	  under	  
reduced	  pressure.	  Exogenous	  water	  was	  azeotropically	  removed	  with	  benzene	  (3x	  10	  mL)	  
and	   trichloroacetimidate	   5.4	   was	   used	   without	   further	   purification	   in	   the	   subsequent	  
reaction.	  Since	  this	  product	  was	  not	  stable,	  it	  was	  either	  used	  immediately	  after	  formation	  




























AmB	  aglycone	  5.5	  (2.19	  g,	  1.34	  mmol,	  1.0	  equiv)	  was	  azeotripically	  dried	  with	  benzene	  (3x	  
10	   mL)	   and	   left	   on	   high	   vac	   overnight	   in	   a	   500	   mL	   round	   bottom	   flask.	  	  
Trichloroacetimidate	   5.4	   (944	   mg,	   1.93	   mmol,	   1.44	   equiv)	   was	   added	   to	   the	   flask	  
containing	  5.5	   as	   a	   solution	   in	   benzene	   and	   concentrated	   down.	   	   Hexanes	   (70	  mL)	  was	  
added	   and	   subsequently	   cooled	   to	   0	   °C	   after	   the	   system	   was	   placed	   under	   an	   N2	  
atmosphere.	   2-­‐chloro-­‐6-­‐methylpyridine	   (147	   mL,	   1.34	   mmol,	   1.0	   equiv)	   was	   added	  
followed	   by	   2-­‐chloro-­‐6-­‐methylpyridinium	   triflate	   (186.0	  mg,	   0.67	  mmol,	   0.5	   equiv)	   as	   a	  
solid	   in	   one	   portion.	   After	   8	  min	   a	   color	   change	  was	   observed	   from	   orange	   to	   greenish	  
yellow	   and	   slight	   precipitate	   formation.	   	   The	   reaction	   was	   quenched	   at	   30	   min	   after	  
addition	   of	   triflate	   salt	   by	   pouring	   into	   a	   separatory	   funnel	   containing	   hexanes	   and	  























































(2x	   50	  mL)	   and	   the	   subsequent	   organic	   phases	  were	  washed	  with	   saturated	   brine	   then	  
dried	  over	  sodium	  sulfate,	  filtered	  and	  concentrated	  under	  reduced	  pressure.	  	  Purification	  
by	  flash	  chromatography	  (gradient	  elution	  5:95	  EtOAc:Hex	  to	  1:9	  EtOAc:Hex)	  afforded	  an	  
inseparable	   1:1	   mixture	   of	   β-­‐glycoside	   5.6	   and	   its	   orthoester	   (1.21	   g	   46%	   yield)	   as	   a	  
yellowish-­‐orange	   solid.	   	   This	   mixture	   was	   carried	   on	   to	   the	   subsequent	   reaction	   where	  




	  Rf	  =	  0.73	  (1:9	  EtOAc:Hex,	  CAM	  stain)	  
	  
1H	  NMR:	   (500	  MHz,	  CD3C(O)CD3)	  δ	  6.52	  (ddd,	   J	  =	  14.0,	  10.5,	  3.3	  Hz,	  5H),	  6.46	  –	  5.97	  (m,	  
31H),	  5.53	  (ddd,	   J	  =	  14.3,	  9.5,	  3.6	  Hz,	  2H),	  4.76	  –	  4.54	  (m,	  11H),	  4.45	  (td,	   J	  =	  10.5,	  4.7	  Hz,	  
3H),	  4.29	  –	  4.19	  (m,	  4H),	  4.15	  (s,	  3H),	  4.07	  –	  3.99	  (m,	  4H),	  3.92	  –	  3.83	  (m,	  3H),	  3.77	  –	  3.67	  
(m,	  4H),	  3.67	  –	  3.59	  (m,	  4H),	  3.15	  (s,	  3H),	  3.07	  (s,	  4H),	  2.68	  –	  2.52	  (m,	  5H),	  2.44	  (q,	  J	  =	  8.3	  
Hz,	  2H),	  2.24	  (s,	  3H),	  2.13	  –	  1.98	  (m,	  150H),	  1.98	  –	  1.59	  (m,	  39H),	  1.52	  (d,	  J	  =	  12.6	  Hz,	  3H),	  
1.28	   (d,	   J	   =	  9.1	  Hz,	   3H),	   1.25	   (d,	   J	   =	  6.2	  Hz,	   7H),	   1.18	   (d,	   J	   =	  6.0	  Hz,	  8H),	   1.13	  –	  0.91	   (m,	  
191H),	  0.91	  –	  0.82	  (m,	  5H),	  0.81	  –	  0.56	  (m,	  112H),	  0.22	  (d,	  J	  =	  1.2	  Hz,	  7H),	  0.16	  (d,	  J	  =	  3.4	  Hz,	  
7H).	  
	  
13CNMR:	   (126	  MHz,	   Acetone)	   δ	   172.89,	   139.33,	   135.50,	   134.89,	   133.85,	   133.69,	   133.06,	  
132.81,	  132.76,	  131.64,	  130.31,	  129.83,	  119.34,	  119.04,	  101.55,	  98.52,	  77.20,	  76.93,	  75.92,	  
74.28,	   74.20,	   72.97,	   71.35,	   70.50,	   69.63,	   69.27,	   68.93,	   67.71,	   67.11,	   66.27,	   66.17,	   58.17,	  
48.33,	   48.26,	   43.72,	   41.49,	   32.51,	   30.51,	   30.35,	   30.20,	   30.05,	   29.89,	   29.74,	   29.66,	   29.58,	  
27.74,	   26.46,	   26.38,	   24.37,	   21.12,	   20.18,	   19.53,	   18.88,	   18.81,	   18.75,	   18.73,	   14.58,	   11.33,	  
7.91,	  7.88,	  7.87,	  7.75,	  7.69,	  7.56,	  7.54,	  7.48,	  7.38,	  7.37,	  6.68,	  6.65,	  6.41,	  6.13,	  6.08,	  6.04,	  6.02,	  
























Calculated	  for	  C101H191N3O18Si8	  (M	  +	  Na)+:	  1981.2175	  
	   Found:	   	   	   	   	   1981.2169	  
	  




To	  a	  stirred	  solution	  of	  a	  mixture	  of	  5.6	  and	  the	  corresponding	  orthoester	  as	  a	  1:1	  mixture	  
(1.01	  g,	  0.515	  mmol,	  1.0	  equiv)	   in	  THF:MeOH	  (51	  mL:	  51	  mL)	  at	  0	  °C	  in	  a	  200	  mL	  round	  
bottom	  flask	  was	  added	  K2OC3	  (2.85	  g,	  20.6	  mmol,	  40.0	  equiv).	  	  After	  stirring	  at	  0	  °C	  for	  2.5	  
hours	   the	   reaction	  was	   allowed	   to	  warm	   to	   23	   °C	   and	   stir	   for	   an	   additional	   1.5	   h.	   	   The	  
reaction	  was	  then	  worked	  up	  by	  transferring	  to	  a	  separatory	   funnel	  containing	  saturated	  
brine	   and	   hexanes.	   	   The	   combined	   organic	   phases	  were	  washed	  with	   saturated	   aqueous	  
bicarbonate,	  followed	  by	  DI	  water,	  saturated	  brine,	  and	  then	  they	  were	  dried	  over	  sodium	  
sulfate,	   filtered	   and	   concentrated	   under	   reduced	   pressure.	   	   Purification	   by	   flash	  
chromatography	   (gradient	   elution	   5:95	   EtOAc:Hex	   isocratic)	   afforded	   pure	   persilyl-­‐
C41allyl-­‐C2’epiOH-­‐methylketal-­‐azidoAmB	  5.7	  (333	  mg,	  0.174	  mmol	  68%	  based	  on	  0.2575	  





































































1H	  NMR:	  (500	  MHz,	  CD3C(O)CD3)	  δ	  6.57	  –	  5.97	  (m,	  14H),	  4.74	  –	  4.59	  (m,	  3H),	  4.43	  (q,	  J	  =	  
6.2,	  5.3	  Hz,	  1H),	  4.38	  (d,	  J	  =	  7.5	  Hz,	  1H),	  4.21	  (s,	  1H),	  4.05	  (qd,	  J	  =	  8.1,	  7.6,	  4.8	  Hz,	  3H),	  3.71	  
(dt,	  J	  =	  6.5,	  4.5	  Hz,	  1H),	  3.64	  (dd,	  J	  =	  10.6,	  4.7	  Hz,	  1H),	  3.35	  (ddt,	  J	  =	  10.3,	  4.1,	  2.6	  Hz,	  2H),	  
3.28	  (t,	  J	  =	  9.4	  Hz,	  1H),	  3.15	  (s,	  3H),	  3.08	  (t,	  J	  =	  9.0	  Hz,	  1H),	  2.63	  –	  2.52	  (m,	  2H),	  2.09	  (s,	  1H),	  
1.99	  –	  1.69	  (m,	  14H),	  1.69	  –	  1.57	  (m,	  5H),	  1.57	  –	  1.46	  (m,	  3H),	  1.40	  –	  1.23	  (m,	  33H),	  1.23	  –	  
1.09	  (m,	  10H),	  1.09	  –	  0.91	  (m,	  90H),	  0.91	  –	  0.82	  (m,	  29H),	  0.80	  –	  0.55	  (m,	  48H),	  0.21	  (s,	  3H),	  
0.14	  (s,	  3H).	  
	  
13CNMR:	  (126	  MHz,	  CD3C(O)CD3)	  δ	  172.81,	  169.91,	  134.76,	  134.17,	  133.32,	  132.81,	  132.48,	  
132.00,	  131.80,	  131.69,	  130.73,	  130.06,	  129.88,	  118.41,	  101.82,	  100.77,	  76.58,	  76.07,	  75.14,	  
73.90,	   73.40,	   72.96,	   70.94,	   70.47,	   68.41,	   66.87,	   66.71,	   65.53,	   59.87,	   56.85,	   47.52,	   43.65,	  
42.83,	   40.70,	   36.83,	   36.21,	   34.60,	   31.66,	   29.65,	   28.73,	   26.87,	   25.66,	   25.52,	   25.15,	   22.64,	  
20.26,	  20.17,	  19.31,	  18.37,	  18.10,	  18.07,	  13.85,	  13.71,	  11.04,	  10.56,	  7.03,	  7.01,	  6.89,	  6.77,	  
6.70,	  6.67,	  6.53,	  5.77,	  5.71,	  5.55,	  5.29,	  5.27,	  5.24,	  5.21,	  5.17,	  5.02,	  -­‐4.53,	  -­‐4.73.	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C99H189N3O17Si8	  (M	  +	  Na)+:	  1939.2069	  
	   Found:	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  1939.2126	  
	  
	  




To	  a	  stirred	  solution	  of	  pyridine	  (5	  mL,	  62	  mmol,	  351	  equiv)	  in	  MeOH	  250	  µL	  in	  a	  50	  mL	  



































 HF-pyr, pyridine, 
    THF, MeOH (10:1)





To	  this	  solution	  was	  added	  via	  cannula	  5.7	  (333	  mg,	  174	  µmol,	  1.0	  equiv)	  as	  a	  solution	  in	  
THF	   (1.5	   mL).	   	   The	   vial	   containing	   5.7	   was	   washed	   with	   THF	   (3x	   500	   µL)	   to	   ensure	  
quantitative	   transfer	   of	  material.	   	   The	   reaction	  was	   then	   allowed	   to	  warm	   to	   23	   °C	   and	  
stirred	   for	  18	  h.	   the	   reaction	  was	   then	  cooled	   to	  0	  °C	  and	  quenched	  via	   slow	  addition	  of	  
MeOSiMe3	  (gross	  excess)	  then	  allowed	  to	  warm	  to	  23	  °C	  and	  stirred	  for	  1	  h.	  	  The	  reaction	  
was	  then	  concentrated	  under	  reduced	  pressure	  and	  pyridine	  was	  azeotropically	  removed	  
with	  benzene	  (3x	  15	  mL).	  	  	  Purification	  by	  preparative	  reverse	  phase	  HPLC	  (C18	  SiO2,	  5:95	  
to	   95:5	   MeCN:H2O	   25	   mL/min	   over	   20	   min)	   afforded	   C41allyl-­‐C2’epiOH-­‐methylketal-­‐
azidoAmB	  5.8	  (48.6	  mg,	  0.047	  mmol,	  27%	  yield)	  as	  a	  flaky	  yellow	  solid.	  Material	  with	  extra	  
silyl	   groups	   remaining	  was	   also	   recovered	   (111	  mg).	   	   This	  material	  was	   re-­‐subjected	   to	  
similar	   reaction	   conditions	   (assuming	   fully	   silylated	  5.7	   as	   a	  molecular	  weight:	   pyridine	  
585	  µL,	  7.25	  mmol,	  125	  equiv;	  HF-­‐pyr	  70%,	  345	  µL,	  19	  mmol,	  328	  equiv;	  1.2	  mL:0.2	  mL	  
THF:MeOH).	  A	  second	  cycle	  and	  HPLC	  purification	  yielded	  5.8	  (152.6	  mg,	  152	  µmol,	  88%	  




Rf	  =	  15.68	  min	  (C18SiO2	  analytical	  HPLC,	  5:95	  to	  95:5	  MeCN:H2O	  over	  20	  min,	  1	  mL/min)	  
	  
1H	  NMR:	  (500	  MHz,	  CD3C(O)CD3)	  δ	  6.55	  –	  6.15	  (m,	  23H),	  6.06	  –	  5.89	  (m,	  3H),	  5.54	  –	  5.46	  
(m,	  2H),	  5.41	  (dq,	  J	  =	  17.3,	  1.7	  Hz,	  1H),	  5.38	  –	  5.31	  (m,	  1H),	  5.24	  (dq,	  J	  =	  10.5,	  1.5	  Hz,	  2H),	  
4.76	  –	  4.61	  (m,	  8H),	  4.36	  –	  4.32	  (m,	  1H),	  4.32	  –	  4.15	  (m,	  4H),	  4.15	  –	  4.05	  (m,	  5H),	  3.97	  (dt,	  J	  
=	  19.0,	  4.2	  Hz,	  3H),	  3.91	  –	  3.84	  (m,	  2H),	  3.84	  –	  3.71	  (m,	  5H),	  3.64	  –	  3.49	  (m,	  12H),	  3.44	  –	  
3.26	  (m,	  9H),	  3.22	  (d,	  J	  =	  6.3	  Hz,	  7H),	  3.01	  (td,	  J	  =	  9.0,	  5.1	  Hz,	  2H),	  2.49	  –	  2.20	  (m,	  8H),	  2.17	  –	  
2.08	  (m,	  3H),	  2.04	  –	  1.72	  (m,	  13H),	  1.71	  –	  1.53	  (m,	  16H),	  1.53	  –	  1.39	  (m,	  12H),	  1.21	  (qd,	  J	  =	  





















13CNMR:	  (126	  MHz,	  CD3C(O)CD3)	  δ	  172.92,	  172.30,	  137.60,	  136.91,	  135.04,	  134.98,	  134.35,	  
133.89,	   133.82,	   133.76,	   133.68,	   133.36,	   133.18,	   132.79,	   131.24,	   118.46,	   104.39,	   102.54,	  
102.51,	   78.81,	   77.90,	   76.00,	   75.24,	   75.17,	   73.99,	   73.54,	   72.91,	   71.14,	   70.63,	   69.47,	   68.66,	  
68.30,	   67.49,	   67.18,	   67.06,	   65.94,	   62.57,	   62.36,	   56.45,	   48.68,	   44.49,	   43.60,	   42.74,	   42.43,	  
41.38,	   38.46,	   36.82,	   33.03,	   31.79,	   30.66,	   30.63,	   30.40,	   30.31,	   30.25,	   30.23,	   30.19,	   30.09,	  
30.07,	  30.01,	  27.21,	  24.24,	  18.97,	  18.20,	  17.52,	  12.46.	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C51H77N3O17	  (M	  +	  Na)+:	  1026.5151	  
	   Found:	   	   	   	   	  	  	  	  	  1026.5115	  
	  




Intermediate	  5.8	  (104	  mg,	  0.135	  mmol,	  1.0	  equiv)	  was	  azeotropically	  dried	  with	  benzene	  
(3x	  2	  mL)	  placed	  on	  high	  vac	  over	  night	  in	  a	  20	  mL	  iChem	  vial.	  	  In	  the	  glove	  box,	  Pd(PPh3)4	  
(35.9	  mg,	  0.03105	  mmol,	  30	  mol%)	  and	  thiosalicylic	  acid	  (79.8	  mg,	  0.517	  mmol,	  5.0	  equiv)	  
was	  added	  followed	  by	  DMF	  (3.5	  mL)	  and	  sealed	  under	  Ar	  atmosphere	  and	  stirred	  for	  1	  h	  
at	  23	  °C.	  The	  reaction	  was	  transferred	  drop-­‐wise	  into	  rapidly	  stirring	  Et2O	  (100	  mL).	  	  The	  
precipitate	  was	  filtered	  through	  a	  5”	  pipette	  containing	  a	  small	  piece	  of	  a	  kim-­‐wipeTM	  as	  a	  
filter.	  	  The	  filter	  cake	  was	  then	  washed	  with	  additional	  Et2O	  then	  eluted	  through	  the	  filter	  
with	   DMSO.	   	   The	   filter	   was	   washed	   further	   with	   minimal	   DMSO.	   The	   combined	   DMSO	  
fractions	  were	  lyophilized	  to	  yield	  5.9	  (68.9	  mg,	  0.714	  mmol,	  69%)	  as	  a	  yellow	  powder	  and	  
taken	   on	   to	   the	   next	   reaction	   without	   additional	   purification.	   By	   analytical	   HPLC	   full	  












































Rf	  =	  	  18.7	  min	  (C18SiO2	  analytical	  HPLC,	  5:95	  to	  95:5	  MeCN:H2O	  w/0.1%	  formic	  acid	  over	  20	  
min,	  1	  mL/min)	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C48H73N3O17	  (M	  +	  Na)+:	  986.4838	  
	   Found:	   	   	   	   	  	  	  	  	  986.4825	  
	  




To	  a	  stirred	  solution	  of	  5.9	  (68.9	  mg,	  0.0715	  mmol,	  1.0	  equiv)	  in	  THF:H2O	  (1.59	  mL:	  0.8	  mL	  
2:1)	  in	  a	  7	  mL	  vial	  at	  23	  °C	  was	  added	  CSA	  (4.5	  mg,	  0.0178	  mmol,	  0.25	  equiv)	  and	  stirred	  
for	   2	   h.	   	   Aqueous	   saturated	   bicarbonate	   (0.5	   mL)	   was	   added	   and	   then	   filtered	   through	  
HPLC	   filters	   (need	   Fischer	   brand	   part	   No.)	   followed	   by	   preparative	   reverse	   phase	  HPLC	  
purification	   (C18SiO2,	   5:95	   to	   95:5	   MeCN:H2O	   with	   0.1%	   formic	   acid	   for	   25	   min	   at	   25	  






























































Rf	  =	  	  19.3	  min	  (C18SiO2	  analytical	  HPLC,	  5:95	  to	  95:5	  MeCN:H2O	  over	  20	  min,	  1	  mL/min)	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C47H71N3O17	  (M	  +	  Na)+:	  972.4681	  
	   Found:	   	   	   	  	   	  	  	  	  	  972.4661	  
	  
	  




To	  a	  stirred	  solution	  of	  5.10	  (30.8	  mg,	  32.2	  µmol,	  1.0	  equiv)	  in	  DMSO	  (1.1	  mL)	  and	  H2O	  (58	  
µL,	  100	  equiv)	   in	  a	  7	  mL	  vial	   at	  23	  °C	  under	  Ar	  atmosphere	  was	  added	  PMe3	  as	  a	  1.0	  M	  
solution	   in	   THF	   (97	  µL,	   97.0	   µmol,	   3.0	   equiv)	   and	   then	   warmed	   to	   55	   °C	   for	   6	   h.	   	   The	  
reaction	  was	   then	  concentrated	  under	   reduced	  pressure	   followed	  by	  preparative	   reverse	  
phase	  HPLC	  purification	   (C18SiO2,	   5:95	   to	   95:5	  MeCN:NH4OAc	   (15	  mM)	   for	   20	  min	   at	   25	  


































































Extinction	  coefficient:	  92,000	  cm2/mol	  
	  
1H	  NMR:	  (500	  MHz,	  CD3S(O)CD3)	  δ	  6.55	  –	  6.03	  (m,	  10H),	  5.97	  (dd,	  J	  =	  15.5,	  8.7	  Hz,	  1H),	  5.75	  
(d,	  J	  =	  10.9	  Hz,	  1H),	  5.44	  (dd,	  J	  =	  15.0,	  10.1	  Hz,	  1H),	  5.34	  (s,	  1H),	  5.21	  (d,	  J	  =	  7.9	  Hz,	  1H),	  4.89	  
–	  4.71	  (m,	  3H),	  4.62	  (d,	  J	  =	  5.7	  Hz,	  1H),	  4.41	  (d,	  J	  =	  6.3	  Hz,	  1H),	  4.39	  –	  4.30	  (m,	  2H),	  4.25	  (t,	  J	  
=	  10.5	  Hz,	  2H),	  4.06	  (s,	  1H),	  3.91	  (d,	  J	  =	  10.4	  Hz,	  1H),	  3.49	  (d,	  J	  =	  31.6	  Hz,	  2H),	  3.17	  –	  3.04	  
(m,	  2H),	  3.04	  –	  2.84	  (m,	  2H),	  2.66	  (d,	  J	  =	  11.9	  Hz,	  1H),	  2.40	  (s,	  1H),	  2.28	  (dd,	  J	  =	  14.6,	  7.5	  Hz,	  
1H),	  2.17	  (t,	  J	  =	  8.5	  Hz,	  2H),	  2.05	  –	  1.68	  (m,	  5H),	  1.65	  –	  1.47	  (m,	  5H),	  1.47	  –	  1.29	  (m,	  7H),	  
1.24	  (q,	  J	  =	  5.6,	  4.6	  Hz,	  6H),	  1.20	  –	  1.08	  (m,	  6H),	  1.04	  (t,	  J	  =	  7.4	  Hz,	  3H),	  0.91	  (d,	  J	  =	  7.1	  Hz,	  
3H),	  0.86	  (td,	  J	  =	  7.1,	  4.2	  Hz,	  1H).	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C47H73NO17	  (M	  +	  H)+:	  	  924.4957	  























Synthesis	  of	  intermediate	  5.11	  
	  
	  
To	  a	  stirred	  suspension	  of	  AmB	  (4.0	  g,	  4.3	  mmol,	  1.0	  equiv)	  in	  DMF:MeOH	  (75	  mL:	  75	  mL)	  
in	  a	  300	  mL	  round	  bottom	  at	  23	  °C,	  was	  added	  sequentially,	  pyridine	  (5.0	  mL,	  50.0	  mmol,	  
11.5	  equiv)	  and	  	  alloc-­‐succinimide	  (2.4	  g,	  12.05	  mmol,	  2.8	  equiv).	  	  After	  stirring	  for	  16	  h	  at	  
23	  °C,	  the	  dark	  orange,	  homogeneous	  solution	  was	  slowly	  poured	  into	  rapidly	  stirring	  Et2O	  
(3.5	   L).	   	   	   The	   yellow	   suspension	   was	   filtered	   through	   WhatmanTM	   42	   filter	   paper	   and	  
washed	  with	  Et2O	  (3x	  100	  mL)	  before	   the	  cake	  was	  allowed	  to	   fully	  dry.	   	  The	   fully	  dried	  
alloc-­‐AmB	   yellow	   powder	   (4.3	   mmol,	   quantitative)	   was	   taken	   on	   to	   the	   subsequent	  
reaction	  without	  further	  purification.	  
	  
To	  a	  stirred	  suspension	  of	  alloc-­‐AmB	  (4.3	  mmol,	  1.0	  equiv)	   in	  MeOH	  (35	  mL,	  0.1	  M)	   in	  a	  
300	  mL	  round	  bottom	  flask	  at	  23	  °C	  was	  added	  anisaldehyde	  dimethylacetal	  (4.0	  mL,	  23.5	  
mmol,	  5.5	  equiv)	  and	  stirred	  for	  10	  min	  until	  a	  very	  fine,	  uniform	  suspension	  formed.	  CSA	  
(250	  mg,	  1.08	  mmol,	  0.25	  equiv)	  as	  a	  white	  crystalline	  solid	  was	  then	  added	  in	  one	  portion.	  	  
After	  stirring	  at	  23	  °C	  for	  30	  min,	  Et3N	  was	  added	  (~160	  µL)	  followed	  by	  THF	  (81	  mL	  to	  
dilute	  down	  to	  0.03M).	  The	  reaction	  was	  slowly	  poured	  into	  rapidly	  stirring	  hexane	  (3.5	  L).	  	  	  
The	   subsequent	   yellow	   suspension	   was	   filtered	   through	   Whatman	   42	   filter	   paper	   and	  
washed	  with	  Et2O	  (3x	  100	  mL)	  before	   the	  cake	  was	  allowed	  to	   fully	  dry.	   	  The	   fully	  dried	  
alloc-­‐bisPMP-­‐methylketal	   (4.3	   mmol,	   quantitative)	   was	   taken	   on	   to	   the	   subsequent	  
reaction	  as	  a	  yellow	  powder	  without	  further	  purification.	  	  
	  
To	   a	   stirred	   suspension	   of	   alloc-­‐bisPMP-­‐methylketal	   (4.0	   g,	   4.3	   mmol,	   1.0	   equiv)	   in	  







































    pyridine, DMF, MeOH
   23 oC, rt, 16 h
2. anisaldehydedimethylacetal
    CSA, THF, MeOH
    23 oC, 1 h
3. Allylbromide, Hunig's base
    DMF, MeOH, 23 oC, 8 h




base	  (3.75	  mL,	  21.5	  mmol,	  5.0	  equiv)	  and	  allyl	  bromide	  (11.2	  mL,	  129.0	  mmol,	  30	  equiv).	  	  
After	  stirring	  for	  8	  h	  at	  23	  °C,	  the	  dark	  orange,	  homogeneous	  solution	  was	  transferred	  into	  
a	   separatory	   funnel	   containing	   EtOAc	   and	   deionized	  H2O	   (1:1).	   	   	   The	   organic	   phase	  was	  
washed	  with	  water	   (3x	  200	  mL)	   followed	  by	  brine.	   	  The	  combined	  aqueous	  phases	  were	  
extracted	  with	  EtOAc.	  The	  combined	  organic	  phases	  were	  washed	  with	  saturated	  brine	  and	  
dried	  over	  sodium	  sulfate,	   filtered	  and	  concentrated	  under	  reduced	  pressure.	  Purification	  
by	   flash	   chromatography	   (SiO2,	   gradient	   elution	   50:49:1	   EtOAc:Hex:MeOH	   	   to	   75:24:1	  
EtOAc:Hex:MeOH)	  afforded	  5.12	  (1.42	  g,	  1.09	  mmol,	  30%)	  as	  an	  orange	  solid.	  
	  
	  
Rf	  =	  	  0.21	  (50:49:1	  EtOAc:Hex:MeOH)	  
	  
1H	  NMR:	  (500	  MHz,	  CD3C(O)CD3)	  δ	  7.43	  (d,	  J	  =	  8.5	  Hz,	  2H),	  7.38	  –	  7.33	  (m,	  2H),	  6.90	  –	  6.82	  
(m,	  4H),	  6.48	  –	  6.18	  (m,	  11H),	  6.05	  –	  5.84	  (m,	  3H),	  5.59	  (dd,	  J	  =	  14.3,	  9.3	  Hz,	  1H),	  5.52	  (s,	  
1H),	  5.46	  (s,	  1H),	  5.45	  –	  5.38	  (m,	  1H),	  5.28	  –	  5.22	  (m,	  1H),	  4.71	  –	  4.62	  (m,	  3H),	  4.60	  (d,	  J	  =	  
7.0	  Hz,	  1H),	  4.53	  (q,	  J	  =	  7.2,	  4.6	  Hz,	  2H),	  4.17	  (tt,	  J	  =	  10.4,	  6.0	  Hz,	  2H),	  3.95	  (dd,	  J	  =	  9.9,	  6.9	  Hz,	  
3H),	  3.79	  (d,	  J	  =	  2.9	  Hz,	  7H),	  3.77	  –	  3.66	  (m,	  3H),	  3.61	  (td,	  J	  =	  9.0,	  3.2	  Hz,	  1H),	  3.45	  (d,	  J	  =	  8.0	  
Hz,	  1H),	  3.39	  (p,	  J	  =	  6.8	  Hz,	  2H),	  3.33	  (q,	  J	  =	  8.6	  Hz,	  3H),	  3.08	  (s,	  2H),	  2.36	  –	  2.25	  (m,	  3H),	  
1.96	  –	  1.88	  (m,	  2H),	  1.88	  –	  1.78	  (m,	  3H),	  1.73	  (dt,	  J	  =	  16.4,	  8.1	  Hz,	  3H),	  1.69	  –	  1.42	  (m,	  8H),	  
1.41	  –	  1.21	  (m,	  28H),	  1.19	  (p,	  J	  =	  5.2	  Hz,	  4H),	  1.13	  –	  1.08	  (m,	  5H),	  1.02	  (d,	  J	  =	  7.1	  Hz,	  4H),	  
0.95	  (d,	  J	  =	  6.6	  Hz,	  2H),	  0.87	  (dt,	  J	  =	  12.0,	  7.0	  Hz,	  22H).	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C71H95NO21	  (M	  +	  Na)+:	  1320.6294	  




























Intermediate	  5.11	  (2.83	  g,	  2.18	  mmol,	  1.0	  equiv)	  was	  azeotropically	  dried	  with	  benzene	  (3x	  
10	  mL)	  and	  placed	  on	  high	  vac	  overnight	  in	  a	  300	  mL	  round	  bottom	  flask.	  	  To	  intermediate	  
5.11	  was	   added	  THF	   (74	  mL)	   followed	  by	  DIPEA	   (0.61	  mL,	   3.49	  mmol,	   1.6	   equiv).	   	   In	   a	  
separate	  200	  mL	  round	  bottom	  flask	  was	  added	  sequentially,	  THF	  (46	  mL),	  DMAP	  (426	  mg,	  
3.49	  mmol,	  1.6	  equiv),	  and	  drop-­‐wise	  p-­‐tertbutylbenzoylchloride	  (595	  µL,	  3.05	  mmol,	  1.4	  
equiv)	   forming	  a	   fine,	  white	  suspension.	   	  Most	  of	   this	  suspension	  was	  slowly	  added	  drop	  
wise	  via	  cannula	  to	  the	  THF,	  DIPEA	  and	  5.11	  solution	  over	  50	  min	  until	  a	  majority	  of	  the	  
starting	  material	  was	   converted	  as	   judged	  by	  TLC.	   	  The	   reaction	  was	  diluted	  with	  EtOAc	  
and	   transferred	   to	  a	  separatory	   funnel	  containing	  aqueous	  saturated	  sodium	  bicarbonate	  
and	  extracted	  with	  EtOAc.	  The	  combined	  organic	  phases	  were	  dried	  over	  sodium	  sulfate,	  
filtered	   and	   concentrated	   under	   reduced	   pressure.	   Purification	   by	   flash	   chromatography	  
(SiO2,	   gradient	   eluent	   65:33:2	   EtOAc:Hex:MeOH	   isocratic)	   afforded	   5.11	   (930	   g,	   0.654	  














































































1H	  NMR:	  (500	  MHz,	  CD3C(O)CD3)	  δ	  8.07	  –	  7.89	  (m,	  2H),	  7.64	  –	  7.48	  (m,	  2H),	  7.38	  (ddt,	  J	  =	  
25.4,	  8.0,	  2.2	  Hz,	  4H),	  6.86	  (ddd,	  J	  =	  9.5,	  4.6,	  2.4	  Hz,	  4H),	  6.46	  –	  6.11	  (m,	  10H),	  6.10	  –	  5.96	  
(m,	  3H),	  5.96	  –	  5.82	  (m,	  3H),	  5.82	  –	  5.65	  (m,	  1H),	  5.58	  (d,	  J	  =	  3.7	  Hz,	  1H),	  5.52	  –	  5.38	  (m,	  
2H),	  5.33	  –	  5.18	  (m,	  1H),	  5.11	  (td,	  J	  =	  9.2,	  7.5,	  3.9	  Hz,	  1H),	  4.88	  (s,	  0H),	  4.73	  –	  4.56	  (m,	  2H),	  
4.49	  (t,	  J	  =	  5.9	  Hz,	  1H),	  4.24	  –	  4.10	  (m,	  1H),	  4.01	  –	  3.82	  (m,	  2H),	  3.82	  –	  3.75	  (m,	  4H),	  3.75	  –	  
3.63	  (m,	  1H),	  3.59	  (td,	  J	  =	  9.6,	  6.1	  Hz,	  1H),	  3.56	  –	  3.46	  (m,	  1H),	  3.45	  –	  3.34	  (m,	  1H),	  2.85	  (s,	  
1H),	  2.60	  (s,	  1H),	  2.45	  –	  2.35	  (m,	  1H),	  2.35	  –	  2.23	  (m,	  1H),	  2.02	  –	  1.94	  (m,	  1H),	  1.91	  –	  1.82	  
(m,	  1H),	  1.80	  –	  1.40	  (m,	  6H),	  1.36	  (d,	  J	  =	  3.6	  Hz,	  8H),	  1.32	  –	  1.26	  (m,	  3H),	  1.22	  –	  1.15	  (m,	  
2H),	  1.12	  (d,	  J	  =	  6.7	  Hz,	  2H),	  1.01	  (d,	  J	  =	  7.1	  Hz,	  2H).	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C82H107NO22	  (M	  +	  Na)+:	  	   1480.7182	  
	   Found:	   	   	   	   	  	  	   1480.7172	  
	  
	  




FIntermediate	   5.12	   (910	   mg,	   0.624	   mmol,	   1.0	   equiv)	   was	   azeotropically	   dried	   with	  
benzene	  (3x	  10	  mL)	  and	  placed	  on	  high	  vac	  overnight	  in	  a	  300	  mL	  round	  bottom	  flask.	  	  To	  
intermediate	  5.13	  was	  added	  DCM	  (10.5	  mL)	  and	  hexanes	  (10.5	  mL)	   followed	  by	   freshly	  
distilled	  2,6-­‐lutidine	  (654	  µL,	  5.61	  mmol,	  9.1	  equiv)	  and	  cooled	  to	  0	  °C.	  	  DEIPSOTf	  (743	  µL,	  
3.74	  mmol,	  6.0	  equiv)	  was	  added	  dropwise	  over	  10	  min	  and	  stirred	  for	  another	  hour.	  The	  



















































bicarbonate	   and	   extracted	   with	   Et2O.	   The	   combined	   organic	   phases	   were	   dried	   over	  
sodium	   sulfate,	   filtered	   and	   concentrated	   under	   reduced	   pressure.	   Purification	   by	   flash	  
chromatography	   (SiO2,	   gradient	   eluent	   1:9	   EtOAc:Hex	   to	   1:4	   EtOAx:Hex)	   afforded	   5.13	  




Rf	  =	  	  0.21	  (1:4	  EtOAc:Hex)	  
	  
1H	  NMR:	  (500	  MHz,	  CD3C(O)CD3)	  δ	  8.07	  –	  7.95	  (m,	  2H),	  7.65	  –	  7.54	  (m,	  2H),	  7.37	  –	  7.31	  (m,	  
4H),	  6.94	  –	  6.81	  (m,	  6H),	  6.41	  –	  6.32	  (m,	  5H),	  6.32	  –	  6.24	  (m,	  3H),	  6.20	  –	  6.13	  (m,	  3H),	  6.10	  –	  
5.84	  (m,	  4H),	  5.72	  (ddd,	  J	  =	  21.6,	  15.2,	  6.4	  Hz,	  2H),	  5.52	  (d,	  J	  =	  3.3	  Hz,	  1H),	  5.45	  (q,	  J	  =	  1.6	  Hz,	  
0H),	  5.41	  (d,	  J	  =	  10.3	  Hz,	  3H),	  5.34	  (dt,	  J	  =	  10.3,	  1.4	  Hz,	  1H),	  5.27	  (dq,	  J	  =	  17.3,	  1.8	  Hz,	  1H),	  
5.13	  (dq,	  J	  =	  10.4,	  1.5	  Hz,	  1H),	  4.91	  (d,	  J	  =	  1.1	  Hz,	  1H),	  4.75	  (s,	  1H),	  4.71	  –	  4.62	  (m,	  2H),	  4.62	  
–	  4.55	  (m,	  2H),	  4.52	  (dt,	  J	  =	  5.6,	  1.6	  Hz,	  2H),	  4.33	  –	  4.25	  (m,	  1H),	  4.19	  –	  4.08	  (m,	  1H),	  4.07	  –	  
3.94	  (m,	  1H),	  3.93	  –	  3.81	  (m,	  3H),	  3.81	  –	  3.73	  (m,	  10H),	  3.72	  –	  3.60	  (m,	  4H),	  3.51	  (dq,	  J	  =	  8.8,	  
6.1	  Hz,	  1H),	  2.75	  (s,	  3H),	  2.53	  –	  2.39	  (m,	  2H),	  2.27	  (dd,	  J	  =	  17.7,	  4.4	  Hz,	  1H),	  2.23	  –	  2.11	  (m,	  
2H),	  2.09	  (s,	  7H),	  1.99	  –	  1.94	  (m,	  1H),	  1.89	  (ddt,	   J	  =	  12.5,	  8.0,	  3.9	  Hz,	  1H),	  1.78	  –	  1.56	  (m,	  
5H),	  1.56	  –	  1.41	  (m,	  4H),	  1.37	  (d,	  J	  =	  3.4	  Hz,	  14H),	  1.32	  –	  1.21	  (m,	  6H),	  1.21	  –	  1.11	  (m,	  7H),	  
1.09	  (d,	  J	  =	  6.8	  Hz,	  3H),	  1.07	  –	  0.76	  (m,	  79H),	  0.76	  –	  0.65	  (m,	  12H),	  0.61	  –	  0.49	  (m,	  7H),	  0.43	  
(dqd,	  J	  =	  14.1,	  7.9,	  1.7	  Hz,	  5H).	  
	  
13CNMR:	  (126	  MHz,	  CD3C(O)CD3)	  δ	  172.60,	  170.01,	  166.28,	  160.93,	  160.80,	  157.48,	  157.01,	  
138.66,	   135.17,	   134.93,	   134.66,	   134.40,	   134.27,	   134.01,	   133.67,	   133.05,	   132.92,	   132.79,	  
132.29,	   131.26,	   130.93,	   130.90,	   129.29,	   129.12,	   128.87,	   128.47,	   127.24,	   126.28,	   119.43,	  

























74.17,	   73.14,	   73.02,	   72.98,	   68.92,	   66.82,	   65.95,	   65.84,	   58.56,	   57.01,	   55.68,	   48.58,	   43.99,	  
42.91,	   41.29,	   38.08,	   36.90,	   35.90,	   33.75,	   32.97,	   31.64,	   30.77,	   28.14,	   19.27,	   18.24,	   18.19,	  
18.07,	  18.01,	  17.70,	  17.68,	  14.19,	  14.17,	  14.03,	  13.76,	  7.94,	  7.90,	  7.82,	  7.77,	  7.72,	  7.71,	  7.48,	  
7.36,	  5.21,	  5.10,	  4.94,	  4.89,	  4.69,	  4.44.	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C110H171NO22	  (M	  +	  Na)+:	  	   1993.1268	  
	   Found:	   	   	   	   	   1993.1189	  
	  
	  




Intermediate	  5.13	  (980	  mg,	  0.497	  mmol,	  1.0	  equiv)	  was	  azeotropically	  dried	  with	  benzene	  
(3x	  10	  mL)	  and	  placed	  on	  high	  vac	  overnight	  in	  a	  40	  mL	  iChem.	  	  To	  intermediate	  5.13	  was	  
added	   THF	   (6.2	   mL)	   and	   MeOH	   (12.3	   mL)	   followed	   by	   KCN	   (48.5	   mg,	   0.745	   mmol,	   1.5	  
equiv)	  placed	  under	  Ar	  atmosphere	  and	  warmed	  to	  40	  °C	  and	  stirred	  for	  72	  h.	  The	  reaction	  
transferred	  to	  a	  separatory	  funnel	  containing	  Et2O	  and	  aqueous	  saturated	  bicarbonate.	  	  The	  
organic	  phase	  was	  washed	  with	  water	   followed	  by	  brine.	  The	   combined	   aqueous	  phases	  
were	  extracted	  with	  Et2O.	  The	  combined	  organic	  phases	  were	  dried	  over	   sodium	  sulfate,	  
filtered	   and	   concentrated	   under	   reduced	   pressure.	   Purification	   by	   flash	   chromatography	  
(SiO2,	   gradient	   eluent	   1:9	   EtOAc:Hex	   to	   1:4	   EtOAx:Hex)	   afforded	   5.14	   (542	   mg,	   0.298	  



















































Rf	  =	  	  0.22	  (3:7	  EtOAc:Hex)	  
	  
1H	  NMR:	   	  NMR	  (500	  MHz,	  CD3C(O)CD3)	  δ	  7.43	  –	  7.30	  (m,	  5H),	  6.92	  –	  6.79	  (m,	  5H),	  6.48	  –	  
6.14	  (m,	  12H),	  6.11	  (dd,	  J	  =	  15.0,	  10.0	  Hz,	  1H),	  6.03	  –	  5.89	  (m,	  3H),	  5.88	  –	  5.73	  (m,	  2H),	  5.43	  
(d,	  J	  =	  3.6	  Hz,	  3H),	  5.37	  (dq,	  J	  =	  21.8,	  1.6	  Hz,	  1H),	  5.33	  –	  5.26	  (m,	  2H),	  5.17	  (dq,	  J	  =	  10.6,	  1.5	  
Hz,	  1H),	  4.79	  (s,	  1H),	  4.71	  –	  4.48	  (m,	  7H),	  4.27	  (td,	  J	  =	  10.6,	  4.7	  Hz,	  1H),	  4.21	  –	  4.11	  (m,	  1H),	  
3.95	  –	  3.82	  (m,	  4H),	  3.79	  (s,	  4H),	  3.78	  (s,	  4H),	  3.77	  –	  3.63	  (m,	  6H),	  3.54	  (t,	  J	  =	  9.2	  Hz,	  1H),	  
3.38	  –	  3.26	  (m,	  1H),	  2.49	  (dd,	  J	  =	  17.6,	  7.6	  Hz,	  1H),	  2.43	  (q,	  J	  =	  7.1	  Hz,	  1H),	  2.32	  –	  2.24	  (m,	  
3H),	  1.96	  (s,	  3H),	  1.94	  –	  1.86	  (m,	  2H),	  1.82	  –	  1.67	  (m,	  3H),	  1.66	  –	  1.57	  (m,	  2H),	  1.58	  –	  1.27	  
(m,	  7H),	  1.26	  (d,	  J	  =	  6.1	  Hz,	  4H),	  1.23	  –	  1.10	  (m,	  8H),	  1.10	  –	  0.86	  (m,	  58H),	  0.86	  –	  0.76	  (m,	  
15H),	  0.70	  (tdt,	  J	  =	  8.2,	  4.4,	  2.9	  Hz,	  11H),	  0.63	  –	  0.48	  (m,	  5H),	  0.48	  –	  0.36	  (m,	  4H).	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C99H159NO21	  (M	  +	  Na)+:	  	  1833.0379	  
































Synthesis	  of	  intermediate	  5.15	  
	  
	  
Intermediate	  5.14	  (##	  mg,	  ##	  mmol,	  1.0	  equiv)	  was	  azeotropically	  dried	  with	  benzene	  (3x	  
10	  mL)	   and	  placed	   on	   high	   vac	   overnight	   in	   a	   40	  mL	   iChem.	   	   To	   intermediate	  5.14	  was	  
added	  p-­‐nitrobenzoic	  acid	  (#	  mg,	  0.##	  mmol,	  6.0	  equiv),	  PPh3	  (#	  mg,	  ##	  mmol,	  6.0	  equiv)	  
and	   toluene	   (#	  mL).	   	   The	   solution	  was	   cooled	   to	   0	   °C	   and	  DIAD	   (##	  µl,	   0.##	  mmol,	   6.0	  
equiv)	  was	  added	  drop-­‐wise	  and	  stirred	  at	  0	  °C	  for	  1	  h.	  The	  reaction	  was	  then	  heated	  to	  70	  
°C	  for	  3	  h.	  The	  reaction	  was	  transferred	  to	  a	  separatory	  funnel	  containing	  Et2O	  and	  aqueous	  
saturated	   sodium	   bicarbonate.	   	   The	   organic	   phase	   was	   washed	   with	   water	   followed	   by	  
brine.	   The	   combined	   aqueous	   phases	   were	   extracted	   with	   Et2O.	   The	   combined	   organic	  
phases	  were	  dried	  over	  sodium	  sulfate,	  filtered	  and	  concentrated	  under	  reduced	  pressure.	  
Purification	   by	   flash	   chromatography	   (SiO2,	   gradient	   eluent	   1:9	   EtOAc:Hex	   to	   1:4	  
EtOAx:Hex)	  afforded	  C2’epi	  nitrobenzoate	  5.15	   (#	  mg,	  ##	  µmol,	  84%	  yield)	  as	  an	  orange	  
solid.	  
	   	  
	  
Rf	  =	  	  0.2	  (1:4	  EtOAc:Hex)	  
	  
1H	  NMR:	  (500	  MHz,	  CD3C(O)CD3)	  δ	  8.37	  (s,	  4H),	  7.37	  –	  7.30	  (m,	  4H),	  6.89	  –	  6.81	  (m,	  5H),	  









































































5.8	  Hz,	  2H),	  5.67	  (ddt,	  J	  =	  17.3,	  10.6,	  5.4	  Hz,	  1H),	  5.47	  –	  5.39	  (m,	  2H),	  5.35	  (s,	  1H),	  5.30	  (dq,	  J	  
=	  10.4,	  1.3	  Hz,	  1H),	  5.15	  (dd,	  J	  =	  10.4,	  7.9	  Hz,	  1H),	  5.08	  (dq,	  J	  =	  17.2,	  1.7	  Hz,	  1H),	  4.92	  (dq,	  J	  =	  
10.5,	  1.4	  Hz,	  1H),	  4.82	  (d,	  J	  =	  7.8	  Hz,	  1H),	  4.79	  –	  4.69	  (m,	  2H),	  4.61	  (qdt,	  J	  =	  13.1,	  6.0,	  1.4	  Hz,	  
3H),	  4.33	  (qdt,	  J	  =	  13.6,	  5.4,	  1.5	  Hz,	  2H),	  4.18	  –	  4.09	  (m,	  1H),	  3.97	  (td,	  J	  =	  10.6,	  4.6	  Hz,	  1H),	  
3.90	  –	  3.81	  (m,	  3H),	  3.77	  (d,	  J	  =	  2.9	  Hz,	  8H),	  3.75	  –	  3.63	  (m,	  7H),	  3.52	  (dq,	  J	  =	  9.0,	  6.1	  Hz,	  1H),	  
2.69	  (s,	  3H),	  2.53	  –	  2.39	  (m,	  2H),	  2.34	  –	  2.21	  (m,	  1H),	  2.19	  –	  2.07	  (m,	  2H),	  2.04	  –	  1.98	  (m,	  
1H),	  1.88	  (dddd,	  J	  =	  12.9,	  10.2,	  6.6,	  3.8	  Hz,	  1H),	  1.79	  (d,	  J	  =	  15.5	  Hz,	  1H),	  1.76	  –	  1.64	  (m,	  2H),	  
1.61	  (dt,	  J	  =	  13.0,	  2.5	  Hz,	  1H),	  1.56	  –	  1.40	  (m,	  5H),	  1.37	  –	  1.24	  (m,	  14H),	  1.23	  –	  1.12	  (m,	  8H),	  
1.10	  –	  0.95	  (m,	  45H),	  0.94	  –	  0.84	  (m,	  19H),	  0.84	  –	  0.76	  (m,	  13H),	  0.74	  –	  0.60	  (m,	  15H),	  0.53	  
(dqd,	  J	  =	  26.8,	  7.8,	  3.2	  Hz,	  5H),	  0.42	  –	  0.28	  (m,	  5H).	  
	  
13CNMR:	  (126	  MHz,	  CD3C(O)CD3)	  δ	  173.00,	  170.05,	  164.87,	  160.93,	  160.79,	  157.06,	  151.67,	  
138.05,	   136.54,	   134.87,	   134.73,	   134.64,	   134.56,	   134.45,	   134.16,	   133.82,	   133.65,	   133.35,	  
132.91,	   132.75,	   132.48,	   132.40,	   131.84,	   130.96,	   128.86,	   128.47,	   127.65,	   124.39,	   119.57,	  
117.11,	   114.07,	   113.98,	   101.97,	   101.21,	   100.71,	   98.47,	   81.53,	   76.09,	   76.00,	   75.09,	   74.92,	  
73.67,	   73.04,	   72.94,	   68.84,	   66.84,	   66.12,	   65.56,	   59.60,	   58.12,	   55.66,	   55.12,	   48.39,	   43.94,	  
42.99,	   41.32,	   38.08,	   36.35,	   33.68,	   32.96,	   28.21,	   22.01,	   18.87,	   18.20,	   18.14,	   18.00,	   17.98,	  
17.93,	  17.62,	  17.60,	  14.15,	  14.12,	  14.02,	  13.67,	  7.90,	  7.86,	  7.76,	  7.73,	  7.69,	  7.66,	  7.36,	  5.15,	  
5.06,	  4.93,	  4.91,	  4.88,	  4.63,	  4.36.	  
	  
HRMS	  (ESI)	  
Calculated	  for	  C106H162N2O24Si4	  (M	  +	  Na)+:	  1982.0492	  















Intermediate	  5.15	  (80.4	  g,	  40.4	  µmol,	  1.0	  equiv)	  was	  azeotropically	  dried	  with	  benzene	  (3x	  
10	  mL)	  and	  placed	  on	  high	  vac	  overnight	  in	  a	  7	  mL	  iChem.	  	  To	  intermediate	  5.15	  was	  added	  
THF	  (1.0	  mL)	  and	  MeOH	  (0.5	  mL)	  followed	  by	  KCN	  (4.08	  mg,	  61.4	  µmol,	  1.5	  equiv)	  placed	  
under	  Ar	  atmosphere	  and	  warmed	  to	  40	  °C	  and	  stirred	  for	  72	  h.	  The	  reaction	  transferred	  to	  
a	  separatory	  funnel	  containing	  Et2O	  and	  aqueous	  saturated	  bicarbonate.	  	  The	  organic	  phase	  
was	  washed	  with	  water	  followed	  by	  brine.	  The	  combined	  aqueous	  phases	  were	  extracted	  
with	   Et2O.	   The	   combined	   organic	   phases	   were	   dried	   over	   sodium	   sulfate,	   filtered	   and	  
concentrated	  under	  reduced	  pressure.	  Purification	  by	  flash	  chromatography	  (SiO2,	  gradient	  
eluent	  1:9	  EtOAc:Hex	  to	  1:4	  EtOAx:Hex)	  afforded	  5.16	  (42.6	  mg,	  23.4	  µmol,	  57%	  yield)	  as	  
an	  orange	  solid.	  
	  
	  
Rf	  =	  	  0.2	  (3:7	  EtOAc:Hex)	  
	  
1H	  NMR:	  (500	  MHz,	  CD3C(O)CD3)	  δ	  7.43	  –	  7.32	  (m,	  4H),	  6.87	  (ddd,	  J	  =	  13.9,	  8.9,	  2.1	  Hz,	  4H),	  
6.47	  –	  6.15	  (m,	  13H),	  6.10	  (dd,	  J	  =	  15.1,	  10.0	  Hz,	  1H),	  6.06	  –	  5.82	  (m,	  3H),	  5.78	  (dd,	  J	  =	  15.1,	  





































































(dt,	  J	  =	  10.7,	  1.5	  Hz,	  1H),	  4.81	  (s,	  1H),	  4.66	  –	  4.55	  (m,	  3H),	  4.51	  (td,	  J	  =	  4.9,	  3.9,	  1.5	  Hz,	  2H),	  
4.37	  (d,	  J	  =	  6.5	  Hz,	  1H),	  4.33	  –	  4.23	  (m,	  1H),	  4.22	  –	  4.12	  (m,	  1H),	  4.01	  –	  3.82	  (m,	  3H),	  3.79	  (d,	  
J	  =	  1.8	  Hz,	  3H),	  3.78	  (d,	  J	  =	  1.9	  Hz,	  3H),	  3.76	  –	  3.66	  (m,	  4H),	  3.43	  (tt,	  J	  =	  9.2,	  3.9	  Hz,	  3H),	  3.34	  
(h,	  J	  =	  6.3	  Hz,	  1H),	  3.05	  (d,	  J	  =	  1.9	  Hz,	  3H),	  2.49	  (dd,	  J	  =	  17.6,	  7.7	  Hz,	  1H),	  2.46	  –	  2.38	  (m,	  1H),	  
2.27	  (dt,	  J	  =	  14.3,	  4.6	  Hz,	  3H),	  2.09	  (d,	  J	  =	  1.6	  Hz,	  4H),	  2.01	  –	  1.93	  (m,	  1H),	  1.93	  –	  1.85	  (m,	  
2H),	  1.85	  –	  1.77	  (m,	  1H),	  1.73	  (q,	  J	  =	  10.2,	  9.4	  Hz,	  1H),	  1.68	  –	  1.38	  (m,	  7H),	  1.31	  (q,	  J	  =	  10.9	  
Hz,	  5H),	  1.24	  (t,	  J	  =	  5.4	  Hz,	  4H),	  1.22	  –	  1.16	  (m,	  6H),	  1.10	  –	  0.86	  (m,	  52H),	  0.86	  –	  0.75	  (m,	  
14H),	  0.69	  (dddd,	  J	  =	  13.6,	  11.6,	  8.0,	  3.8	  Hz,	  10H),	  0.63	  –	  0.49	  (m,	  4H),	  0.49	  –	  0.34	  (m,	  4H).	  
	  
13CNMR:	  (126	  MHz,	  CD3C(O)CD3)	  δ	  173.37,	  170.15,	  160.95,	  160.81,	  157.34,	  137.97,	  134.87,	  
134.84,	   134.77,	   134.74,	   134.35,	   134.15,	   133.96,	   133.77,	   133.56,	   133.36,	   132.90,	   132.78,	  
132.42,	   131.08,	   129.69,	   128.90,	   128.50,	   119.55,	   117.30,	   114.08,	   114.01,	   103.12,	   102.07,	  
101.27,	  100.90,	  81.60,	  76.29,	  76.20,	  75.23,	  74.59,	  73.32,	  73.28,	  72.97,	  69.07,	  67.63,	  66.27,	  
65.64,	   61.38,	   57.67,	   55.66,	   48.58,	   44.14,	   43.33,	   41.41,	   38.08,	   37.66,	   33.73,	   32.93,	   30.76,	  
28.33,	   19.26,	   19.11,	   18.21,	   18.14,	   18.05,	   18.02,	   18.00,	   17.69,	   17.67,	   14.15,	   14.04,	   13.72,	  
7.90,	  7.87,	  7.80,	  7.78,	  7.75,	  7.71,	  7.47,	  7.45,	  5.18,	  5.06,	  5.02,	  4.96,	  4.90,	  4.88,	  4.66,	  4.43.	  
	  
HRMS	  (ESI)	  
	   Calculated	  for	  C99H159NO21Si4	  (M	  +	  Na)+:	  	   1833.0379	  
	   Found:	   	   	   	   	   1833.0309	  
	  
Synthesis	  of	  intermediate	  5.17	  
	  
	   To	  a	  30	  mL	  Teflon	  vial	  charged	  with	  MeOH	  (14.5	  mL)	  at	  0	  °C	  was	  added	  HF-­‐pyridine	  
70%	  solution	  (2.05	  mL).	  	  To	  a	  separate	  100	  mL	  Teflon	  vial	  containing	  5.16	  (0.65	  mmol	  1.05	  














































contents	  of	  the	  1st	  vial	  were	  transferred	  slowly	  via	  cannula	  to	  the	  second	  vial	  over	  20	  min.	  	  
At	  this	  point	  the	  ice	  bath	  was	  removed	  and	  the	  reaction	  was	  allowed	  to	  stir	  at	  23	  °C	  for	  6	  h.	  	  	  
Upon	   completion,	   the	   reaction	   was	   cooled	   to	   0	   °C	   and	   quenched	   by	   slow	   addition	   of	  
saturated	  aqueous	  sodium	  bicarbonate	  (60	  mL)	  and	  allowed	  to	  warm	  to	  23	  °C	  for	  1	  h.	  	  The	  
biphasic	   suspension	   was	   then	   transferred	   to	   a	   separatory	   funnel	   containing	   saturated	  
aqueous	  sodium	  bicarbonate	  and	  EtOAc.	   	  The	  combined	  organics	  were	  washed	  with	  H2O,	  
saturated	   brine,	   dried	   with	   sodium	   sulfate,	   filtered	   and	   concentrated	   under	   vacuum.	  	  
Purification	   by	   flash	   chromatography	   (SiO2,	   gradient	   eluent	   49:1	   DCM:MeOH	   to	   97:3	  
DCM:MeOH	  to	  19:1	  DCM:MeOH)	  afforded	  5.17	   (473.3	  mg,	  µmol,	  68%	  yield)	  as	  an	  orange	  
solid.	  
	  
Rf	  =	  	  0.2	  (19:1	  DCM:MeOH)	  
	  
1H	  NMR	  (500	  MHz,	  Acetone-­‐d6)	  δ	  7.48	  –	  7.32	  (m,	  5H),	  6.91	  –	  6.81	  (m,	  5H),	  6.35	  (dddd,	  J	  =	  
53.1,	  19.0,	  13.1,	  8.3	  Hz,	  18H),	  6.06	  –	  5.87	  (m,	  3H),	  5.60	  (p,	  J	  =	  8.4,	  7.5	  Hz,	  1H),	  5.54	  –	  5.38	  
(m,	  3H),	  5.35	  –	  5.20	  (m,	  3H),	  5.19	  –	  5.11	  (m,	  1H),	  4.70	  –	  4.56	  (m,	  4H),	  4.52	  (d,	  J	  =	  5.4	  Hz,	  
3H),	  4.38	  (d,	  J	  =	  7.5	  Hz,	  2H),	  4.27	  –	  4.08	  (m,	  3H),	  4.10	  –	  3.90	  (m,	  3H),	  3.89	  –	  3.83	  (m,	  1H),	  
3.77	  (d,	  J	  =	  3.6	  Hz,	  9H),	  3.56	  (d,	  J	  =	  5.6	  Hz,	  1H),	  3.52	  –	  3.33	  (m,	  6H),	  3.22	  –	  3.13	  (m,	  1H),	  3.08	  
(s,	  3H),	  2.59	  (dt,	  J	  =	  14.5,	  7.3	  Hz,	  1H),	  2.36	  (tdd,	  J	  =	  27.1,	  16.2,	  7.3	  Hz,	  5H),	  2.09	  (s,	  1H),	  2.07	  
–	  1.99	  (m,	  2H),	  1.97	  (s,	  1H),	  1.96	  –	  1.82	  (m,	  3H),	  1.83	  –	  1.64	  (m,	  3H),	  1.62	  –	  1.56	  (m,	  1H),	  
1.38	  (d,	  J	  =	  11.8	  Hz,	  1H),	  1.28	  –	  1.19	  (m,	  8H),	  1.15	  (d,	  J	  =	  6.4	  Hz,	  4H),	  1.04	  (d,	  J	  =	  7.0	  Hz,	  4H).	  
	  
13C	   NMR	   (126	  MHz,	   Acetone)	   δ	   206.32,	   173.28,	   170.86,	   169.77,	   160.51,	   160.43,	   158.26,	  
150.38,	   137.62,	   137.01,	   134.35,	   134.24,	   134.18,	   134.06,	   133.88,	   133.77,	   133.42,	   133.05,	  
132.81,	   132.57,	   132.51,	   132.32,	   130.13,	   128.29,	   128.24,	   128.19,	   124.55,	   118.50,	   117.18,	  
114.18,	   113.87,	   102.86,	   101.05,	   100.73,	   100.55,	   81.03,	   77.97,	   76.51,	   76.34,	   75.25,	   73.92,	  
73.25,	   73.19,	   72.92,	   70.58,	   67.58,	   67.10,	   65.74,	   65.67,	   60.88,	   60.46,	   56.96,	   55.45,	   48.64,	  
43.54,	   42.66,	   41.80,	   41.47,	   37.89,	   37.66,	   33.85,	   33.34,	   30.58,	   28.76,	   23.21,	   20.80,	   18.99,	  




	   Calculated	  for	  C71H95NO21(M	  +	  Na)+:	  	   1320.6274	  
	   Found:	   	   	   	   	   1320.6294	  
	  
Synthesis	  of	  intermediate	  5.18	  
	  
	   To	  a	  40	  mL	  iChem	  vial	  charged	  with	  5.17	   (##	  mg,	  ##	  mmol,	  1.0	  eq)	  was	  added	  in	  
the	  glove	  box	  Pd(PPh3)4	  (##	  mg,	  ##	  mmol,	  0.3	  eq),	  thiosalicylic	  acid	  (##	  mg,	  ##	  mmol,	  1.0	  
eq)	  and	  sealed.	  	  Outside	  of	  the	  glove	  box	  was	  then	  added	  DMF	  (##	  mL)	  at	  23	  °C	  and	  stirred	  
for	   1	   h.	   	   The	   reaction	  was	   then	   added	   dropwise	   to	   stirring	   Et2O	   (#	  mL).	   	   The	   resulting	  
yellow	   precipitate	   was	   then	   filtered	   through	   Whatman	   50	   filter	   paper	   and	   rinsed	   with	  
excess	  Et2O.	  	  The	  filtrate	  was	  then	  concentrated	  and	  slowly	  added	  to	  stirring	  Et2O	  (#	  mL).	  	  
This	  process	  was	  repeated	  until	  all	  of	  the	  precipitate	  was	  collected.	  The	  orange-­‐yellow	  solid	  
intermediate	  5.18	  was	  taken	  on	  to	  the	  next	  reaction	  without	  further	  purification.	  
	  
Rt	  =	  	  15.9	  min	  (C18SiO2	  5:95	  -­‐>	  95:5	  MeCN:H2O	  5mM	  NH4OAc	  over	  20	  min	  @	  1	  mL/min)	  
	  
1H	  NMR	  (500	  MHz,	  Methanol-­‐d4)	  δ	  7.51	  –	  7.39	  (m,	  4H),	  6.84	  –	  6.75	  (m,	  4H),	  6.32	  (dddd,	  J	  =	  
36.2,	  31.5,	  17.4,	  9.9	  Hz,	  13H),	  6.01	  (dd,	  J	  =	  14.5,	  6.0	  Hz,	  1H),	  5.57	  (s,	  1H),	  5.52	  (q,	  J	  =	  4.5	  Hz,	  
2H),	  5.40	  –	  5.35	  (m,	  1H),	  5.30	  (s,	  18H),	  4.81	  –	  4.74	  (m,	  1H),	  4.72	  (d,	  J	  =	  7.5	  Hz,	  1H),	  4.47	  (td,	  
J	  =	  10.7,	  4.6	  Hz,	  1H),	  4.36	  –	  4.27	  (m,	  2H),	  4.08	  –	  4.00	  (m,	  1H),	  3.86	  –	  3.72	  (m,	  2H),	  3.69	  –	  
3.54	  (m,	  9H),	  3.47	  –	  3.35	  (m,	  3H),	  3.33	  (dq,	  J	  =	  3.1,	  1.4	  Hz,	  7H),	  3.09	  (d,	  J	  =	  0.9	  Hz,	  3H),	  2.64	  
(dd,	  J	  =	  16.8,	  6.6	  Hz,	  1H),	  2.52	  (dd,	  J	  =	  13.1,	  4.6	  Hz,	  1H),	  2.49	  –	  2.37	  (m,	  2H),	  2.34	  (dd,	  J	  =	  
16.9,	  6.1	  Hz,	  1H),	  2.15	  –	  2.04	  (m,	  1H),	  2.02	  –	  1.83	  (m,	  5H),	  1.70	  (q,	  J	  =	  11.7	  Hz,	  1H),	  1.61	  –	  
1.52	  (m,	  4H),	  1.44	  –	  1.36	  (m,	  1H),	  1.33	  (d,	  J	  =	  6.0	  Hz,	  3H),	  1.28	  (dd,	  J	  =	  12.9,	  10.4	  Hz,	  1H),	  













































13C	   NMR	   (126	   MHz,	   CD3OD)	   δ	   179.76,	   170.66,	   160.94,	   160.80,	   135.39,	   135.30,	   134.42,	  
134.30,	   134.16,	   134.40,	   133.98,	   133,54,	   133.45,	   132.89,	   132.78,	   132.67,	   131.25,	   128.72,	  
128.59,	  114.22,	  114.17,	  102.51,	  101.69,	  101.26,	  101.14,	  81.52,	  78.40,	  77.94,	  77.00,	  74.38,	  
73.37,	   73.66,	   73.49,	   72.28,	   71.21,	   68.59,	   67.89,	   60.19,	   59.72,	   55.62,	   55.60,	   41.82,	   38.22,	  
33.80,	  19.31,	  18.29,	  17.75,	  12.37.	  
	  
HRMS	  (ESI)	  
	   Calculated	  for	  C64H88NO19:	  	   1174.5941	  
	   Found:	   	   	   1174.5951	  
	  
Synthesis	  of	  C2’epiAmB	  
	  
	   To	  a	  300	  mL	  round	  bottom	  flask	  containing	  in	  azeotropically	  dried	  5.18	  (##	  mg,	  ##	  
mmol,	  1.0	  eq)	  was	  added	  MeCN	  (##	  mL)	  and	  DI	  H2O	  (##	  mL).	   	  The	  suspension	  was	  then	  
cooled	  to	  0	  °C	  whereupon	  CSA	  (##	  mg,	  ##	  mmol,	  150	  eq)	  was	  added	  in	  one	  portion.	  	  The	  
yellow	  orange	  suspension	  became	  a	  yellow	  orange	  clear	  solution	  upon	  the	  addition	  of	  CSA.	  	  
Overtime	  a	  fine	  precipitate	  forms.	  	  After	  stirring	  for	  3	  h	  at	  0	  °C,	  	  triethyl	  amine	  (##	  mL,	  ##	  
mmol,	  300	  eq)	  was	  added.	  	  The	  reaction	  was	  then	  concentrated	  and	  purified	  by	  preparative	  
HPLC	   (C18SiO2	  5:95	   -­‐>	  95:5	  MeCN:H2O	  5mM	  NH4OAc	  over	  20	  min	  @	  1	  mL/min)	   to	   yield	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